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Abstract
Evaluation of Array Comparative genomic Hybridisation in
prenatal diagnosis of fetal anomalies: a multicentre cohort
study with cost analysis and assessment of patient, health
professional and commissioner preferences for array
comparative genomic hybridisation
Stephen C Robson,1* Lyn S Chitty,2 Stephen Morris,3 Talitha Verhoef,3
Gareth Ambler,4 Diana G Wellesley,5 Ruth Graham,6 Claire Leader,1
Jane Fisher7 and John A Crolla8
1Institute of Cellular Medicine, Newcastle University, Newcastle, UK
2Institute of Child Health, University College London, London, UK
3Department of Applied Health Research, University College London, London, UK
4Department of Statistical Science, University College London, London, UK
5Department of Genetics, Princess Anne Hospital, Southampton, UK
6School of Geography, Politics and Sociology, Newcastle University, Newcastle, UK
7Antenatal Results and Choices, London, UK
8Wessex Regional Genetics Laboratory, Salisbury, UK
*Corresponding author s.c.robson@ncl.ac.uk
Background: Current pathways for testing fetuses at increased risk of a chromosomal anomaly because of
an ultrasound anomaly involve karyotyping after rapid aneuploidy exclusion. Chromosomal microarray
(CMA) may detect more clinically significant chromosomal imbalances than karyotyping but evidence to
guide UK health service providers on whether or not CMA should replace karyotyping is limited.
Objectives: (1) To compare detection rates of copy number variants (CNVs) and laboratory turnaround
times (TATs) by karyotyping and CMA in fetuses with ultrasound anomalies, (2) to calculate test costs and
the cost per additional pathogenic CNV detected by CMA relative to karyotyping and (3) to determine
what factors influence parents’ and health professionals’ choice and decision-making about CMA.
Design: A multicentre experimental research cohort study with an additional cost analysis.
Setting: A total of 20 fetal medicine units and nine cytogenetic laboratories across England and Wales.
Participants: Women with a fetus undergoing quantitative fluorescent polymerase chain reaction (QF-PCR)
and karyotyping for clinical indications with (1) one or more structural anomalies identified on ultrasound
or (2) an isolated nuchal translucency (NT) of ≥ 3.5 mm.
Interventions: Karyotyping and CMA after exclusion of major chromosomal anomalies by QF-PCR. The
array design consisted of 8-plex 60,000 60-mer oligonucleotides with a backbone resolution of ≈75 kb.
Main outcome measures: Rates of abnormal karyotypes and pathogenic CNVs and variants of unknown
significance on CMA. Laboratory TATs for karyotyping and CMA. Costs of karyotyping and CMA and cost
per additional pathogenic CNV detected by CMA. Parent and health professional attitudes to CMA.
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Results: Out of the 1718 probands recruited, 1123 cases with normal QF-PCR and both karyotype and
CMA were available for analysis. In the group with structural anomalies (n = 629), CMA detected more
CNVs [6.8%, 95% confidence interval (CI) 4.4% to 9.3%] and more pathogenic CNVs (3.5%, 95% CI
1.5% to 5.5%) than karyotyping. In the increased NT group (n = 494), CMA detected more CNVs (4.5%,
95% CI 1.8% to 7.1%) than karyotyping but not more pathogenic CNVs. Compared with karyotyping,
median TAT was 3 days [interquartile range (IQR) 0–13 days] longer with CMA but when actual set-up
to reporting times were compared, CMA was 5 days (IQR 2–8 days) quicker. Cost calculations of the
respective pathways indicated that, per patient, CMA is on average £113 more costly than karyotyping.
The incremental cost per extra pathogenic CNV detected by CMA was greater in the increased NT than the
structural anomaly group (£9439 vs. £3635). Qualitative evaluation suggested that parents find CMA
acceptable, despite the uncertainties it may introduce, and that in the main it is acceptable to health
professionals and commissioners.
Conclusions: CMA is a robust, acceptable and probably cost-effective method to detect more clinically
significant chromosomal imbalances in the anomalous fetus. The results suggest that CMA should replace
karyotyping in these care pathways.
Future work: The application of CMA (and exome sequencing) on cell-free DNA in maternal plasma.
Trial registration: Current Controlled Trials ISRCTN01058191.
Funding: This project was funded by the Efficacy and Mechanism Evaluation programme, a MRC and
NIHR partnership. The funder had no role in the identification, design and conduct of the study and the
reporting of the analysis. The funder did recommend the inclusion of the cell-free DNA aspects of the
EACH study. Funding was also received from the Great Ormond Street Biomedical Research Centre.
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Plain English summary
One of the main aims of ultrasound scans during pregnancy is to detect fetal abnormalities, some ofwhich are due to imbalances (gains or losses) of part or all of a chromosome. Each cell in the body
contains 23 pairs of chromosomes and one of each pair is inherited from each parent. The chromosomes
carry a person’s genetic information stored as deoxyribonucleic acid. Babies with chromosomal imbalances
have complex problems. Testing for chromosome imbalances involves tests (e.g. amniocentesis) that
occasionally cause miscarriage. Major chromosome problems (e.g. Down syndrome) can be detected
quickly by a polymerase chain reaction (PCR) test. Less common imbalances require the baby’s cells to be
grown and examined; this test (karyotyping) detects only large chromosomal imbalances. Chromosomal
microarray (CMA) is a new genetic test that detects smaller chromosomal imbalances. Interpreting CMA is
complex as not all imbalances cause problems. The purpose of the Evaluation of Array Comparative genomic
Hybridisation (EACH) study was to help the NHS decide whether or not CMA should replace karyotyping.
Over 1100 women with a fetal abnormality detected on ultrasound and without a major chromosomal
problem (as indicated by a normal PCR test) participated in the EACH study. CMA detected 3–4% more
significant chromosome imbalances than karyotyping when the reason for testing was a major abnormality
in one of the baby’s organs, but not when there was increased fluid at the back of the baby’s neck (nuchal
translucency). The time from setting up the test to reporting the result of the test was 5 days less with
CMA than karyotyping. Although the cost of CMA (£322) was slightly more than karyotyping, the cost for
each extra chromosome imbalance detected (which was thought to explain the abnormal scan) was
£9418. Interviews suggested that parents and health professionals found the CMA test acceptable despite
the uncertainties it may introduce. The results suggest that CMA should replace karyotyping for the
detection of chromosome imbalances in abnormal fetuses.
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Scientific summary
Background
Current pathways for testing fetuses at increased risk of a chromosomal anomaly because of an ultrasound
anomaly involve karyotyping after rapid aneuploidy exclusion by quantitative fluorescent polymerase chain
reaction (QF-PCR). Chromosomal microarray (CMA) may detect more clinically significant chromosomal
imbalances, but evidence to guide UK health service providers on whether or not CMA should replace
karyotyping is limited.
Objectives
1. To compare detection rates of copy number variants (CNVs) and variants of unknown significance
(VOUS) by karyotyping and CMA in two target populations of fetuses with anomalies detected on
ultrasound and to compare laboratory turnaround times (TATs) from receipt of sample to issuing of
results for karyotyping with CMA.
2. To calculate costs of karyotyping and CMA to NHS and Personal Social Services [including
deoxyribonucleic acid (DNA) extraction, quality metrics, labelling and follow-on tests on fetal/parental
DNA] and to calculate the cost per additional pathogenic CNV detected by array comparative genomic
hybridisation (CGH) relative to karyotyping.
3. To evaluate parents’ and health professionals’ attitudes to CMA and to determine what factors
influence their choice and decision-making about CMA (and the potential to replace karyotyping).
4. To contribute maternal blood samples to the National Institute for Health Research (NIHR)-funded
Reliable Accurate Prenatal non-Invasive Diagnosis (RAPID) project (the methods and results of which will
be reported separately).
Methods
The Evaluation of Array Comparative genomic Hybridisation (EACH) study was a multicentre experimental
research cohort study with an additional cost analysis and qualitative substudy. The study population consisted
of women with a fetus undergoing QF-PCR and conventional karyotyping by amniocentesis, chorionic villus
sampling or fetal blood sampling for clinical indications with one or more structural anomalies identified on an
ultrasound scan at any gestational age or an isolated nuchal translucency (NT) of ≥ 3.5 mm at 11+2 to 14+1 weeks
of pregnancy. With the exception of fetuses with a nuchal fold of > 6mm at 18+0 to 20+6 weeks of pregnancy,
fetuses with single or multiple ultrasound variants (or markers) were excluded.
Eligible women attending 20 fetal medicine units in England and Wales gave written informed consent to
use any excess fetal material available after setting up routine testing (QF-PCR and karyotyping) and
donate a blood sample. When partners were in attendance they were also approached to donate a blood
sample. Only fetuses with a normal QF-PCR result or a sex chromosome aneuploidy that was unlikely to
explain the ultrasound anomaly (e.g. XXX, XXY and XYY underwent CMA).
All nine participating cytogenetic laboratories followed their existing clinical pathways for karyotyping and
adapted their workflows to incorporate DNA extraction from amniocytes and chorionic villi for both QF-PCR and
CMA. The same oligonucleotide-CGH array design, consisting of an 8-plex of 60,000 60-mer oligonucleotides
with a backbone resolution of ≈75 kb but with considerably higher coverage over chromosomal regions of
interest, was used by all laboratories. CMA results were analysed using the software supplied with the array and
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presented in GRch37/hg19 format. Several laboratory techniques (including parental karyotyping, parent versus
parent CMA and fluorescence in situ hybridisation) were used to determine the parental origins of CNVs
detected by karyotyping or CMA.
For the purposes of the EACH study, all structural and numerical karyotype abnormalities, whether
balanced or not, were included as abnormal karyotypes. Laboratories utilised their own standard operating
procedures to classify CNVs detected by their analytical CMA software as (1) pathogenic, (2) VOUS
(when the possible genotype and phenotypic effects were uncertain) or (3) benign and not relevant to the
presenting phenotype. When local laboratories were uncertain about classifying a CNV, an expert review
panel (comprising at least two clinical geneticists and two cytogeneticists) was available for advice. All
pathogenic CNVs were reported to clinicians but VOUS were not reported. Clinical and laboratory data
(including fetal ultrasound findings and postnatal outcome information) were recorded on a bespoke
database (Cartagenia Bench™ version 4.0, Cartagenia N.V., Leuven, Belgium).
Turnaround times for conventional karyotyping and CMA were measured from the date the fetal sample
was received in the laboratory to the date the final karyotype or CMA report was issued by the laboratory.
Data on actual set-up to reporting times were also collected for each test.
A sample of 500 in each target population was selected to give in excess of 90% power to detect a
difference in detection rates at the 5% significance level, assuming karyotyping- and CMA-detected
anomalies in 5% and 10% of fetuses, respectively. This sample size would give a 95% confidence interval
(CI) for the difference in detection rates of ±2%. The proportion of subjects with pathogenic CNVs and
VOUS were calculated with exact 95% CIs. Statistical comparisons of pathogenic CNVs/VOUS between
karyotyping and CMA were made using McNemar’s test.
For the economic analysis, a decision-analytic model was developed describing the two diagnostic options
(karyotyping and CMA) and the possible follow-on pathways using data collected on Cartagenia Bench.
Data on the costs of karyotyping and CMA were collected from nine cytogenetic laboratories. The average
costs were used as base-case values in the current model. The costs of clinical follow-up focused specifically
on follow-up consultations related to test results. The costs of the EACH panel review were also calculated.
All costs are expressed in 2012–13 Great British pounds. The time horizon in this study was the duration of
pregnancy; therefore, no discounting was necessary. The main outcome of the model was the incremental
costs per pathogenic CNV detected by CMA compared with karyotyping. Uncertainty around input
parameters was taken into account using one-way sensitivity analysis and probabilistic sensitivity analysis.
The qualitative substudy used a purposive sampling approach, to enhance diversity of views represented
within the sample. Women who had participated in the EACH trial at three study sites and who had
agreed to be interviewed about their experience were contacted and interviewed a minimum of 3 months
after completion of the pregnancy. Health professionals from two study sites were selected to ensure the
inclusion of a range of professional viewpoints. National and local commissioners were identified via a
convenience sample through a national contact. The aim was to undertake 15–20 interviews in both the
parent and health professional groups. Data collection was via in-depth, semistructured interviews, and
data analysis of anonymised transcripts was informed by a generative thematic approach using the
software package ATLAS.ti (version 7.0, Cleverbridge AG, Cologne, Germany). Coded data were organised
into key themes and subthemes.
Results
In total, 1718 probands were recruited between March 2012 and May 2014. A paternal blood sample was
obtained in 1347 (78.4%) cases and 1460 (84.9%) women gave their consent to be contacted after the
birth to arrange assessment of their infant. Source tissue for DNA extraction was chorionic villi in 55.8% of
cases, amniotic fluid in 40.8% and other fetal tissue in 2.7%. After exclusions (including 509 cases with a
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common chromosomal anomaly detected by QF-PCR) and test failures (CMA in 49 cases, karyotype in
nine cases), 1123 cases were available for comparison; 494 in the increased NT group and 629 in the
structural anomaly group. The latter group included 105 (16.7%) cases in which an anomaly was detected at
11–14 weeks’ gestation (with or without increased NT) and 75 (11.9%) cases detected after 24 weeks’
gestation. After a total of 268 follow-up tests (including 91 parent vs. parent arrays and 81 fluorescence in situ
hybridisation studies), 15 (1.3%) cases were classified as abnormal karyotype and normal CMA, 58 (5.2%)
as abnormal karyotype and pathogenic CNV on CMA, 42 (3.7%) as normal karyotype and pathogenic CNV
on CMA and 38 (3.4%) as normal karyotype and VOUS on CMA. Within the increased NT group, 55 out of
307 (17.9%) with known pregnancy outcome opted for termination of pregnancy [including 24/62 (38.7%)
with an abnormal karyotype with or without CMA] compared with 153 out of 462 (33.1%) in the structural
anomaly group [including 46/88 (52.2%) with an abnormal karyotype with or without CMA].
In the increased NT group, there was no difference in the rates of abnormal karyotype and pathogenic
CNV on CMA but the rate of any CNV (pathogenic + VOUS) on CMA was 4.5% (95% CI 1.8% to 7.1%)
higher than the rate of abnormal karyotype. The rate of pathogenic CNVs on CMA was higher in fetuses
with a NT of > 5 mm than in fetuses with a NT of 3.5–5 mm (13.2% vs. 5.4%; p < 0.003). In the structural
anomaly group, CMA detected more CNVs (6.8%, 95% CI 4.4% to 9.3%) and more pathogenic CNVs
(3.5%, 95% CI 1.5% to 5.5%) than karyotyping. The rate of pathogenic CNVs on CMA was similar in
fetuses with multiple structural anomalies or one structural anomaly (11.1% vs. 8.8%; p = 0.34) but was
higher in fetuses with a cardiac than a non-cardiac anomaly (14.5% vs. 7.9%; p = 0.013).
Median [interquartile range (IQR)] TATs were 12 days (IQR 10–14 days) for karyotyping and 15 days (IQR
12–25 days) for CMA (difference 3 days, IQR 0–13 days; p < 0.0001). However, when actual set-up to
reporting times were compared, CMA was 5 days (IQR 2–8 days) quicker. Median set-up to reporting times
varied significantly between laboratories. In total, 32 cases with CNVs on CMA were referred to the EACH
review panel; 16 were classified as pathogenic and reported and 16 were classified as VOUS and not
reported. Out of the 16 recommended for reporting, 9 (56%) were < 1 Mb in size and 6 out of 16 (38%)
of those not reported were > 1 Mb.
The average cost of CMA was higher (£322, range £280–367) than the cost of karyotyping of chorionic
villi (£272, range £240–307) and amniotic fluid (£234, range £212–258). Cost calculations of the
respective pathways indicated that the per-patient CMA was, on average, £113 more costly than
karyotyping. The incremental cost per extra pathogenic CNV detected by CMA was £4703 for the whole
study group, £9418 in the increased NT group and £3635 in the structural anomaly group. In a one-way
sensitivity analysis, the only parameters found to affect the results appreciably were the number of
pathogenic results and the test costs. In the probabilistic sensitivity analysis, 0% of the simulations were
found to be cost-effective if the willingness to pay per incremental anomaly found was £1000 and 87% of
the simulations were found to be cost-effective if the willingness to pay was £10,000.
Out of the 98 individuals invited to participate in the qualitative evaluation, 48 respondents were interviewed
[16 women (five with partners present), 21 health professionals and six commissioners]. Using generative
thematic analysis, four key themes emerged from the data: (1) the functionality of CMA, (2) introducing
CMA into the clinical consultation, (3) decision-making and (4) embedding CMA as standard clinical practice.
Overall, the findings suggested that parents find CMA acceptable, despite the uncertainties it may introduce,
on the basis that the test offers additional information. The majority of health professionals also found CMA
acceptable and, along with commissioners, were supportive of its integration into clinical practice. The
challenges of informed consent and managing uncertain prognosis were highlighted.
Conclusions
The EACH study was designed to provide guidance to health service providers on whether or not CMA
should replace karyotyping in the prenatal diagnosis of fetal anomalies. The results suggest that CMA is a
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robust, acceptable and probably cost-effective diagnostic test and should replace karyotyping in care
pathways when the indication for fetal testing is one or more structural anomalies or an isolated NT of
≥ 3.5 mm on an ultrasound scan after a normal QF-PCR result. Replacement for both indications will
ensure there is a consistent prenatal (and postnatal) diagnostic technology.
There is some evidence from the study that, until more national (and international) information on prenatal
variants has been collected that specifically links clinical phenotypic and molecular data, there may be
benefit in a national advisory group that can provide expert advice to local health-care professionals about
variants of possible pathogenic significance. Such a group could also identify incidental findings not to be
reported. The operating model of the EACH review panel could serve as a template for such a group.
Furthermore, to ensure consistent high-quality information is provided to parents undergoing CMA,
consideration should be given to producing a national information sheet and consent form.
Trial registration
This trial is registered as ISRCTN01058191.
Funding
This project was funded by the Efficacy and Mechanism Evaluation programme, a MRC and NIHR
partnership. The funder had no role in the identification, design and conduct of the study and the
reporting of the analysis. The funder did recommend the inclusion of the cell-free DNA aspects of the
EACH study. Funding was also received from the Great Ormond Street Biomedical Research Centre.
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Chapter 1 Introduction
Major congenital anomalies affect 1–1.5% of births and are a leading cause of neonatal death anddisability, resulting in substantial emotional and economic burden for families and society.1
Chromosomal anomalies are responsible for 20–25% of major fetal anomalies.1 The national Fetal
Anomaly Screening Programme (FASP) recommends ultrasound screening for congenital anomalies at
11–14 and 18–20 weeks of pregnancy.2 Early screening for chromosomal anomalies at 11–14 weeks
incorporates ultrasound measurement of nuchal translucency (NT); 2–3% of pregnant women are
identified as being at high risk of having a baby with the chromosomal anomaly after screening and are
offered chorionic villus sampling (CVS) or amniocentesis.3 When the NT is ≥ 3.5 mm (equivalent to a 99th
centile) the risk of a chromosomal anomaly is > 20% and FASP recommends the offer of invasive prenatal
diagnosis irrespective of other screening markers.4 Fetuses with a NT of ≥ 3.5 mm are also at increased risk
of structural anomalies and genetic syndromes.4
Screening for structural anomalies is recommended at the 18+0 to 20+6 week ultrasound scan,5 although a
recent systematic review has shown that approximately 50% of fetal structural anomalies can be detected
by an ultrasound scan at 11–14 weeks of pregnancy.6 Approximately 15% of fetuses with a structural
anomaly detected in the second trimester have an underlying chromosomal anomaly although rates vary
with the specific structural anomaly and whether or not the anomaly is isolated or one of a number of
ultrasound-detected defects;7,8 rates increase from 29%, when two or more structural anomalies are
detected, to > 70% with six or more.7
When women opt for invasive testing because of an increased fetal risk of chromosomal anomaly,
laboratories perform quantitative fluorescent polymerase chain reaction (QF-PCR) for rapid aneuploidy
detection. This test detects chromosome copy number by amplification of repeat sequences at polymorphic
loci. It is efficient (one technician can examine up to 5000 samples per year) and detects trisomies 21,
18 and 13 as well as sex chromosome anomalies and triploidy within 2 days in 5–14% of cases.9 In addition,
G-banded karyotyping of cultured cells detects other aneuploidies and large unbalanced chromosome
rearrangements at a resolution of 5–10 Mb in a further 5% of cases.10–12 However, karyotyping is slow
(it can take 2 weeks to receive the results of the test) and labour intensive (one technician can examine
≈250 samples/year).10 The majority of these other aneuploidies and rearrangements occur in fetuses with
multiple anomalies or an increased NT.7,11,13,14 Furthermore, when a structural anomaly is suggestive of a
well-defined microdeletion/duplication syndrome (e.g. del22q11), additional targeted fluorescence in situ
hybridisation (FISH) or multiplex ligation-dependent probe amplification (MLPA) may be performed.12,15
When testing fails to identify a chromosomal anomaly in a fetus with a sonographic anomaly, counselling
parents about aetiology and prognosis is difficult because some babies are later found to have other
abnormalities and/or learning difficulties.
Array comparative genomic hybridisation (CGH) or chromosomal microarray (CMA) involves the isolation
and differential labelling of genomic deoxyribonucleic acid (DNA) from a patient and a reference (control)
followed by co-hybridisation to a matrix of DNA fragments (probes) that can be short (25- to 60-mer)
oligonucleotides or larger fragments (up to 250 kb).16 The fluorescence ratio for each probe reflects the
average copy number ratio between patient and control DNA. Use of probes with known genome
positions allows identification of DNA copy number variants (CNVs).
The first CMA platforms used bacterial artificial chromosome (BAC) clones of 100–150 kb in length,
generating an intense hybridisation signal with a high signal-to-noise ratio.17 BAC arrays have an average
resolution of 0.5–1Mb and multiplexing is limited; therefore, they are suitable only for low throughput.
Subsequent oligonucleotide comparative genomic hybridisation (oligoCGH) arrays use shorter probes
(typically 50–60 base pairs), providing higher resolution (40–400 kb) but the shorter probes result in less
specific hybridisation and lower signal-to-noise ratio. Single nucleotide polymorphism (SNP) arrays use
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probes that are either 25 or 50 base pairs long and, therefore, tend to have the lowest signal-to-noise
ratio. The resolution of oligonucleotide-based arrays is dependent on the number and spacing (density) of
the probes and the number of consecutive probes required for a CNV call. Resolution therefore varies with
the array design and the calling parameters.17
Interpretation of CMA results in a clinical setting can be challenging as copy number variation occurs in
normal individuals; approximately 12% of the human genome exhibits such variation.18 Variants can be
classified as pathogenic (i.e. causative of the phenotype), benign or novel variants of unknown significance
(VOUS). More than 99% of benign CNVs are inherited and the vast majority of these are < 500 kb.19 Thus,
in order to classify novel CNVs, follow-up studies (e.g. parental arrays sometimes followed by FISH, MLPA
and QF-PCR on fetal/parental DNA) are often required. Regularly updated online databases that catalogue
CMA results from normal individuals and those with phenotypic anomalies provide invaluable information
to assist in array classification. One perceived disadvantage of the increased diagnostic yield of smaller
CNVs with oligonucleotide-based (either CGH or SNP) arrays is the need for more parental follow-up tests
and the increased rate of VOUS.17,20
Microarray technology has identified novel microdeletion/duplication syndromes, many of which are
mediated by specific genomic motifs called segmental duplications. In postnatal life, these account for
25% of all recurring microdeletion/duplication cases. Array CGH has also been used to further characterise
visible chromosomal rearrangements and, in some cases, unmask novel Mendelian disorders. When CMA
has been applied to children with undiagnosed developmental delay and an apparently normal G-banded
karyotype, 10–15% had pathogenic de novo CNVs of 150–15,000 kb.21,22 The improved detection of
pathogenic CNVs, together with reduced cost of arrays, led to the recommendation that CMA should be
the first-line test for postnatal referrals with developmental delay and dysmorphism.23 UK guidelines,
published in 2011,24 recommended postnatal CMA for the investigation of developmental delay and
dysmorphism. This policy has been implemented in regional genetics laboratories across the country.
Initial prenatal studies employed low-resolution BAC arrays on fetal DNA extracted after fetal loss25 and
pathogenic CNVs were detected in ≈10% of cases. Subsequent studies confirmed that CMA could be
applied to uncultured and cultured amniocytes and chorionic villi with detection of aneuploidies, known
microdeletion syndromes and large unbalanced CNVs.26–28 Shaffer et al.29 and Coppinger et al.30 used BAC
arrays in two studies of 151 and 182 prenatal samples with normal karyotypes collected for varying clinical
indications. Pathogenic CNVs were detected in 1.3–2.7% of cases and benign CNVs in a further 8.8%.
The highest yield of pathogenic CNVs (4.5%) was found in cases with an abnormal ultrasound scan.
Following the introduction of higher resolution oligonucleotide arrays, Van den Veyver et al.31 used a
targeted array in 300 prenatal samples from cases referred primarily for advanced maternal age. They
detected 58 (19.3%) CNVs, of which 15 (5.0%) were deemed pathogenic and three (1.0%) of uncertain
significance. Subsequent studies used CMA in fetuses with structural anomalies identified on ultrasound
but a normal karyotype, and CNVs were reported in 2–15% of cases.32–35 In 2011, Hillman et al.36 reported
a meta-analysis of eight prenatal studies which showed that overall array CGH detected 12% [95%
confidence interval (CI) 8.8% to 16.4%] more chromosomal imbalances when karyotyping was normal.
When the analysis was confined to fetuses with a structural anomaly on ultrasound (six studies, 359 cases)
CMA detected 11.2% (95% CI 5.7% to 22.1%) more chromosomal imbalances overall. The rate fell to
5.2% (95% CI 1.9% to 13.9%) when benign CNVs were removed.36 This included 1.9% (95% CI 0.4%
to 9.5%) for which the result reported was of unknown significance.36 The largest of these studies
included only 151 cases. In the same year, Leung et al.37 reported the first study of CMA in a cohort of
48 fetuses with increased NT (> 3.5 mm) at 11+2–14+1 weeks’ gestation and a normal karyotype. CNVs
were reported in six (12.5%) cases and considered pathogenic in four (8.3%) cases. Thus, at the time of
commencing the Evaluation of Array Comparative genomic Hybridisation (EACH) study, the available
literature suggested that CMA may detect more pathogenic CNVs in fetuses with ultrasound-identified
structural anomalies and increased NT than karyotyping.
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Policy development in NHS-based health care is complex. This is particularly apparent in the area of fetal
anomaly, in which health care involves a significant degree of scientific uncertainty about prognoses,
alongside difficult decision-making for parents about the care pathways and reproductive choices available
to them following prenatal diagnosis. With respect to CMA, there is concern that reporting of VOUS may not
only increase parental anxiety but lead parents to choose to terminate a fetus that is potentially at low risk of
an adverse outcome.36 Although technological developments in fetal medicine can help reduce uncertainty,
Williams38 noted that sometimes developments have been implemented without due consideration of the
ethical and social issues that may arise from the technology for the parents and health professionals involved
in care provision. Furthermore, implementation of health policy is influenced by a range of factors, including
local level staff views about changes to service provision.39 Prior to commencing the EACH study, no work
had been done on patient or professional views on prenatal CMA or on possible barriers to or facilitators of
implementation. In their systematic review of prenatal CMA, Hillman et al.36 emphasised the need for
qualitative research in this area.
In England and Wales, around 35,000 women undergo karyotyping per annum (at a cost of £3.3M).10
Since CMA was introduced into prenatal diagnosis, when the cost per case was estimated at ≈£600,40
array costs have decreased dramatically and higher-density oligonucleotide arrays are now available for
< £150. However, given the reported increased detection rates of pathogenic variants and VOUS with
CMA, the associated costs of additional tests, reviewing results and clinical follow-up to explain CMA
results are expected to be higher than karyotyping. Thus, at the time of commencing the EACH study,
there was an urgent need to assess the clinical and cost efficacy of CMA before introduction into NHS
practice, as had already occurred in some US centres. Indeed, despite the limited evidence, an American
College of Obstetrics and Gynecology Committee Opinion in 2009 stated that ‘Targeted array CGH,
in concert with genetic counselling, can be offered as an adjunct tool in prenatal cases with abnormal
anatomic findings and a normal conventional karyotype’.41
If CMA is shown to detect pathogenic genomic imbalances more effectively than karyotyping and at a
lower cost, then array CGH should replace karyotyping, allowing the streamlining of genetic service
delivery with a single diagnostic platform across prenatal and postnatal life. CMA could also dramatically
further our understanding of fetal anomalies and, in so doing, enhance patient counselling and
management. The rationale for the EACH study was, therefore, to evaluate the potential for CMA to
replace karyotyping for the investigation of fetuses with ultrasound anomalies after rapid exclusion of
common aneuploidies by QF-PCR. The specific research aim was to provide guidance to health service
providers on whether CMA should replace karyotyping in the prenatal diagnosis of fetal anomalies by
determining whether or not CMA is an acceptable, cost-effective and robust method to detect more
clinically significant de novo chromosomal imbalances than conventional karyotyping in fetuses with
(1) one or more structural anomalies identified by ultrasound and (2) an isolated NT of ≥ 3.5 mm identified
at the routine 11- to 14-week ultrasound scan.
Over recent years, along with developments in CMA, there have also been considerable advances in the
development of non-invasive prenatal testing (NIPT) based on cell-free fetal deoxyribonucleic acid (cffDNA)
in maternal plasma. By 2011, when the EACH study was funded, several studies had demonstrated the
potential for NIPT for common trisomies and even other large CNVs.42–45 The National Institute for Health
Research (NIHR) had funded the Reliable Accurate Prenatal non-Invasive Diagnosis (RAPID) project to
(1) develop standards for implementation of NIPT into routine NHS practice for fetal sex determination and
single gene disorders, (2) evaluate the potential of NIPT for trisomy 21 and other major trisomies and
(3) explore the potential for NIPT of significant unbalanced CNVs using next generating sequencing of
cffDNA.46 As the EACH study would be recruiting a cohort enriched for both aneuploidy and other
CNVs, combining studies would allow a large-scale evaluation of NIPT on the EACH cohort. Therefore,
a secondary research aim was to contribute maternal blood samples to the RAPID project. The results of
the RAPID project will be reported separately.46
In order to achieve these aims the specific research objectives of the EACH study were as follows.
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Laboratory evaluation
1. To compare detection rates of:
i. pathogenic CNVs and VOUS by karyotyping and CMA in two target populations of fetuses with
ultrasound-detected anomalies after exclusion of major numerical sex and autosomal chromosomal
anomalies by QF-PCR
ii. trisomy 21 and other major trisomies by QF-PCR and NIPT (to be reported with the RAPID project).
2. To compare turnaround times (TATs) from receipt of sample to issuing of results for:
i. karyotyping and CMA
ii. QF-PCR and NIPT (to be reported with the RAPID project).
Cost issues
1. To calculate costs of karyotyping and CMA to NHS and Personal Social Services (including DNA
extraction, quality metrics, labelling and follow-on tests on fetal/parental DNA).
2. To calculate the cost per additional pathogenic CNV detected by array CGH (and associated follow-on
testing) relative to karyotyping.
Public and health professional attitudes
1. To evaluate parent and health professional attitudes to CMA.
2. To determine which factors influence parents’ and health professionals’ choices and decision-making
about CMA (and the potential to replace karyotyping).
An economic evaluation of NIPT and an evaluation of public and health professional attitudes to NIPT was
already included as part of the RAPID project.
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
4
Chapter 2 Methods
The EACH study was designed as a multicentre experimental research cohort study with an additionalcost analysis and assessment of patients’, health professionals’ and commissioners’ preferences for
array CGH.
Study population
Inclusion criteria
Women with a fetus (singleton or dichorionic twin) undergoing QF-PCR and conventional karyotyping by
amniocentesis, CVS or fetal blood sampling for clinical indications with
1. one or more structural anomalies identified on an ultrasound scan at any gestational age or
2. an isolated NT of ≥ 3.5 mm in a fetus with a crown–rump length of 45.0–84.0 mm
were included in the study.
Fetuses with isolated fetal growth restriction (defined as an abdominal circumference of more than two
standard deviations below the mean for gestational age according to local standards) were also included in
the structural anomaly group. Following feedback from Trial Steering Committee members and site
principal investigators, fetuses with a thickened nuchal fold (NF) (defined as a NF of > 6 mm) at 18+0 to
20+6 weeks were also included in the structural anomaly group.47
Fetuses with a structural anomaly and a NT of ≥ 3.5 mm identified at 11+2 to 14+1 weeks of pregnancy
were included in the structural anomaly group. Fetuses diagnosed with an isolated cystic hygroma
between 11+2 and 14+1 weeks of pregnancy were included in the NT group.
Only those fetuses with a normal QF-PCR result or a sex chromosome aneuploidy that was unlikely to
explain the ultrasound anomaly (e.g. XXX, XXY and XYY) underwent CMA. Cases were recruited from
selected fetal medicine units in England and Wales. Sunderland Royal Hospital (City Hospitals Sunderland
NHS Foundation Trust) also acted as a patient identification centre for the study; suitable women were
given the patient information leaflet and those interested in participating were referred to the Royal
Victoria Infirmary Fetal Medicine Unit where they were approached to take part in the study.
Exclusion criteria
Women meeting the following criteria were regarded as ineligible for the study:
1. A fetus with single or multiple ultrasound variants (or markers). In this context fetal cerebral
ventriculomegaly (ventricular atrium of ≥ 10 mm) was classed as a structural anomaly.
2. Participant declined to take part in the study.
3. Participant was under the age of 16 years.
4. Participant was unable to read English and understand the study information leaflet.
Women who had consented to the EACH study but who were subsequently found to have a fetus with a
common aneuploidy on QF-PCR were also excluded from the study.
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Recruitment and consent
Eligible women attending fetal medicine clinics were identified by a member of the medical staff providing
care or by a research nurse/midwife screening the medical notes. Those meeting the inclusion criteria were
approached to take part in the study and given an information leaflet (see Appendix 1). Informed consent
discussions were undertaken by appropriate site staff (as per the delegation log) involved in the study,
including medical staff and research nurses/midwives, with opportunity for participants to ask questions.
Those wishing to participate in the study gave informed written consent to use any excess fetal material
(villi, amniocytes or fetal blood) available after setting up routine testing (QF-PCR and karyotyping). They
also consented to donating a blood sample of up to 20 ml. In addition, women were also asked to give
written consent to contact after birth to arrange assessment of their infant (see Appendix 2). When
partners were in attendance they were also approached and asked for written informed consent to take a
blood sample. Parents were advised that this was a research study designed to evaluate new methods of
fetal chromosomal analysis but that in a few cases the research may reveal additional information that may
inform pregnancy management. Should this occur, the information would be transmitted to them via the
health professionals responsible for their care.
The original signed consent form was retained in the investigator site file, with a copy in the clinical notes
and a copy provided to the participant. Women taking part in the study and those who declined were added
to the screening and recruitment log to ensure that they were not approached again later in their pregnancy.
Ethics approval was granted by National Research Ethics Service Committee North East – Newcastle and
North Tyneside (reference 11/NE/0331) on 4 January 2012. Three subsequent amendments were approved:
1. Amendment 1 (approval date 26 October 2012) to include an updated health economic analysis plan
and to amend the definition of increased NT to ≥ 3.5 mm (to be consistent with national guidance from
NHS Screening Programmes).
2. Amendment 2 (approval date 14 February 2013) to include Sunderland Royal Hospital as a participant
identification centre site, Birmingham Women’s Hospital as a recruitment site and also widening the
inclusion criteria to include structural anomalies identified at any gestation.
3. Amendment 3 (approval date 23 December 2013) to include the use of fetal blood samples.
The Newcastle upon Tyne Hospitals NHS Foundation Trust acted as study Sponsor (reference 5878).
Laboratory workflow
All nine participating cytogenetic laboratories followed their existing clinical pathways for karyotyping and
adapted their workflows to incorporate DNA extraction from amniocytes and chorionic villi for both
QF-PCR and CMA (Figure 1). In most instances, parental blood samples were routinely stored until the
results of the CMA were known and DNA was extracted. Parental chromosome preparations were made
only if follow-up parental studies were required (see Figure 1).
Deoxyribonucleic acid extraction
Deoxyribonucleic acid was extracted from the available uncultured fetal samples, predominantly chorionic
villi and amniotic fluid. DNA extraction was achieved in accordance with to either local laboratory protocols
or using a method developed specifically for obtaining high-quality DNA from small volumes of source
prenatal material.48 This method was developed during planned preliminary (pre-recruitment) studies
undertaken at the Wessex Regional Genetics Laboratory (WRGL) and the North-East Thames Regional
Genetics Laboratory (NETRGL). In brief, a collection of commercially available DNA extraction kits and
METHODS
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quantification techniques were evaluated and compared using minimal quantities of amniotic fluid
(2–4 ml), chorionic villi (2–5 mg) and cultured cells (under 150,000 cells). The work identified the following
optimised technical workflow:
(a) DNA extraction using the iGENatalTM kit (iLab Tech, Madrid, Spain)
(b) Quantification by the Qubit® 2.0 Fluorometer with the Qubit® dsDNA BR assay kit (InvitrogenTM/Life
TechnologiesTM, Thermo Fisher Scientific, Waltham, MA, USA).
Subsequent CMA experiments using Oxford Gene Technology’s CytoSure™ (Oxford, UK) International
Standards for Cytogenomic Arrays (ISCAs) 8 × 60,000 oligonucleotide array platform demonstrated
good-quality array profiles, providing further evidence that the extracted DNA was of high quality. The
extractions yielded between 210 ng and 1825 ng of prenatal DNA from 4 ml of amniotic fluid and, using
this platform, successful arrays were achieved with as little as 125 ng of prenatal DNA, provided this was
matched with an equivalent amount of control DNA in the experiment.48
Quantitative fluorescent polymerase chain reaction
Quantitative fluorescent polymerase chain reaction was carried out using either commercial kits [QStar plus
(Elucigene® QST*R Plus v2 kit, Elucigene Diagnostics, Manchester, UK) or Devyser Complete v2 kit (Devyser
Pathogenic CNV/known
microdeletion/duplication
Health
professionals
 and patient
Genetic 
counselling
Normal/benign CNVArray CGH
failed
Genetic 
counselling
Health
professionals
 and patient
DNA extraction
(cultured cells)
FMU – recruitment/sampling (CVS or amniocentesis)
Maternal and paternal blood
QF-PCR
CNV of unknown
clinical significance
Follow-up – array CGH
MLPA/FISH
The EACH review panel
Abnormal
Evidence-based array CGH
ISCA 8 × 60,000
Local laboratory
DNA extractionKaryotyping
Normal
FIGURE 1 Laboratory workflow in the EACH study. FMU, fetal medicine unit; ISCA, International Standards for
Cytogenomic Array.
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AB, Hagersten, Sweden)] or in-house products and protocols. Primers targeting chromosomes 13, 18, 21,
X and Y were used. Cases of trisomies 13, 18 and 21, triploidy and 45X were reported to the referring
clinicians and patients and no further actions with respect to the EACH study and CMA were performed.
When other sex chromosome aneuploidies were detected (47,XXY, 47,XYY, 47,XXX and one case of
49,XXXXX), these were processed by CMA as these chromosomal abnormalities were not expected to be
associated with fetal structural abnormalities.
Standard karyotyping
Prenatal samples were processed for standard karyotyping in accordance with the standard operating
procedures in operation in each of the participating cytogenetic laboratories. All laboratories retained
samples of viable fibroblasts in vitro in case these were needed for either (1) repeat DNA extraction
and repeat CMA using fibroblast DNA and/or (2) additional cytogenetic preparations required for FISH
follow-up studies.
Array comparative genomic hybridisation
At the outset of the EACH study it was agreed that all of the participating laboratories would use the same
array design based on the International Standard for Cytogenomic Array Consortium consensus.49 The array
selected for use consisted of an 8-plex of 60,000 60-mer oligonucleotides with a backbone resolution of
≈75 kb, but with considerably higher coverage over telomeric and pericentromeric chromosomal regions in
known microdeletion and microduplication syndromic regions and also for a number of key developmental
and haploinsufficient genes. The laboratories obtained their arrays from a number of commercial vendors
and in most cases used the analytical software supplied with the arrays. All CMA results are presented in
GRch37/hg19 format.50
All CMA tests were carried out using the protocol provided by the manufacturers and the QF-PCR sex
chromosome result was used to (1) detect cases with significant maternal cell contamination (MCC) (in the
event of which the DNA was extracted from cultured fibroblasts) and (2) select the sex-matched control for
the array CGH experiment. All but one of the laboratories incorporated the EACH samples into their
routine postnatal CMA protocols; the exception ran separate prenatal arrays in batches. In cases with a
normal result, or when only known benign CNVs were observed, normal CMA and karyotyping results
were reported to the referring clinician. When an abnormal array CGH result [e.g. involving one of the
known microdeletion syndromes or further quantifying the extent of the imbalance(s) associated with
chromosomally visible abnormalities] was received, this was reported to the referring clinician. In cases for
which the clinical significance of the CNV was uncertain (VOUS), the laboratory carried out follow-up
studies, principally parent versus parent array CGH or FISH, to determine whether the CNV had been
inherited or was de novo. Once this information was available, the case was either reported on the basis
of the information to hand or referred to the EACH review panel for further consideration. It should be
noted that the participating laboratories recorded all cases of pathogenic CNVs and VOUS into a bespoke
database designed by Cartagenia Bench™ (version 4.0, Cartagenia N.V., Leuven, Belgium). Known benign
CNVs were recorded only locally and not incorporated into the Cartagenia Bench laboratory proforma.
Database of phenotypes, demographics and laboratory results
To accommodate the multicentre design of the EACH study, the recording of all data sets was facilitated
by a bespoke online version of Cartagenia Bench. The proformas were designed by SCR and LC (fetal
phenotyping and demographics) and JAC (laboratory results). Demographic and fetal phenotypic data were
uploaded by research nurses/midwives from the participating fetal medicine units and all identifiable
patient information was removed. Clinical scientists at the participating cytogenetic laboratories were
METHODS
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then provided access to the demographic and fetal phenotyping information and added all aspects of the
laboratory processes via the laboratory proformas. Pregnancy outcome data, when available, were
uploaded by research nurses/midwives. Anonymised post-mortem reports and paediatric discharge
summaries were uploaded into Cartagenia Bench.
Data queries and outstanding pregnancy outcomes were sent to each participating centre every 4–6 months.
In the period between close of recruitment and data closure (for cleaning and analysis). Efforts to get
complete outcome data focused on cases with an abnormal karyotype and/or CMA. Data monitoring and
analyses were facilitated by downloading all of the data fields into Microsoft Excel® 2010 (Microsoft
Corporation, Redmond, WA, USA) spreadsheets.
Follow-up studies
Several laboratory techniques were used to determine the parental origins of CNVs detected by
karyotyping or CMA: parental karyotyping, parent versus parent CMA [in which DNA from both parents
was run on a single array but only the area of imbalance(s) observed in the fetus was analysed to
determine whether or not the CNV was inherited], FISH, MLPA, QF-PCR and, rarely, other molecular
cytogenetic techniques.
For cases requiring FISH follow-up studies, the WRGL had an in-house collection of FISH clones consisting
of the 30,000 Sanger BACs set, which was acquired by the WRGL in 2007. Since then, ≈2500 of the
30,000 clones have been used for FISH studies and labelled DNA was available for distribution to the
participating laboratories, if required. A database of these clones was made available to all participating
laboratories. FISH-ready clones were aliquoted within 24 hours and sent by post to the requesting
laboratory. TATs for producing FISH-ready clones for other targeted regions of the genome were ≈10 days.
All clones were sent to the requesting laboratory in a ‘FISH-ready’ format and use of these FISH clones was
contingent on each laboratory verifying the position and how informative the clone(s) were by using the
proband’s chromosomes as the positive control.
The EACH study copy number variant exclusion criteria
At the outset of the study, a clinical review group was established to review the available literature and
to draw up a list of VOUS with low penetrance and/or low expressivity which would therefore not be
reported within the context of prenatal diagnosis (Table 1). However, the final decision whether or not to
report CNVs on this list was made by the local clinical scientists and ultimately the referring clinicians.
TABLE 1 Copy number variants excluded
Variant Start (build 37) End (build 37) Interval
1q21.1 microdeletion 146,512,930 147,737,500 1.22
1q21.1 microduplication 146,512,930 147,737,500 1.22
15q11.2 BP1–BP2 22,765,637 23,217,454 0.45
16p13.11 microdeletion 15,504,454 16,284,248 0.78
16p13.11 microduplication 15,504,454 16,284,248 0.78
22q11 duplication 18,546,349 22,336,469 3.79
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Classification of karyotype and chromosome microarray findings
All structural and numerical abnormalities identified by karyotyping were reported according to standard
laboratory protocols. All such cases were included as an abnormal karyotype for the purposes of the EACH
study, whether balanced or not (e.g. translocations and inversions); this included cases ultimately found to
represent confined placental mosaicism (CPM) and rare, probably benign, variants (e.g. mosaic loss of Y).
The laboratories participating within the EACH study utilised their own standard operating procedures to
classify the CNVs detected by their analytical CMA software. These classifications have been divided into
the following three categories.
1. Pathogenic CNVs with a clearly defined abnormal phenotype (e.g. known microdeletion syndrome) or a
variant with a probability of a phenotypic effect.
2. Variants of unknown significance for which the possible genotype and phenotypic effects were uncertain.
In some cases, based on parental origin studies and informed by local and international CNV data sets, a
local decision was made not to report the VOUS. In other cases, based on the recommendation of the
EACH review panel (see EACH review panel), a decision was made not to report the VOUS.
3. Common variants, or those recognised as benign and not relevant to the presenting phenotype, were
not reported. These cases included those on the EACH predetermined list of CNVs (see Table 1).
The EACH review panel
The EACH review panel consisted of five consultant clinical cytogeneticists and five consultant clinical
geneticists chaired by DGW. Cases for review were sent to the clinical (DGW) and scientific (JAC) leads for
distribution and decision feedback by e-mail. All cases were examined by a quorum of two geneticists and
two cytogeneticists. The length of time between referral and decision was recorded as well as the details
of the case and the final recommendation of the panel.
At the outset of the study, it was planned that only CNVs with direct relevance to the ongoing clinical fetal
phenotype would be reported but this was amended when VOUS with significant clinical risks to other
and/or future family members were recorded {e.g. the 455-kb deletion with a maternally inherited Duchenne
muscular dystrophy (DMD) gene ascertained in a set of female twins [NCL65675(2)], which was classified as a
pathogenic variant}.
Final result groupings
Based on the results of the karyotype and CMA and any follow-up tests, the results of the EACH study
were grouped as follows:
l normal karyotype and normal CMA
l abnormal karyotype and normal CMA
l abnormal karyotype and pathogenic CNV on CMA
l normal karyotype and pathogenic CNV on CMA
l normal karyotype and VOUS on CMA.
Two more complex scenarios arose when assigning final result groups:
1. The finding of a VOUS on CMA when it was assessed that there was a high probability of a phenotypic
effect but one of the parents was unavailable either for analysis or to confirm parental origin and/or
parental phenotype. Such cases were assigned to the ‘pathogenic CNV’ group.
2. The finding of a pathogenic CNV on CMA but the karyotype failed and, given the CMA result, the
karyotype was not repeated by the laboratory. The two cases in this group (CAN62785 and
UCH1372792) were assigned to the ‘abnormal karyotype and pathogenic CNV on CMA’ group.
METHODS
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Evaluation of laboratory turnaround time
Turnaround times for conventional karyotyping and CMA were measured from the date the fetal sample
was received in the laboratory to the date the final karyotype or CMA report was issued by the laboratory.
This reflects the way in which NHS laboratories collect reporting time data for comparison with Clinical
Pathology Accreditation (CPA) standards. This TAT not only includes the technical aspects of the testing
but also a robust process of writing, reviewing and authorising the test reports. Laboratories followed their
own reporting protocols and the EACH study design had no direct impact on the order in which the
karyotyping and CMA results were reported. The EACH laboratory protocol also required that all samples
were first tested using QF-PCR. The time taken for QF-PCR was not analysed separately but considered
part of the overall reporting process.
The EACH study assessed the use of CMA within the context of prenatal diagnosis of chromosomal
anomalies in the UK NHS. The primary responsibility of participating laboratories was therefore to provide
the commissioned test (i.e. karyotyping) and CMA was a supplementary technique, although laboratories
strove to produce the CMA report as quickly as possible. To try and better understand the actual
timescales for undertaking and reporting each test, including the time taken to perform any additional
laboratory tests (e.g. parental karyotyping, parent versus parent CMA), laboratories were also asked to
record the following on Cartagenia Bench:
(a) the dates the karyotype and CMA were set up and reported
(b) the dates any follow-up tests were set up and reported.
Given the EACH design, use of the date of CMA set-up and reporting may provide a more reliable
estimate of TAT should CMA replace karyotyping and, hence, be carried out as a standalone test.
Exclusions
Karyotype TAT results excluded data from London centres because karyotype testing was rarely performed
by the participating laboratory (NETRGL at Great Ormond Street Hospital, London), the majority being
undertaken by other non-NHS providers.
Economic analysis
Implementation of CMA into prenatal diagnosis may have significant cost consequences. The costs of
the CMA test and associated costs of reviewing the results are expected to be higher than the costs
of conventional karyotyping. In addition, women undergoing CMA may need extra clinical visits or
additional tests to investigate an abnormality. The EACH economic analysis aimed to investigate the
cost-effectiveness of replacing conventional karyotyping with CMA in the prenatal diagnosis pathway of
fetal anomalies.
Model structure
A decision-analytic model was developed describing the two diagnostic options (conventional karyotyping
and CMA) and the possible pathways following these. The structure of this model is depicted in Figure 2.
The population consists of women referred for diagnostic testing (karyotyping) with a normal QF-PCR
result. In the karyotyping pathway, women underwent either CVS or amniocentesis. A small proportion
of cases had diagnostic testing on other fetal tissues (e.g. fetal blood) but, for simplification, they were
not considered in this model. In the case of an abnormal karyotype, a proportion of women underwent
one or more follow-up tests (see Chapter 3). If the karyotype was normal, women did not undergo any
follow-up tests. In the CMA pathway, array CGH was performed using extracted DNA. When the result of
the test showed a CNV, a proportion of women underwent one or more follow-up tests (see Chapter 3).
If these suggested a benign variant, no further action was taken but, if the results suggested a pathogenic
CNV or a VOUS, some cases were referred to the EACH review panel, which made a recommendation
about whether or not the variant was likely to be clinically significant and should be reported.
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Model inputs
Data from the EACH study (collected on Cartagenia Bench) were used to identify the number of women in
each branch of the pathway. All women underwent karyotyping as well as CMA and the analysis was
run for all women referred for diagnostic testing, but also separately for women in the increased NT and
structural anomaly groups. As in the main EACH analysis, cases for which the fetus had a structural
anomaly and an increased NT were analysed in the structural anomaly group.
Costs
Data on the costs of karyotyping and CMA were collected from nine cytogenetic laboratories participating
in the EACH study. The average costs were used as base-case values in the current model. Costs of
laboratory follow-up testing were collected from WRGL, Salisbury. Costs of clinical follow-up (either at a
clinical genetics and/or a fetal medicine department) focused specifically on follow-up consultations related
to test results (i.e. not just because of the underlying ultrasound finding). These costs were estimated using
NHS reference costs.51 Finally, we estimated the costs of the EACH panel review by looking at the time
spent on each case and the number of participants in the panel. The costs per minute for a medical
consultant and a senior laboratory scientist were estimated using data from the Personal Social Services
Research Unit.52 We assumed that for each review there was an equal chance that each person involved
Karyotyping
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diagnostic testing
CVS
pCNV
VOUS
Normal karyotype
Normal/bCNV
Abnormal karyotype
Normal karyotype
Abnormal karyotype
No follow-up test
Follow-up test
Follow-up test
Follow-up test
No follow-up test
No follow-up test
No follow-up test
No follow-up test No panel/review
No panel/review
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Panel/review
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Panel/review
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Follow-up test
No follow-up test
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FIGURE 2 Decision tree depicting the current diagnostic pathway and the new pathway using CMA.
AM, amniocentesis; bCNV, benign copy number variant; pCNV, pathogenic copy number variant.
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was a medical consultant or a senior laboratory scientist. All costs are expressed in 2012–13 British pounds.
The time horizon in this study was the duration of pregnancy and, therefore, no discounting was necessary.
Model outputs
The main outcome of the model was the incremental costs per pathogenic CNV detected by CMA
compared with conventional karyotyping, using the base-case values for every parameter. This summarises
how much more it costs to detect one additional significant abnormality with CMA than karyotyping. In
the UK, the recommended outcomes for economic evaluations are quality-adjusted life-years (QALYs) and
the recommended cost-effectiveness measure is based on the incremental costs per QALY gained.53 One
advantage of using the incremental costs per QALY gained is that there is a published threshold that can
be used to judge whether or not an intervention is good value for money (£20,000 to £30,000 per QALY
gained53). However, measuring QALYs arising from prenatal testing is challenging. It is problematic to
determine the quality of life of a child with an abnormality and of other unaffected children as well as the
quality of life of the parents. There is also uncertainty about what happens when a pregnant mother
decides to terminate an affected pregnancy. She might get pregnant again and have another (healthy)
baby or she might not. Owing to these complexities, the economic consequences of prenatal testing are
not usually reported using QALYs.
Uncertainty around our input parameters was taken into account using one-way sensitivity analysis and
probabilistic sensitivity analysis. In the one-way sensitivity analysis, parameters were varied one at a time
over a plausible range (mostly equal to 95% confidence limits) to assess how the main outcome varied.
A scenario analysis was performed excluding the costs of the review panel to investigate the costs per case
detected if no review panel would be required or if it were not available. In this scenario, we assumed that
the costs of the review panel were £0 but that the outcomes in terms of abnormalities would not change.
A probabilistic sensitivity analysis was performed, producing 1000 simulations of the outputs based on
drawing random samples from the probability distributions of all input parameters to calculate the chance
that CMA would be cost-effective at different levels of willingness to pay for extra cases detected. Beta
distributions were used for all probabilities and gamma distributions for all costs.
Statistical analysis
The sample size was based on a comparison of the rates of chromosome imbalances and pathogenic CNVs
detected by karyotyping and CMA in each of the two target populations using McNemar’s test for paired
binary outcomes (for each fetus each result is either normal or abnormal, giving four possible outcome pairs)
and a quantification of the difference in detection rates. A sample of 500 in each target population gave in
excess of 90% power to detect a difference in detection rates at the 5% significance level, assuming that
karyotyping and CMA detected anomalies in 5% and 10% of fetuses, respectively (nQuery 6.0, Statsols,
Cork, Ireland). This increase in diagnostic yield was deemed clinically important by collaborators and was
consistent with the meta-analysis reported by Hillman et al.36 in 2011. Array CGH was assumed to detect all
the imbalances detected by karyotyping (i.e. the proportion of discordant outcomes was assumed to be close
to 5%). This sample size would give a 95% CI for the difference in detection rates of ±2%.
Continuous variables were described by either means (standard deviations) or medians [interquartile ranges
(IQRs)] depending on their distribution and binary and categorical variables were described using numbers
(proportions). The proportions of subjects with pathogenic CNVs and VOUS were calculated with exact
95% CIs. Statistical comparisons of pathogenic CNVs/VOUS between karyotyping and CMA were made
using McNemar’s test and the exact version of the test was used when numbers were too small.
Comparisons between patient subgroups (e.g. NT of ≤/> 6 mm) were made using the chi-squared test,
and Fisher’s exact test was used when numbers were too small. A statistical comparison of the differences
in TATs between karyotyping and CMA was made using the paired t-test. A comparison of times by
laboratory, year and epoch was made using one-way analysis of variance; the Kruskal–Wallis test was used
when the distribution of times was skewed.
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Qualitative substudy
The qualitative substudy aimed to explore the ways in which CMA is viewed by parents, health
professionals and commissioners, and to examine the social and policy issues that result from the
experiences of those most closely involved with the intervention.
The sampling approach used was purposive, to enhance the diversity of views represented within the sample
(rather than aiming to be statistically representative of some wider population). Women who had participated
in the main EACH trial at two of the study sites (Newcastle and Leeds) were asked at the time of consent
whether or not they would agree to be interviewed about their experience. The details of those who agreed
were passed to the researcher (CL), who posted them a study pack a minimum of 3 months after completion
of the pregnancy (birth or termination of pregnancy). The pack contained information about the substudy
and a consent to contact form with a reply slip. Those agreeing were contacted and an interview was
arranged at a place of their choosing. After 2–4 weeks, if no reply had been received, women were sent a
further letter by way of reminder. If no response was received it was assumed that they did not wish to take
part and no further contact was made. The aim was to undertake a total of 15–20 parent interviews (with up
to 10 in each of the two study groups). Once sufficient numbers of women who had received ‘normal’ CMA
results had been interviewed, women with a pathogenic CNV only were purposively sampled. Owing to
difficulties recruiting sufficient women with an abnormal result, recruitment was extended to involve a third
study site (Birmingham).
Health professionals from two of the study sites (Newcastle and Leeds) were identified by using an initial
list of eligible professionals compiled by the principal investigator at each site. From this list, a purposive
sample was identified to ensure the inclusion of a range of professional viewpoints. National and local
commissioners were identified through a convenience sample through a contact with the Accountable
Commissioner for NHS commissioning of national specialised fetal medicine services.
Identified individuals were sent a study pack by post or e-mail (via their work addresses) with a consent
to contact form and reply slip. Those agreeing were contacted and an interview was arranged at a place
of their choosing. If no response was received from the initial invitation, professionals were sent another
invitation 2–4 weeks later by way of reminder. If no response was received, it was assumed that they did
not wish to take part and no further contact was made. The aim was to undertake a total of 15–20
professional interviews.
Prior to the planned interviews, the participant was given the opportunity by CL to ask any questions.
If the participant was happy to proceed, written consent was obtained. Data collection was via in-depth,
semistructured, interviews with the participants. This allowed the researcher to draw on a standard topic
guide (see Appendices 3 and 4) to ensure that key topics were covered, but also allowed participants
sufficient freedom to describe their experiences in a narrative of their choice. All interviews were audio-
recorded, transcribed verbatim and anonymised. All participants were given a study identifier and all
identifying names and locations were removed from the transcripts and replaced with identifiers. The
anonymised transcripts formed the data for the analysis.
The data analysis was informed by a generative thematic approach,54 drawing on Silverman’s55 approach
to the analysis of interview texts to evaluate how participants describe and conceptualise their experiences.
The qualitative analysis software package ATLAS.ti (version 7.0, Cleverbridge AG, Cologne, Germany) was
used to facilitate the thematic analysis of the data. The parent data and the professional data were analysed
as separate groupings initially, before being brought together for the final analysis. Each transcript was
coded by the substudy research associate (CL). Another member of the project team (RG) worked with a
sample of the transcripts to contribute to the design of the coding framework and to provide an element of
inter-rater reliability to the coding of the data. After the data were coded, they were organised into key
themes and subthemes.
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Chapter 3 Results
Study recruitment
Cases were recruited from 20 fetal medicine units with samples analysed in nine cytogenetic laboratories
in England and Wales (Table 2). Two large centres (Cardiff and Birmingham) joined the study after the
initial set-up, having secured independent resources (for staff and consumables). In total, 1718 probands
were recruited to the EACH study between May 2012 and May 2014 (Figure 3).
A total of 1460 (85.0%) women also gave consent to contact them after birth to arrange assessment of their
infant. A paternal blood sample was obtained in 1347 (78.4%) cases. Thus, in total, 3065 subjects consented
to the study. The source tissue used for DNA extraction was recorded in 1546 cases (90.0%) (Table 3).
Out of the 1718 probands recruited, 28 were subsequently excluded. The reasons for exclusion are shown
in Table 4. No parent requested withdrawal from the study.
TABLE 2 Cytogenetic laboratories and fetal medicine units contributing to the EACH study
Cytogenetic laboratory Fetal medicine units Number of cases
North East Thames Regional Genetics
Service, London
University College Hospital, London 470
Royal Free Hospital, Londona 1
Royal London Hospitala 2
Homerton University Hospital, Londona 3
Queens Hospital, Romford, Essex 29
Queen Charlotte’s and Chelsea Hospital, London 23
St George’s Hospital, London 123
WRGL, Salisbury Princess Anne Hospital, Southampton 105
Frimley Park Hospital, Camberley 55
Queen Alexandra Hospital, Portsmouth 19
East Anglian Medical Genetics Service,
Cambridge
The Rosie Hospital, Cambridge 59
Norfolk and Norwich University Hospitalb 16
Northern Genetics Service, Newcastle Royal Victoria Infirmary, Newcastle 168
James Cook University Hospital, Middlesbrough 37
Yorkshire Regional Genetics Service, Leeds Leeds General Infirmary, Leeds 118
Merseyside and Cheshire Regional
Molecular Genetics Laboratory, Liverpool
Liverpool Women’s Crown Street Hospital, Liverpool 120
Bristol Genetics Laboratory, Bristol St Michael’s Hospital, Bristol 131
Royal Devon and Exeter Hospital, Exeter 53
All Wales Medical Genetics Service, Cardiffb University Hospital of Wales, Cardiffb 57
West Midlands Regional Genetics
Laboratory, Birminghamb
Birmingham Women’s Hospital, Birminghamb 129
a Centres where recruitment was stopped because of lack of local support.
b Centres that joined the study after initial set-up (not listed in the original Efficacy and Mechanism Evaluation application).
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Out of the 1690 included cases, 509 cases (30.3%) had a common chromosomal anomaly detected by
QF-PCR and, therefore, did not proceed to CMA (Table 5). In a further 10 cases, fetal material was not
available for DNA extraction and subsequent CMA. In total, karyotyping failed in 9 out of 1181 cases
(0.8%) and CMA failed in 39 out of 1171 cases (3.3%).
Thus, 1123 probands with a karyotype and CMA result were available for analysis and this group
constituted the EACH study population (Figure 4).
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FIGURE 3 Number of probands recruited to the EACH study.
TABLE 3 Fetal source tissue used for DNA extraction
Source tissue for DNA extraction Number of cases (%)
Chorionic villi 863 (55.8)
Amniotic fluid 631 (40.8)
Fetal blood 12 (0.8)
Fetal tissue 13 (0.8)
Cultured fibroblastsa 17 (1.1)
a Following failed extraction from the primary sample.
TABLE 4 Reasons for exclusion
Reason for exclusion Number of cases
Failure to meet ultrasound inclusion criteria
Isolated increased NT identified after 14+1 weeks 22
Single or multiple ultrasound variants 4
Insufficient data to classify 2
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TABLE 5 Chromosomal anomalies detected by QF-PCR
Chromosomal anomaly Number (%) of cases
Trisomy 21 231 (45.5)
Trisomy 18 121 (24.0)
Trisomy 13 43 (8.5)
XO 66 (13.0)
Triploidy 26 (5.0)
Aneuploidy with structural chromosome anomaly 14 (2.5)
Autosomal mosaicsa 8 (1.5)
a Involving one of the above listed aneuploidies.
Probands with ultrasound
anomaly recruited to trial
(n = 1718)
Probands eligible for inclusion
(n = 1690)
Probands with karyotype and
CMA EACH study population
(n = 1123)
Isolated NT of > 3.5 mm at 11+2–14+1 weeks
(n = 494)
Structural fetal anomaly
(n = 629)
Paternal blood sample obtained
(n = 1347)
No karyotype result
(n = 9)
• Karyotype failed, n = 9
Exclusions 
(n = 28)
• Isolated increased NT after 14+1 weeks, 
   n = 22
• Ultrasound variant, n = 4
• Insufficient data to classify, n = 2
No CMA result
(n = 49)
• CMA failed, n = 39
• CMA not attempted, n = 10
Chromosomal anomaly on QF-PCR
(n = 509)
FIGURE 4 Trial profile of the EACH study.
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Study groups
Increased nuchal translucency group
Of the 1123 cases making up the EACH study population, 494 (44.0%) had an isolated NT identified on
a routine scan at 11+2 to 14+1 weeks of pregnancy. The clinical characteristics of this group are shown in
Table 6. Pregnancy outcome data were unavailable in 187 (38%) cases but in only 2 out of the 64 (3%)
cases with an abnormal karyotype and/or CMA.
The distribution of recorded NT measurements is shown in Figure 5. A further 20 cases recruited between
11+2 and 14+1 weeks’ gestation had an ultrasound diagnosis of isolated cystic hygroma but no NT
measurement recorded. These cases were included in the increased NT group.
TABLE 6 Clinical characteristics of 494 cases in the increased NT group
Clinical characteristic Data
Age (years), mean (SD) 30.7 (5.4)
Primiparous (%) 197 (47.6%)a
Gestation (weeks), mean (SD) 13.1 (1.5)
NT of > 5mm 161 (32.6%)b
NT of > 6 mm 82 (17.2%)b
Pregnancy outcome Normal karyotype and CMA Abnormal karyotype +/– CMA
Live birth 203 33
Stillbirth/neonatal death 5 3
Miscarriage 6 2
Termination of pregnancy 31 24
Unknown 185 2
Total 430 64
Figures are mean (standard deviation) or number (%).
a Parity was recorded in 414 cases.
b Includes 20 cases with isolated cystic hygroma but no NT measurement.
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FIGURE 5 Nuchal translucency measurements in 474 fetuses in the increased NT group.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
18
Structural anomaly group
A total of 629 cases (56%) had a structural anomaly identified. The clinical characteristics of this group are
shown in Table 7. Pregnancy outcome data were unavailable in 167 (27%) cases but in only 1 out of the
89 (1%) cases with an abnormal karyotype and/or CMA.
The fetal anomalies detected are shown in Table 8 broken down by the body system. Brain anomalies
were the most common (17.6% of all anomalies detected by ultrasound), followed by cardiac (17.5%)
and skeletal (14.5%). Overall, 382 cases (60.7%) had an single (isolated) fetal anomaly.
The distribution of gestational age at diagnosis in the structural anomaly group is shown in Figure 6.
In total, 105 cases (16.7%) were detected at 11–14 weeks’ gestation and 75 (11.9%) were detected after
24 weeks’ gestation.
TABLE 7 Clinical characteristics of the 629 cases in the structural anomaly group
Clinical characteristic Data
Age (years), mean (SD) 30.7 (5.7)
Primiparous (%) 299 (55.8%)a
Gestation (weeks), mean (SD) 20.2 (4.8)
Number of fetal anomalies
One 382 (60.7%)
Two 156 (24.8%)
Three 49 (7.8%)
More than three 42 (6.7%)
Pregnancy outcome Normal karyotype and CMA Abnormal karyotype +/– CMA
Live birth 225 38
Stillbirth/neonatal death 31 4
Miscarriage 11 0
Termination of pregnancy 107 46
Unknown 166 1
Total 540 89
Figures are mean (standard deviation) or number (%).
a Parity was recorded in 536 cases.
TABLE 8 Fetal anomalies detected by ultrasound in the structural anomaly group
Structure Anomaly Isolated Multiple Total
Face Cleft lip and/or palate 29 45 74
Micrognathia 0 9 9
Other (including flat face, abnormal nose, macroglossia,
hypertelorism and not defined)
2 12 14
Total 31 66 97
continued
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TABLE 8 Fetal anomalies detected by ultrasound in the structural anomaly group (continued )
Structure Anomaly Isolated Multiple Total
Brain Ventriculomegaly and/or agenesis of corpus callosum
and/or posterior fossa anomaly
65 23 88
Agenesis of corpus callosum 5 6 11
Posterior fossa anomaly 10 21 31
Holoprosencephaly 7 9 16
Encephalocele 1 3 4
Anencephaly 1 1 2
Cyst 1 2 3
Microcephaly 5 2 7
Other (including abnormal cavum septum pellucidum,
choroid plexus cyst, dolichocephaly and not defined)
1 11 12
Total 96 78 174
Spine Spina bifida and/or ventriculomegaly 13 5 18
Kyphoscoliosis (including hemivertebrae) 0 8 8
Sacrococcygeal teratoma 3 1 4
Other (not defined) 0 7 7
Total 16 21 37
Neck NF of > 6mm at 18+0 to 20+6 weeks 7 29 36
Cystic hygroma 0 9 9
Other (not defined) 0 1 1
Total 7 39 46
Thorax Diaphragmatic hernia 14 5 19
Pleural effusion 10 14 24
Other (including echogenic lungs, short ribs) 1 9 10
Total 25 28 53
Cardiac Abnormal four chamber (specific anomaly undefined) 20 40 60
Abnormal outflow tracts (specific anomaly undefined) 8 1 9
Ventricular septal defect 7 19 26
Atrioventricular septal defect 9 3 12
Tetralogy of Fallot 11 3 14
Hypoplastic left heart 9 4 13
Pulmonary atresia, hypoplastic right heart 5 3 8
Transposition of great arteries 6 1 7
Coarctation of aorta 4 1 5
Pericardial effusion 3 6 9
Other (including total anomalous pulmonary venous
drainage, double outlet right ventricle, dextrocardia,
Ebstein’s anomaly)
1 9 10
Total 83 90 173
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TABLE 8 Fetal anomalies detected by ultrasound in the structural anomaly group (continued )
Structure Anomaly Isolated Multiple Total
Abdominal wall Exomphalos 27 12 39
Other (including bladder exstrophy, body stalk anomaly) 2 2 4
Total 29 14 43
Gastrointestinal tract Isolated ascites 4 13 17
Echogenic bowel and/or liver 0 31 31
Absent stomach or stomach anomaly undefined 0 20 20
Bowel obstruction (including duodenal atresia) 3 9 12
Cyst 1 2 3
Total 8 75 83
Genitourinary tract Megacystis 20 6 26
Multicystic kidney 2 7 9
Hydronephrosis 1 8 9
Renal agenesis 0 4 4
Enlarged echogenic kidney 2 6 8
Other (including pelvic kidney, horseshoe kidney,
duplex kidney)
1 6 7
Abnormal genitalia (including clitoromegaly, microphalus,
bifid scrotum)
0 5 5
Total 26 42 68
Skeletal Talipes 17 27 44
Other hand/foot abnormalities (including absent,
ectrodactyly, polydactyly)
5 22 27
Absent, short or abnormal long bones (including
micromelia and undefined skeletal dysplasia)
14 27 41
Short femur 0 12 12
Flexion/extension anomalies of limbs 6 13 19
Total 42 101 143
Other Hydrops 2 1 3
Fetal growth restriction 11 38 49
Cord anomalies (single umbilical artery, cyst) 0 11 11
Amniotic fluid anomalies (oligohydramnios, hydramnios) 0 7 7
Total 13 57 70
Overall total 376 611 987
DOI: 10.3310/eme04010 EFFICACY AND MECHANISM EVALUATION 2017 VOL. 4 NO. 1
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Robson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
21
Laboratory karyotype and chromosome microarray results
The breakdown of the karyotype and CMA results according to the final EACH groups is shown in Table 9.
In total, 42 cases (3.7%) had a normal karyotype but a pathogenic CNV detected on CMA. A further 38
(3.4%) had a normal karyotype and a VOUS detected on CMA.
The follow-up tests undertaken in each of the final groups are shown in Table 10. In total, 268 additional
investigations were performed and, in some cases, CNVs detected by CMA could be classified as benign
(and, hence, the CMA normal) only after parental origin studies were carried out.
Abnormal karyotype and normal chromosome microarray group
Fifteen (1.3%) cases were found to have an abnormal karyotype and a normal CMA: eight in the increased
NT group (Table 11) and seven in the structural anomaly group (Table 12). Eight cases involved apparently
balanced structural rearrangements, two involved inversions and a further two involved low-grade mosaics
involving autosomal trisomies. The remaining three cases were shown, using FISH, to be heterochromatic
supernumerary marker chromosomes (two derived from either chromosome 14 or 22 and one from
chromosome 15), none of which showed an imbalance on CMA. Further molecular studies on the parental
0
50
100
150
200
N
u
m
b
er
 o
f 
ca
se
s
250
300
350
11–14 15–17 18–21
Gestational age (weeks)
22–24 25–40
FIGURE 6 Gestational age at diagnosis in 629 fetuses in the structural anomaly group.
TABLE 9 Main result groups in the EACH study
Group Increased NT group Structural anomaly group Total (%)
Normal karyotype and normal CMA 430 540 970 (86.4)
Abnormal karyotype and normal CMA 8 7 15 (1.3)
Abnormal karyotype and pathogenic CNV on CMA 26 32 58 (5.2)
Normal karyotype and pathogenic CNV on CMA 13 29 42 (3.7)
Normal karyotype and VOUS on CMA 17 21 38 (3.4)
Total 494 629 1123 (100)
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origin of one of the marker chromosomes (BIRM2357) revealed paternal uniparental disomy (UPD)
for chromosome 14 consistent with a diagnosis of Wang syndrome.
Abnormal karyotype and abnormal chromosome microarray group
A total of 58 visible cytogenetic abnormalities were diagnosed, all of which were also identified and
further characterised by CMA. These comprised three mosaic marker or ring chromosomes, 25 visible
deletions or duplications, 13 numerical abnormalities (not involving chromosomes 13, 18 or 21), 11
unbalanced translocations and six sex chromosome abnormalities (excluding 45X), none of which showed
an additional imbalance on CMA. Twenty-six of these variants were found in the increased NT group
(Table 13) and 32 were found in the structural anomaly group (Table 14).
TABLE 10 Number of follow-up tests performed in each of the main result groups
Group Parental karyotype FISH MLPA PvP Othera Total
Normal karyotype and normal CMA 0 12 3 37 7 59
Abnormal karyotype and normal CMA 14 0 0 1 0 15
Abnormal karyotype and pathogenic CNV on CMA 46 9 0 10 4 69
Normal karyotype and pathogenic CNV on CMA 0 42 15 27 4 88
Normal karyotype and VOUS on CMA 0 18 0 16 3 37
Total 60 81 18 91 18 268
PvP, parent vs. parent CMA.
a Includes 15 cases of QF-PCR.
Note
Multiple tests may have been performed in individual cases.
TABLE 11 Cases in the increased NT group with an abnormal karyotype and normal CMA (n= 8)
Primary
identifier Karyotype
CMA result
(ISCN)
NT
(mm)
Pregnancy
outcome Findings
LIV22978 45,XY,der(13;15)(q10;q10)pat arr(1–22) × 2,
(XY) × 1
5.1 LB (39 weeks),
3820 g
NN: normal. FU: none
UCH1325884 46,X,t(X;2)(q26.3;p21)dn arr(1–22,X) × 2 4.4 TOP (17 weeks) No PM
CAM41514 46,XX,t(13;20)(p13;p11.1)dn arr(1–22,X) × 2 4.6 LB (39 weeks),
3180 g
NN: normal (including
echo). FU: genetics –
normal at 10 weeks
JCU72470 46,XY,t(4;17)(q27;q23,1)mat arr(1–22) × 2,
(XY) × 1
4.0 LB (38 weeks),
3120 g
NN: VSD, positional
talipes right foot. FU:
paediatric cardiology
BIRM2342 47,XX,+16[2]/46,XX[38] arr(1–22,X) × 2 6.9 TOP (16 weeks) PM: achondrogenesis,
pulmonary hyperplasia
EXE43104 47,XX,+mar(15) arr(1–22,X) × 2 4.2 LB (39 weeks),
3390 g
NN: normal. FU: normal
(no details)
NCL112506 47,XY,+mar.ish mar(D14Z1/
D22Z1 +)/46,XY
arr(1–22) × 2,
(XY) × 1
4.0 LB (40 weeks),
3415 g
NN: normal. FU: none
BIRM2357 47,XY,+mar(14/22),
upd(14)pat[7]/46,XY[3]
arr(1–22) × 2,
(XY) × 1
3.6 TOP (21 weeks) No PM
dn, deletion; echo, echocardiography; FU, follow-up; ISCN, International System for Human Cytogenetic Nomenclature;
LB, live birth; mar, marker; mat, maternal; NN, neonatal examination; pat, paternal; PM, post-mortem; TOP, termination of
pregnancy; VSD, ventricular septal defect.
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Normal karyotype and abnormal chromosome microarray group
A total of 42 cases with a normal karyotype and a CMA finding consistent with pathogenic CNV deemed
relevant to clinical findings and prognosis were reported. Thirteen out of the 42 cases were in the
increased NT group (Table 15) and the remaining 29 cases were in the structural anomaly group (Table 16).
A total of 39 cases had a single CNV and three had two CNVs. The parental origins of 36 out of the 42 CNVs
were determined: four were maternal, seven paternal and 25 had arisen de novo.
In two cases (UCH1285528 and SGH86084), the CMA imbalances were subsequently found to be
confined to the placenta (CPM). Both of these cases, which had a normal outcome, represent
false positives.
Excluding the two cases of CPM, 32 of the remaining 40 cases (80%) had at least one CNV within
recognised syndromic regions (e.g. six Di George/velocardiofacial syndrome 22q11.21 deletions, one
17p11.2 Potocki–Lupski syndrome, two 17q12 renal cyst and diabetes imbalances) and eight involved the
coding regions of key developmental genes (e.g. NOTCH2, DMD), or the size and gene content resulted in
classification as pathogenic.
TABLE 12 Cases in the structural anomaly group with an abnormal karyotype and normal CMA group (n= 7)
Primary
identifier Karyotype
CMA result
(ISCN)
GA
(weeks) Anomalies
Pregnancy
outcome Findings
LEE54389 46,XX,t(2;5)
(q21.1;q31.3)
arr(1–22,X) × 2 20 CDH TOP (21 weeks),
310 g
PM: right diaphragmatic
hernia. FGR
UCH1267463 46,XX,t(11;18)
(p15.1:q21.3)
mat
arr(1–22,X) × 2 35 Ebstein’s
anomaly,
hydrops
LB (34 weeks),
2700 g
NN: Ebstein’s anomaly.
Pleural effusions
(drained). FU: paediatric
cardiology
SOU776398 46,XX,t(6;10)
(q14.2?2;
q24.3)pat
arr(1–22,X) × 2 22 CL + P LB (39 weeks) NN: CL + P. FU: cleft
team
BIRM2349 46,XY,t(1;14)
(p13.1;q24.3)
pat
arr(1–22) × 2,
(XY) × 1
22 Pericardial
effusion
LB (33 weeks),
2630 g
Slight thickening
interventricular septum.
No effusion. FU:
paediatric cardiology
BIRM2729 47,XX,+ 20[8]/
46,XX[22]
arr(1–22,X) × 2 20 VM, ACC TOP (23 weeks),
422 g
PM: VM, ACC, mild
micrognathia. FGR
UCH111464 46,XY,inv(15)
(p11.2q11.2)
mat
arr(1–22) × 2,
(XY) × 1
13 Megacystis SB (35 weeks),
1880 g
PM: ASD, left SVC,
pulmonary agenesis
(right), TOF, renal
agenesis (bilateral),
urethral aresia,
polysplenia, intestinal
malrotation, anal atresia,
polymicrogyria and
global hypoxic ischaemia
UCH1336195 46,XY,inv(14)
(q24.3q32.3)
mat
arr(1–22) × 2,
(XY) × 1
20 VM, ACC TOP (21 weeks) No details
ACC, agenesis of the corpus callosum; ASD, atrial septal defect; CDH, congenital diaphragmatic hernia; CL+ P, cleft lip and
palate; FGR, fetal growth restriction; FU, follow-up; GA, gestational age; ISCN, International System for Human Cytogenetic
Nomenclature; LB, live birth; mat, maternal; NN, neonatal examination; pat, paternal; PM, post-mortem; SB, stillbirth;
SVC, superior vena cava; TOF, tracheo-oesophageal fistula; TOP, termination of pregnancy; VM, ventriculomegaly.
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Within this group, 17 cases were referred to the panel and in 16 cases it was recommended the result was
reported. There were two cases for which CMA diagnosed a cryptic chromosome abnormality undetected
by karyotyping:
1. an interstitial proximal 15q duplication involving the Prader–Willi/Angelman critical region which had
arisen on the maternal homologue (BIRM3619)
2. a mosaic trisomy 2 (LIV23966–2) (not visible cytogenetically from cultured CVS cells).
Normal karyotype and variants of unknown significance on chromosome
microarray
In total, 38 cases with a normal karyotype were classified as having VOUS on CMA. This excluded
eight cases on the EACH exclusion list (see Table 1), which consisted of six 15q11.2 BP1–BP2 imbalances
(ranging in size from 319 to 448 kb), one 1q21.1 duplication (1.9 Mb) and one 16p13.11 duplication
(1.6 Mb). Of the remaining 38 VOUS, 17 were in the increased NT group (Table 17) and 21 were in the
structural anomaly group (Table 18). Twelve cases were referred to the EACH review panel and in each
case the panel recommended not reporting the VOUS.
Detection rates of imbalances in each subject group
Increased nuchal translucency group
The percentages of pathogenic CNVs and VOUS in fetuses with a NT of ≥ 3.5 mm are shown in Table 19.
There was no difference in the rates of abnormal karyotype and pathogenic CNV on CMA, but the rate
of any CNV (pathogenic + VOUS) on CMA was 4.5% (95% CI 1.8% to 7.1%) higher than the rate of
abnormal karyotype.
The relationship between karyotypes and CNVs on CMA in fetuses with a NT of > 3.5 mm is shown in
Table 20.
The percentages of pathogenic CNVs and VOUS in the subgroup of 159 fetuses with a NT of > 5 mm
and the 83 fetuses with a NT of > 6 mm (including those with cystic hygroma) are shown in Table 21. In all
subgroups except those with a NT of > 6 mm the percentages of any CNV on CMA were greater than the
percentages of abnormal karyotype.
The relationship between imbalances detected by karyotyping and CMA in fetuses with a NT of ≤ 5 mm
and of > 5 mm and in fetuses with a NT of ≤ 6 mm and of > 6 mm is shown in Table 22.
Abnormal karyotype was more common in fetuses with a NT of > 5 mm than in those with a NT of
≤ 5 mm (p = 0.003), but there was no difference when 6 mm was used as a cut-off point. Similarly,
pathogenic CNVs were more frequent in fetuses with a NT of > 5 mm than in those with a NT of ≤ 5 mm
(p < 0.003), but there was no difference when 6 mm was used as a cut-off point. There was no difference
in the rates of any CNV using either cut-off point.
Structural anomaly group
The percentages of pathogenic CNVs and VOUS in fetuses with one or more structural anomalies are
shown in Table 23. This includes the 36 fetuses with increased NT and one or more structural anomalies.
The rate of pathogenic CNVs on CMA was 3.5% (95% CI 1.5% to 5.5%) higher than the rate of
abnormal karyotype (p < 0.001). The rate of any CNV (pathogenic + VOUS) was 6.8% (95% CI 4.4% to
9.3%) higher than the rate of abnormal karyotype.
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TABLE 19 Percentages of abnormal karyotypes and CNVs on CMA in the increased NT group
Group n Percentage (95% CI) Percentage difference (95% CI) p-value
Abnormal karyotype 34 6.9 (4.8 to 9.5)
Pathogenic CNV on CMA 39 7.9 (5.7 to 10.6) 1.0 (–1.0 to 3.0) 0.28
VOUS on CMA 17 3.4 (2.0 to 5.5)
Any CNV on CMA 56 11.3 (8.7 to 14.5) 4.5 (1.8 to 7.1) < 0.001
Percentage differences (and p-values) refer to CMA vs. karyotyping.
TABLE 20 Number of imbalances detected by karyotype and CMA in the increased NT group
Group CMA
Karyotyping No CNV Pathogenic CNV VOUS
Normal 430 13 17
Abnormal 8 26 0
TABLE 21 Percentages of abnormal karyotypes and CNVs on CMA in fetuses with a NT of > 5mm and a NT
of > 6mm
Group n Percentage (95% CI) Percentage difference (95% CI) p-value
NT of ≤ 5mm (n= 335)
Abnormal karyotype 19 5.7 (3.5 to 8.8)
Pathogenic CNV on CMA 18 5.4 (3.2 to 8.4) –0.3 (–2.5 to 1.9) 0.76
Any CNV on CMA 32 9.6 (6.6 to 13.2) 3.9 (0.7 to 7.1) 0.009
NT of > 5mm (n= 159)
Abnormal karyotype 15 9.4 (5.4 to 15.1)
Pathogenic CNV on CMA 21 13.2 (8.4 to 19.5) 3.8 (–0.7 to 8.3) 0.11
Any CNV on CMA 24 15.1 (9.9 to 21.6) 5.7 (0.7 to 10.6) 0.022
NT of ≤ 6mm (n= 411)
Abnormal karyotype 26 6.4 (4.2 to 9.2)
Pathogenic CNV on CMA 29 7.1 (4.8 to 10.0) 0.7 (–1.5 to 3.0) 0.47
Any CNV on CMA 44 10.7 (7.9 to 14.1) 4.4 (1.5 to 7.3) 0.001
NT of > 6mm (n= 83)
Abnormal karyotype 8 9.6 (4.3 to 18.1)
Pathogenic CNV on CMA 10 12.0 (5.9 to 21.0) 2.4 (–3.4 to 8.1) 0.63
Any CNV on CMA 12 14.5 (7.7 to 23.9) 4.8 (–2.1 to 11.7) 0.22
Percentage differences (and p-values) refer to CMA vs. karyotyping.
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The relationship between imbalances detected by karyotyping and CMA in fetuses with a structural
anomaly is shown in Table 24.
The percentages of pathogenic CNVs and VOUS in the subgroup of 253 fetuses (40.2%) with multiple
structural anomalies are shown in Table 25. In both subgroups of fetuses, the percentages of pathogenic
CNV and any CNV were greater than the percentages of abnormal karyotype. However, although the rate
of pathogenic CNVs on CMA was marginally higher in fetuses with multiple structural anomalies than in
those with one structural anomaly, the difference was not statistically significant (p = 0.34).
The relationship between imbalances detected by karyotyping and CMA in fetuses with one or more
structural anomalies is shown in Table 26.
TABLE 22 Number of imbalances detected by karyotype and CMA in fetuses with a NT of > 5mm and a NT
of > 6mm
Group
CMA
No CNV pCNV VOUS
NT of ≤ 5mm (n = 335)
Karyotyping
Normal 297 5 14
Abnormal 6 13 0
NT of > 5mm (n = 159)
Karyotyping
Normal 133 8 3
Abnormal 2 13 0
NT of ≤ 6mm (n = 409)
Karyotyping
Normal 358 10 15
Abnormal 7 19 0
NT of > 6mm (n = 85)
Karyotyping
Normal 72 3 2
Abnormal 1 7 0
pCNV, pathogenic copy number variant.
TABLE 23 Percentages of abnormal karyotypes and CNVs on CMA in the structural anomaly group
Group n Percentage (95% CI) Percentage difference (95% CI) p-value
Abnormal karyotype 39 6.2 (4.4 to 8.4)
Pathogenic CNV on CMA 61 9.7 (7.5 to 12.3) 3.5 (1.5 to 5.5) < 0.001
VOUS on CMA 21 3.3 (2.1 to 5.1)
Any CNV on CMA 82 13.0 (10.5 to 15.9) 6.8 (4.4 to 9.3) < 0.001
Percentage differences (and p-values) refer to CMA vs. karyotyping.
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The percentages of pathogenic CNV and VOUS in fetuses with a cardiac anomaly (whether isolated or
associated with other structural anomalies) and without a cardiac anomaly are shown in Table 27. In both
subgroups the rates of pathogenic CNVs and any CNV were higher than the rate of abnormal karyotype.
The relationship between imbalances detected by karyotyping and CMA in fetuses with and without a
cardiac anomaly is shown in Table 28.
There was no difference in the percentage of abnormal karyotypes or any CNV among fetuses with and
without a cardiac anomaly. However, the percentage of pathogenic CNVs was greater in the subgroup of
fetuses with a cardiac anomaly than in the subgroup without (p = 0.013).
TABLE 24 Number of imbalances detected by karyotype and CMA in the structural anomaly group
Group CMA
Karyotyping No CNV Pathogenic CNV VOUS
Normal 540 29 21
Abnormal 7 32 0
TABLE 25 Percentages of abnormal karyotypes and CNVs on CMA in fetuses with one structural anomaly and
fetuses with multiple structural anomalies
Group n Percentage (95% CI) Percentage difference (95% CI) p-value
One structural anomaly (n = 376)
Abnormal karyotype 22 5.9 (3.7 to 8.7)
Pathogenic CNV on CMA 33 8.8 (6.1 to 12.1) 2.9 (0.2 to 5.7) 0.022
Any CNV on CMA 43 11.4 (8.3 to 15.1) 5.3 (2.3 to 8.8) < 0.001
Multiple structural anomalies (n= 253)
Abnormal karyotype 17 6.7 (4.0 to 10.5)
Pathogenic CNV on CMA 28 11.1 (7.5 to 15.6) 4.3 (1.2 to 7.5) 0.003
Any CNV on CMA 39 15.4 (11.2 to 20.5) 8.7 (4.7 to 12.7) < 0.001
Percentage differences (and p-values) refer to CMA vs. karyotyping.
TABLE 26 Number of imbalances detected by karyotype and CMA in fetuses with one structural anomaly and
fetuses with multiple structural anomalies
Group
CMA
No CNV Pathogenic CNV VOUS
One structural anomaly (n = 376)
Karyotyping
Normal 327 17 10
Abnormal 6 16 0
More than one structural anomaly (n = 253)
Karyotyping
Normal 213 12 11
Abnormal 1 16 0
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Laboratory turnaround times
For the TAT analysis, the results from the increased NT and structural anomaly groups were combined,
as were the results from amniotic fluid and chorionic villus samples.
The TATs for karyotyping and CMA are shown in Table 29. Valid dates for sample receipt and karyotype
report were available for 685 cases with a median interval of 12 days (IQR 10–14 days). Valid dates for
sample receipt and CMA report were available for 714 cases with a median of 15 days (IQR 12–25 days).
The median difference between the karyotype and CMA TAT was 3 days (IQR 0–13 days) and this was
statistically significant (p < 0.0001). The median TAT for cases for which additional investigations were
required is also shown in Table 29.
A further analysis was performed on times from test set-up to report. As expected, given the EACH
laboratory protocol, the median time for karyotyping was very similar to the TAT reported above (median
12 days, IQR 9–14 days). However, for CMA, when the test was set up after the QR-PCR result was
available, the time was much shorter (median 6 days, IQR 4–9 days). The median difference between
karyotype and CMA TAT was –5 days (IQR –8 to –2 days), indicating that TATs from set-up to report were
quicker with CMA (p < 0.0001).
TABLE 27 Percentages of abnormal karyotypes and CNVs on CMA in fetuses without a cardiac anomaly and fetuses
with a cardiac anomaly
Group n Percentage (95% CI) Percentage difference (95% CI) p-value
No cardiac anomaly (n = 456)
Abnormal karyotype 25 5.5 (3.6 to 8.0)
Pathogenic CNV on CMA 36 7.9 (5.6 to 10.8) 2.4 (0.2 to 4.6) 0.016
Any CNV on CMA 53 11.6 (8.8 to 14.9) 6.2 (3.3 to 9.0) < 0.001
Cardiac anomaly (n= 173)
Abnormal karyotype 14 8.1 (4.5 to 13.2)
Pathogenic CNV on CMA 25 14.5 (9.6 to 20.6) 6.4 (1.5 to 11.2) < 0.001
Any CNV on CMA 29 16.8 (11.5 to 23.2) 8.7 (3.3 to 14.0) 0.001
Percentage differences (and p-values) refer to CMA vs. karyotyping.
TABLE 28 Number of imbalances detected by karyotype and CMA in fetuses without a cardiac anomaly and fetuses
with a cardiac anomaly
Group
CMA
No CNV Pathogenic CNV VOUS
No cardiac anomaly (n = 456)
Karyotyping
Normal 398 16 17
Abnormal 5 20 0
Cardiac anomaly (n = 173)
Karyotyping
Normal 142 13 4
Abnormal 2 12 0
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Factors affecting chromosome microarray turnaround time
Laboratory
To determine if there were differences between laboratories in terms of CMA TAT, median intervals were
compared (Table 30). The differences between laboratories were statistically significant (p < 0.0001).
A similar comparison was undertaken for times from CMA set-up to report (Table 31). As with the overall
TATs, the differences between the laboratories for these times were statistically significant (p = 0.0001),
suggesting that some laboratories were able to perform, interpret and report the CMA faster than others.
Duration of study
To determine if increasing laboratory experience with CMA affected TAT, median intervals were compared
for three successive time epochs (with approximately equal numbers of cases) (Table 32). The differences
between epochs were statistically significant (p = 0.007).
TABLE 29 Laboratory TATs (days) for karyotyping and CMA
Group Median (days) IQR
Karyotyping
Sample receipt to report: all cases (n= 685) 12 10–14
Sample receipt to report where parental karyotyping performed (n= 23) 19.5 14–25.5
Set-up to report: all cases (n = 588) 12 9–14
CMA
Sample receipt to report: all cases (n= 714) 15 12–25
Sample receipt to report: cases where parent vs. parent array performed (n= 61) 22 18–29
Sample receipt to report: cases where FISH performed (n= 17) 26 19–41
Set-up to report: all cases (n = 1105) 6 4–9
n; number of cases with valid dates available.
For karyotyping, figures exclude cases from London fetal medicine units (n= 691).
TABLE 30 Median (IQR) CMA TATs for each GL/GS contributing to the EACH study
Laboratory Number Median TAT (days) (IQR)
West Midlands Regional GL 105 11 (9–14)
East Anglian Medical GS 45 18 (14–29)
All Wales Medical GS 30 28.5 (22–47)
Bristol GL 113 16 (14–26)
Merseyside and Cheshire Regional GL 84 15 (13–32)
Wessex Regional GL 116 12 (9–15)
Northern GS 99 15 (13–19)
Yorkshire Regional GS 66 26 (15–32)
GL, genetic laboratory; GS, genetics service.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
46
The EACH review panel
In total, 32 cases were referred to the EACH review panel (Table 33). Details of the individual cases are
reported in Tables 13–18. In total, the panel recommended that 16 CNVs should be reported, which included
one case for which the karyotyping failed but CNV was deemed pathogenic by the panel (UCH1372792). In
one case (SOU382387), owing to the complex nature of the CNV, the 22q11.2 deletion was not reported
immediately, but after parental follow-up studies had been completed.
When full parental data were available to the panel, the median time to reach a decision was 3 days
(range 1–7 days). When full parental data were not initially available (n = 4), the length of time to make a
recommendation ranged from 6 to 14 days. In 24 cases, two clinical geneticists and two cytogeneticists
reached a decision with at least a 3 out of 4 consensus. In eight cases, additional colleagues were asked
for an opinion when consensus could not be reached or when there was considerable uncertainty about
whether or not to recommend reporting. The relationship between the size of the CNV and the panel
decision is shown in Table 34. It is noteworthy that 9 out of the 16 CNVs (56%) that were recommended
for reporting were < 1 Mb in size, whereas 6 out of 16 (38%) of those not reported were > 1 Mb.
Health economic analysis
A list of data used in the decision-analytic model is provided in Table 35. The decision tree depicting the
current diagnostic pathway and the new pathway using CMA, with corresponding percentages in each
TABLE 31 Median (IQR) times from set-up to reporting of CMA for each GL/GS contributing to the EACH study
Laboratory Number Median TAT (days) (IQR)
West Midlands Regional GL 105 2 (2–5)
East Anglian Medical GS 49 3 (2–5)
All Wales Medical GS 30 9 (6–17)
Bristol GL 115 5 (2–8)
Merseyside and Cheshire Regional GL 86 6 (4–10)
Wessex Regional GL 117 6 (6–7)
Northern GS 136 7 (6–8)
Yorkshire Regional GS 66 6 (3–8)
North East Thames Regional GS 398 8 (5–12)
GL, genetic laboratory; GS, genetics service.
TABLE 33 Summary of cases referred to EACH review panel and their recommendation about reporting the CNV
Group Report Not report
Increased NT (n = 11) 7 6
Structural anomaly (n= 21) 9 10
TABLE 32 Median (IQR) TAT in three successive time epochs during the EACH study
Epoch Number Median TAT (days) (IQR)
One (November 2011to April 2013) 242 17 (13–28)
Two (April 2013 to November 2013) 239 14 (12–22)
Three (November 2013 to May 2014) 233 14 (12–22)
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TABLE 34 Relationship between size of the CNVs on CMA and the decision of the EACH review panel to
recommend reporting or not (n= 32 cases)
Size of CNV
Reported Not reported
Deletions Duplications Deletions Duplications
< 500 kb 4 3 4 2
500–1000 kb 1 1 – 4
1–2Mb 3 1 1 2
> 2Mb 3 1 2
Total 8 8 6 10
TABLE 35 Data used in decision-analytic model
Parameter All cases (n= 1123) Increased NT (n= 494)
Structural anomaly
(n= 629)
Invasive test
Chorionic villus sample 51.4 (48.5 to 54.4) 87.5 (84.4 to 90.3) 22.4 (18.9 to 25.6)
Amniocentesis 48.6 (45.6 to 51.5) 12.5 (9.7 to 15.6) 77.8 (74.4 to 81.1)
Test results
Karyotype abnormal 6.5 (5.1 to 8.0) 6.9 (4.9 to 9.3) 6.2 (4.5 to 8.2)
Pathogenic CNV on CMA 8.9 (7.3 to 10.6) 7.9 (5.7 to 10.4) 9.7 (7.5 to 12.1)
VOUS on CMA 3.4 (2.5 to 4.6) 3.4 (2.0 to 5.2) 3.5 (2.2 to 5.1)
Cases undergoing follow-up tests
Karyotype abnormal 56.2 (44.7 to 67.3) 52.9 (36.4 to 69.2) 59.0 (43.4 to 73.7)
Pathogenic CNV on CMA 73.0 (63.9 to 81.2) 66.7 (51.3 to 80.4) 77.0 (65.8 to 86.6)
VOUS on CMA 48.7 (33.4 to 64.2) 29.4 (11.0 to 52.4) 63.6 (43.0 to 81.9)
Other (benign) CNV on CMA 4.6 (3.4 to 6.1) 5.4 (3.6 to 7.9) 3.9 (2.4 to 5.7)
Proportion of follow-up tests
FISH 18.6 (12.7 to 25.3) 20.0 (11.0 to 30.9) 17.6 (10.4 to 26.4)
Parental karyotype 20.7 (14.5 to 27.6) 21.7 (12.3 to 32.8) 20.0 (12.3 to 29.1)
PvP CMA 62.8 (54.8 to 70.4) 65.0 (52.6 to 76.4) 61.2 (50.7 to 71.2)
MLPA 4.1 (1.5 to 7.9) 1.7 (0.0 to 6.1) 5.9 (2.0 to 11.7)
QF-PCR 3.4 (1.1 to 7.0) 3.3 (0.4 to 9.1) 3.5 (0.7 to 8.3)
Other 2.1 (0.4 to 4.9) 3.3 (0.4 to 9.1) 1.2 (0.0 to 4.3)
Cases sent to the EACH review panel
After pathogenic CNV and follow-up test(s) 26.0 (16.7 to 36.6) 23.1 (9.4 to 40.7) 27.7 (16.0 to 41.1)
After VOUS and follow-up test(s) 73.7 (52.4 to 90.3) 99.8 (99.0 to 100) 64.3 (38.6 to 86.1)
Follow-up action: after abnormal result
Genetics consultation 40.9 (32.1 to 49.9) 40.4 (27.0 to 54.6) 41.2 (29.8 to 53.0)
Fetal medicine consultation 67.0 (58.1 to 75.2) 68.1 (54.2 to 80.5) 66.2 (54.6 to 78.8)
Follow-up action: after normal result
Genetics consultation 7.4 (5.9 to 9.1) 5.4 (3.5 to 7.7) 9.1 (6.8 to 11.6)
Fetal medicine consultation 47.9 (44.8 to 51.0) 51.9 (47.3 to 56.5) 44.8 (40.7 to 48.9)
PvP, parent vs. parent CMA.
Figures are mean percentages (95% CIs). Total percentages may add up to more than 100% because cases could undergo
more than one test.
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branch, is shown in Figure 7. Almost half of the women underwent amniocentesis for karyotyping; this
proportion was smaller in the increased NT group (13%) than in the anomaly group (78%). The karyotype
was abnormal in 6.5% of cases, of which 56% underwent further follow-up testing (which was most
often parental karyotyping). Following CMA, a pathogenic CNV was found in 8.9% of cases, of which
73% underwent follow-up testing, and a VOUS was found in 3.4% of cases, of which than 48%
underwent follow-up testing. In the increased NT group, 23% of the pathogenic CNV cases that had a
follow-up test were sent to the EACH review panel, compared with 100% of the VOUS cases. In the
anomaly group, 28% of the pathogenic CNV cases and 64% of the VOUS cases that had follow-up tests
were sent to the panel. Abnormal results (abnormal karyotype or pathogenic CNV) resulted in a genetics
consultation more often than a normal result (41% vs. 7%).
The cost input parameters are summarised in Table 36. There were minimal differences in follow-up
laboratory costs between the two study groups: £390 in the increased NT group compared with £383 in
the structural anomaly group (average £386). There were also minimal cost differences between the
increased NT and structural anomaly groups in terms of the costs of clinical follow-up actions in abnormal
Karyotyping
CMA CVS/AM
AM
Referral for
diagnostic testing
CVS
pCNV
VOUS
Normal karyotype
Normal/bCNV
Abnormal karyotype
Normal karyotype
Abnormal karyotype
6.5% 6.9% 6.2%
93.5% 93.1% 93.8%
93.5% 93.1% 93.8%
56% 53% 59%
44% 47% 41%
44% 47% 41%
6.5% 6.9% 6.2%
56% 53% 59%
51% 79% 36%
3.5% 3.4% 3.5%
49% 29% 64%
27% 33% 23%
74% 100% 64%
74% 77% 72%
26% 0% 36%
8.9% 7.9% 9.7%
87.6% 88.7% 86.8%
73% 67% 77%
95.4% 94.4% 96.1%
4.6% 5.6% 3.9%
26% 23% 28%
No follow-up test
Follow-up test
Follow-up test
Follow-up test
No follow-up test
100%
100%
100%
100%
100%
100%
No follow-up test
No follow-up test
No follow-up test No panel/review
No panel/review
No panel/review
Panel/review
No panel/review
Panel/review
No panel/review
No panel/review
Follow-up test
No follow-up test
Follow-up test
No follow-up test
51% 88% 22%
49% 12% 78%
FIGURE 7 Decision tree depicting the current diagnostic pathway and the new pathway using CMA. Percentages
of cases in each branch are shown: all cases, increased NT group and anomaly group. AM, amniocentesis;
bCNV, benign CNV; pCNV, pathogenic copy number variant.
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cases [£225 vs. £226, respectively (average £226)] and in normal cases [£79 vs. £85, respectively (average
£82)]. Estimated EACH panel costs are shown in Table 37. All costs are expressed in 2012–13 British
pounds. The time horizon in this study was the duration of pregnancy and, therefore, no discounting
was necessary.
Table 38 shows the total costs of the karyotyping pathway and the CMA pathway, as well as the number of
abnormal karyotypes/pathogenic CNVs found in each pathway. If all cases were considered, the costs per
case in the CMA pathway were £113 higher than in the karyotyping pathway, increasing the number of
abnormalities found by 0.024. Therefore, the incremental cost per additional abnormality found was £4703.
The incremental costs and the number of additional abnormalities found were lower in the increased NT
group than in the anomaly group (£96 vs. £127 and 0.01 vs. 0.035, respectively). The incremental costs per
additional abnormality found were £9439 in the increased NT group and £3635 in the anomaly group.
TABLE 36 Cost inputs for cost-effectiveness model
Parameter Base-case value (range) (£) Source
Laboratory primary test
Chorionic villus karyotyping 272 (240–307) The EACH study laboratories
Amniotic fluid karyotyping 234 (212–258) The EACH study laboratories
CMA 322 (280–367) The EACH study laboratories
Laboratory follow-up test
FISH 393 (225–608) The EACH study laboratories (3 × £131a)
Parental karyotype 508 (453–566) Costs of karyotyping (2 × £254b)
PvP CMA 352 (298–413) One × CMA + two additional DNA extractions (2 × £15)
MLPA 300 (171–465) The EACH study laboratories (3 × £100a)
Other 100 Assumed similar to one MLPA
Clinical follow-up action
Clinical genetics consultation 363 (207–561) NHS reference costs 2012–1352
Fetal medicine consultation 116 (66–179) NHS reference costs 2012–1352
PvP, parent vs. parent CMA.
a Best practice dictates that the probe(s) used should be validated on the proband; we therefore assumed three tests per
case (proband, mother and father). FISH costs were £131 per test, QF-PCR costs were £175 per test and MLPA costs
were £100 per test.
b The original karyotype was part of the EACH protocol so only the parental karyotypes were counted (two tests). A
weighted average of the costs of chorionic villus and amniotic fluid karyotyping was used per test (£254).
TABLE 37 Cost inputs for the EACH review panel
Case type
Number
of cases
Resource use Unit costs (per minute)53 (£) Total
People
involved
Minutes/
person
Total
minutes/case
Medical
consultant
Laboratory
scientist Average
Cost
(£)/case
Brief 1 3 15 45 2.32 2.13 2.22 100.08
Average 22 4.27 25 107 2.32 2.13 2.22 237.57
Difficult 8 5 75 375 2.32 2.13 2.22 834.01
Weighted average 387
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Sensitivity analysis
In the one-way sensitivity analysis, only a few parameters were found to affect the results appreciably.
The largest influence was seen for the number of pathogenic CNV results found by CMA. The costs per extra
pathogenic CNV detected would be £13,690 if a pathogenic CNV result was seen in 7.3% of the cases,
compared with £2851 if a pathogenic CNV result was seen in 10.6% of the cases. A similar influence was
seen for the number of abnormal karyotypes. In addition, the costs of CMA influenced the results appreciably
(costs per extra case detected varied from £2872 to £6686 when the costs of the test were varied from £280
to £367). A smaller, but still relevant, influence was seen for the costs of karyotyping and the costs of the panel
review (Figure 8). Similar results were found for the increased NT group and the structural anomaly group. In
the increased NT group, the number of abnormal results found had a very large influence on the results. If the
percentage of pathogenic CNV results was low (lower limit 5.7%) or the percentage of abnormal karyotype
results was high (upper limit 9.3%), CMA was less effective and more costly than karyotyping (dominated by
karyotyping). The costs of chorionic villus karyotyping had a larger influence in the increased NT group (because
the majority of women in this group underwent CVS instead of amniocentesis) and the costs of amniotic fluid
karyotyping had a larger influence in the anomaly group (because the majority of women in this group
underwent amniocentesis).
In the scenario analysis in which the EACH review panel was excluded, CMA increased costs by £102
(costs per extra case detected was £4230) if all cases were considered, by £87 (costs per extra case
detected was £8588) for the increased NT group and by £114 (costs per extra case detected was £3248)
for the anomaly group.
In the probabilistic sensitivity analysis, 0% of the simulations were found to be cost-effective if the
willingness to pay per incremental abnormality found was £1000 and 87% of the simulations were found
to be cost-effective if the willingness to pay was £10,000. Figure 9 shows the chance that CMA would be
cost-effective at different levels of willingness to pay. For cases with an increased NT, the probability that
CMA would be cost-effective was lower (52%) than for cases with a structural anomaly (93%) at a
willingness to pay of £10,000 per incremental abnormality found.
TABLE 38 Base-case results on costs, effects and cost-effectiveness of karyotyping versus CMA
Parameter Total costs (£) Abnormality found Incremental costs per extra case (pCNV) detected (£)
All cases
Karyotyping 485.90 0.065
CMA 598.97 0.089
Increment 113.07 0.024 4703
Increased NT
Karyotyping 499.09 0.069
CMA 594.63 0.079
Increment 95.54 0.010 9439
Anomaly
Karyotyping 475.17 0.062
CMA 602.30 0.097
Increment 127.13 0.035 3635
pCNV, pathogenic copy number variant.
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aCGH result pCNV (95% CI 7.3% to 10.6%)
(a)
Karyotype abnormal (95% CI 5.1% to 8.0%)
Costs array CGH (95% CI £280 to £367)
Costs CVS karyotyping (95% CI £240 to £307)
Costs AM karyotyping (95% CI £212 to £258)
Costs panel review (95% CI £100 to £834)
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aCGH result pCNV (95% CI 5.7% to 10.5%)
(b)
Karyotype abnormal (95% CI 4.8% to 9.3%)
Costs array CGH (95% CI £280 to £367)
Costs CVS karyotyping (95% CI £240 to £307)
Costs AM karyotyping (95% CI £212 to £258)
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(c)
Karyotype abnormal (95% CI 4.4% to 8.2%)
Costs array CGH (95% CI £280 to £367)
Costs CVS karyotyping (95% CI £240 to £307)
Costs AM karyotyping (95% CI £212 to £258)
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FIGURE 8 Tornado diagram of the incremental costs per extra pathogenic CNV detected by CMA vs. conventional
karyotyping thresholds in all cases and by subgroup. (a) All cases; (b) increased NT; and (c) anomaly. aCGH, array CGH;
AM, amniocentesis.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
52
Qualitative substudy
Out of a total of 98 parents, health professionals and commissioners contacted and invited to participate in
the substudy, 48 respondents were interviewed (Table 39): 16 women (five with their partners present) from
the three study sites, 18 health professionals from two study sites and six commissioners. Two women and
three health professionals declined to participate, one woman was not present when the researcher arrived
at her home, one woman agreed to be interviewed but was thereafter not contactable and the remaining
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FIGURE 9 Cost-effectiveness acceptability curves showing the chance that CMA would be cost-effective given
different willingness to pay thresholds in all cases and by subgroup. (a) All cases; (b) increased NT; and
(c) structural anomaly.
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24 women and 20 health professionals never responded. Thus, the response rates for women and health
professionals were 40% and 58%, respectively. The recruitment rate for commissioner participants was 50%.
Out of the six commissioners interviewed, three were involved with commissioning national specialised
services (e.g. fetal medicine and medical genetics) and three with commissioning local services (as part of
the Area Teams within NHS England North). All women and partners were interviewed in their home and
all health professional and commissioners were interviewed at their place of work. The case details of the
parent participants are shown in Table 40.
TABLE 39 Participants in the EACH qualitative substudy
Category SiteA SiteB SiteC Total
Cytogeneticist 2 0 – 2
Fetal medicine midwife 1 3 – 4
Fetal medicine consultant 5 3 – 8
Consultant clinical geneticist 3 2 – 5
Genetic counsellor 2 0 – 2
Women (partner) 5 (2) 9 (2) 2 (1) 16 (5)
Commissioners – – – 6
Total 20 19 3 48
TABLE 40 Clinical characteristics of the 16 cases for which parents contributed interview data
Participant
site/number
Age
(years)
Gestation+
(weeks) Study group
Karyotype
result CMA result
Pregnancy
outcome
SiteA, WOM1 41 Term Increased NT Normal VOUS LB
SiteA, WOM2 42 12+6 Increased NT Abnormal Normal TOP
SiteA, WOM3 35 21+2 SA Normal Normal TOP
SiteA, WOM4 44 39+6 Increased NT Normal VOUS LB
SiteA, WOM5a 34 16+1 Increased NT Abnormal pCNV TOP
SiteB, WOM1 29 13+3 Increased NT+ SA Normal Normal TOP
SiteB, WOM2 36 22 SA Normal Normal SpA
SiteB, WOM3 37 24 SA Abnormal pCNV TOP
SiteB, WOM4a 35 21+3 SA Normal Normal TOP
SiteB, WOM5 31 37+4 Increased NT Normal Normal LB
SiteB, WOM6 27 39+4 Increased NT Normal pCNV LB
SiteB, WOM7 32 35+6 SA Normal pCNV LB
SiteB, WOM8 33 18+1 SA Abnormal pCNV TOP
SiteB, WOM9a 35 Term SA Normal VOUS LB
SiteC, WOM1 32 32+3 SA Normal pCNV TOP
SiteC, WOM2a 41 30+2 SA Normal pCNV TOP
LB, live birth; pCNV, pathogenic copy number variant; SA, structural anomaly; SpA, spontaneous abortion;
TOP, termination of pregnancy.
a Indicates cases interviewed with partners.+Gestation (weeks) at LB, TOP or SA.
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The generative thematic analysis resulted in the identification of four key themes emerging from the data:
(1) the functionality of CMA, (2) introducing CMA into the clinical consultation, (3) decision-making and
(4) embedding CMA into standard clinical practice.
Theme 1: the functionality of chromosome microarray
Referral pathway for chromosome microarray
Women recruited into the EACH study were referred from hospitals with and without a specialised fetal
medicine centre. Referrals were from obstetric consultants and sonographers. Some women had discussed
karyotyping with their consultant prior to referral. The health professionals’ accounts implied that there
were clear guidelines for referral that were generally understood and followed. Exceptions to this occurred
when a referral to a consultant with a special interest in fetal medicine had taken place before a referral to
the specialised centre. Clearly this pathway is appropriate in some cases, potentially preventing women
attending a fetal medicine centre unnecessarily. However, it did have implications for the care of women
whose referral was delayed:
. . . sometimes that’s entirely appropriate but it can occasionally mean that we get a slightly delayed
referral, erm, which . . . depending on gestation can mean that we’re coming up to pretty time
sensitive areas in terms of whether people are approached in 24 weeks by the time they come to see
us with an abnormality.
SiteA, FM2
The parents interviewed recalled how the time between the initial identification of the ultrasound anomaly
and having the diagnostic testing appeared to move slowly: ‘A minute feels like a day’ (SiteB, WOM4). The
time frames for referral to a fetal medicine centre varied from 1 to 10 days, depending on the availability
of appointments, and all parents highlighted how difficult this waiting time was for them. Once referred,
the parents were seen by a fetal medicine consultant and counselled regarding their options for pregnancy
management. Expectations around invasive testing differed between parent participants; those seen in
specialised fetal medicine centres expected to have access to invasive testing on the same day:
I just wished I could just hopped on that bed that day and got that needle through me. I wanted it
done instantly but I know it doesn’t work that way . . . if people want the test I think it should be
available very quickly if possible.
SiteA, WOM4
The feasibility of array as a replacement for karyotype
The health professionals discussed the advantages and disadvantages of CMA as a clinical test when
compared with karyotyping. Overall, CMA was seen as the better option in most cases owing to the
greater information provided, but there were cautions. Some comparisons were made in terms of time
taken for the test result and the reporting process:
To do a karyotype somebody physically has to look down a microscope, it’s not something you can
rush. Array CGH, it takes a long time to interpret the results but you’ve got machinery that’s doing it
for you, erm, and so it’s, the detail that you get surpasses what you can get from a karyotype.
SiteA, GC1
A fetal medicine consultant commented that arrays were taking longer from their perspective but
acknowledged that this was likely to improve as the laboratory staff became more experienced with the
technology and the reporting procedures. The main issue for the health professionals was the degree of
uncertainty associated with CMA. It was acknowledged that the array was more likely to detect an
abnormality than karyotyping and if this abnormality was a known deletion or duplication, then the test
was perceived to be extremely useful. However, if it was a variant of unknown clinical significance, this
made counselling far more challenging. Despite this, the majority of the health professional group still
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stated that they would rather have more information than less. The implications of this uncertainty for
counselling are covered in greater detail in Theme 3: decision-making.
Some clinicians felt there would still be situations in which they would want karyotyping instead of CMA,
for example following a high-risk screening test for trisomy 21. However, it was more generally felt that
CMA, as a clinical test, could feasibly replace the standard karyotype altogether:
Karyotypes are obsolete . . . I think karyotypes are yesterday’s. Arrays are today’s, just . . . next gen
sequencing is tomorrow and you’ve got to move with the times.
SiteB, CG2
Theme 2: introducing chromosome microarray into the clinical consultation
Understandings of the EACH research
The parents interviewed had varied understandings of the EACH research and the CMA test. Even when
parents received an abnormal result, their comprehension of the information given to them at the time of
enrolment was not always optimal. There were four main areas where patient understanding seemed
problematic: (1) awareness (or lack of awareness) that the test could potentially have an impact on their
own pregnancy, (2) mistaking the EACH research for concurrent research on non-invasive testing,
(3) mistaking the EACH test for whole-genome sequencing and (4) recollection (or lack of recollection)
of any information regarding the array.
The lack of awareness of the potential impact on their own pregnancy was found in the parents’ narratives
around reasons for taking part in the research. They spoke of wishing to give something back, participating
in research to help others and/or their immediate family or taking part in research to support scientific
endeavour. Many of the women who had normal results (or who never received a result confirming normality)
spoke of how they were keen to contribute to research that would enable the clinicians to test women in the
future using non-invasive procedures:
And if it is a case of being able to take blood and stuff from mum and dad and, erm, you know work
out if there is a, a problem there, erm, then it’s got to be easier than having the risk of miscarriage
hasn’t it really.
SiteB, WOM9
Two of the women interviewed confused the array with whole-genome sequencing and felt reassured by
the normal result on aspects not actually covered by the test:
We know that we’re healthy. [Laughter.] That we haven’t got like cancer or owt like that. One thing
that we could say that we are all perfectly healthy and it were, we were both like oh that’s a good
thing we went through all that. At least we know we’re fine.
SiteB, WOM6
Mistaking the array for whole-genome sequencing was also something that some of the health
professionals expressed concerns about. They warned of the importance of ensuring that parents fully
understood the limitations of the array test.
Many of the parents interviewed had no or poor recollection of being spoken to about the array test or
the EACH research:
I just remember the doctor asking if they could, for a study to take extra, they would have to take extra
cells but it wouldn’t, you know it wasn’t going in again with another needle, it was just like a bit extra
at the time that she took the cells that they needed, erm, I can’t really remember to be quite honest.
SiteA, WOM2
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The majority of parents interviewed in both the normal and abnormal (pathogenic copy number variant)
CMA result groups expressed this sort of recollection. Those who received an abnormal test result
subsequently developed a better understanding of the specific condition in their case, but admitted to
not understanding the initial implications of the array test. Only one couple were able to describe their
understanding in a way that suggested a good grasp of the processes involved:
They talked about my blood and X’s blood, to sort of see what genetic problems we might have and then
using that to compare with the, erm, baby’s blood and then looking for any differences that may or may
not be there and the genetic information, erm, some of which would be, erm, sort of known problems,
so kind of a known 22q11, but obviously there were other genetic type problems that aren’t necessarily
diagnosable that easily and it was part of that bigger picture. I, that’s not a very description of it really.
SiteC, WOM1
Knowledge is power
Despite the apparent lack of understanding among the parent participants around CMA, there was a
strong theme of parents believing that more information was always a good thing. They felt that
additional information would enable them to make better choices and would give them definitive answers,
with comments such as ‘I would rather be overloaded with information and, than not have anything at all’
(SiteB, WOM2) and ‘Knowledge is power, it’s all about choice isn’t it?’ (SiteB, WOM3).
Most parents felt that more information would enable them to prepare adequately, again assuming that
the information that they would gain would always offer definitive answers. There appeared to be a lack
of recognition that the additional information gained from the CMA could introduce greater uncertainty.
Only one parent felt that too much information could be worse than none at all in cases where the
information was uncertain:
Erm, but I think the tests, I think it’s good to know that you’re constantly improving it and, but
sometimes I think too much information’s bad as well, so it would have to be a fine line of how much
information . . . I suppose some people, if they knew you were picking up [uncertainties] would wanna
know, but I would probably not wanna know, yeah, just different people.
SiteA WOM4
The health professional participants expressed concern about the desire parents have for more information.
They recognised that parents tend to prefer more information but, as clinicians, they were keen to ensure
that the counselling prior to testing ensured/facilitated an adequate understanding of how an uncertain
result could cause parents greater confusion and distress:
I’m not convinced yet that we’ve got this business of a potential uncertainty, erm, over to couples
because we’re seeing lots of families where that, that hasn’t been understood. That doesn’t
necessarily mean it’s not been explained, it just means it hasn’t been understood.
SiteA, CG4
The issue of ‘true’ informed consent was discussed by many of the health professionals. One fetal
medicine consultant in particular was keen to get across that parents did not need to avail themselves of
CMA just because the technology was available. Conversely, health professional participants also discussed
how parents who had apparently fully understood the test at the time of consent could still be surprised by
an abnormal result:
I think that if people are aware that there’s a significant chance that we’ll find something that we
can’t explain, then they stop and think, but most of them will still go ahead with that and they’re still
surprised when you come back to them and you say ‘Ah guess what, we’ve found something that we
can’t explain’, erm, and I’m not sure there’s an easy way of tackling that because that’s just life.
SiteA, CG5
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Many of the health professionals felt that even when there was an abnormal result or a VOUS, parents
would still prefer to be given as much information as was available. This belief was matched by the data
from parents who had been in this situation. Overwhelmingly, parents wanted as much information as
possible and, even when that information had led them to make a difficult choice, their preference was to
have been informed:
Ultimately, yeah, yeah ‘cos I think it did give us that choice, erm, and we wouldn’t have had that
choice you know. ‘Cos even if we decided to continue with the pregnancy and he needed to have the
heart surgery, it would all be very planned. I would be up in [city] for 3 months or however long it’s
gonna take, erm, so either way, you know, that choice and the ability to prepare yourself is, is so
valuable really, and without that choice you don’t have any options.
SiteC WOM1
Despite the issues expressed by parents around understandings of the array, the health professionals were
confident that they always fully informed parents of all the issues around the array. Many offered an
almost verbatim rendition of the verbal information they would give to parents when consenting for an
array and these accounts consistently highlighted the potential for introducing more uncertainty. One of
the midwives interviewed offered a possible explanation for the disparity between parents’ understandings
and the health professionals’ certainty that informed consent had taken place. She was concerned not only
about the complexity of information but also about the timing:
. . . we also have massive concerns about how much information they are actually taking in at that time.
They’re given a very complicated, it doesn’t matter how easy you’ve tried to make the information
leaflets for any of the studies, it’s very complicated for them to understand and you know they’re willing
to help, you know, for any reason so, so we do have massive reservations, so that’s a big thing about it.
SiteB, MW1
Overall, the data from parents and health professionals around the theme of introducing CMA into the
clinical consultation pointed to differing perspectives of how well the array had been introduced and how
much understanding parents had been able to absorb and retain. Their accounts highlighted the need for
ensuring that parents fully understood the implications of having CMA.
Theme 3: decision-making
Dealing with uncertainty
The health professional data suggest that health professionals grapple with variants where the clinical
significance is uncertain. Evident in the data overall, it was particularly important to their views on clinical
decision-making. Given this context, the multidisciplinary team was identified as important to health
professionals in making decisions about whether or not to report a VOUS to parents. In a similar way,
the Cartagenia Bench database was seen as having a role in assisting with such decisions in the future.
In the context of this study in particular, the function of the expert panel was important.
The health professionals interviewed worked across two sites (A and B). Site A had a formal multidisciplinary
team meeting each week whereas Site B made no formal provision but included wider team members more
informally. At both sites, participants felt it was important to involve colleagues in the decision-making
around uncertain results. Although the clinicians advocated always being completely honest with parents,
they admitted that telling parents that they did not know the clinical significance of a test result made them
feel uneasy. Involving colleagues in their decisions was seen as a way of being ‘as sure as we possibly can of
our own understanding of the position and then being honest with people’ (SiteA, CG4).
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A common concern expressed was the possibility of decisions about pregnancy management being made based
on an uncertain result, which may have been a normal variant. For example, a clinical geneticist explained:
. . . so it’s possible to be completely normal but to have a chunk of DNA missing, er, and that’s just a
normal variant if you like. Er, and some of the things that we pick up on arrays may well be those and
we don’t know that yet, if you see what I mean, and that makes me worry about basing, erm, basing
pregnancy management decisions on this kind of uncertainty . . .
SiteA, CG5
Some of this discussion focused on the issue of reporting only clinically ‘significant’ results. In particular,
a commissioner participant felt quite strongly that there was little benefit in giving a woman a result for
which the implications were uncertain. Some professionals considered the possibility of only looking
for specific abnormalities so there would be no conflict around reporting VOUS. Others suggested that
changing the criteria for having a CMA would reduce the number of VOUS to manage (e.g. increasing the
threshold for the raised NT):
. . . it would appear that in some centres, if there’s multiple abnormalities on a scan and the karyotype’s
normal then they then go on to do an array and I was thinking that might sort of make more sense
because the raised nuchals are just so non-descript and so I personally think that the abnormalities must
be more substantial . . . I just think either a very increased nuchal you know it needed a bigger cut-off
or some structural abnormalities . . . and then there’s also the suggestion of not doing the whole array
and just doing more common micro deletion or duplication syndromes, I don’t . . . we’re, we’re getting
lots of positive arrays for not particularly well . . . erm, well known syndromes but I think there has to be
something where, erm, there’s sort of substantive evidence that, erm, that you can actually go in to
them and say you know ‘80% of these people have whatever or’ . . .
SiteB CG2
However, most participants felt that, despite concerns in the early stages of the study, the reporting of
VOUS was appropriate. A clinician with direct experience of managing two cases with pathogenic
results stated:
I was worried that we would be reporting every copy number variation even if we didn’t think it was
important but that people would be very worried about that and I think the fact that that isn’t how
it’s happening is, is the way to do it.
SiteA, FM2
The role of long-term follow-up
The health professionals pointed to the importance of addressing the uncertainties through long-term
follow-up of children with VOUS, specifically through a database. Such a resource was seen as
fundamental to ensuring that the degree of uncertainty currently faced would decrease over time:
. . . we are building up a database of array results and so it is getting easier. We are then able to
actually have a closer look at which genes are involved. We still don’t know what all the genes do, we
don’t know the complete picture of those genes but we are building that information up and I suspect
that in another 10 years’ time, we will have a lot more information than we do now.
SiteA, CG2
In order for any database to have maximum effect, the importance of continually and universally updating
the information stored was stressed. In order to avoid a fragmented approach and ensure that individual
laboratories could access the relevant information, there needed to be ownership of the database, but
with collaboration in mind:
. . . as more and more information comes in about what is abnormal and what is normal, that needs to
be fed back into the database or somebody needs to hold the database so that each individual lab can
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get access to the information and that’s gonna be incredibly important otherwise if it’s fragmented
round the country, every individual unit is going to go through the same hassle every time they find
something that they don’t know what the significance is.
SiteB, FM2
The panel
As part of the EACH study an expert panel was set up to support cytogeneticists and clinical geneticists in
decision-making around the reporting of VOUS during the study and the discussion around the panel
came predominantly from these professional groups. There were differing opinions as to when the panel
should be consulted. It was felt by two clinical geneticists that the panel should be a last resort and that
they should make as much of the decision as possible, deferring to the panel only when they were
absolutely unsure of the significance of the result. Others from across the health professional group saw
the panel as an extension of the multidisciplinary team whose expertise should be called on wherever
there was doubt to gain a consensus. However, there was some uncertainty among clinical geneticists as
well as fetal medicine consultants at both sites about what they would do if the panel made a decision
that they did not agree with, and on one occasion this did actually occur:
. . . in the end they [the panel] said don’t report it, it’s not relevant, but they also said, this is our
advice but the final decision is down to you as a team. Thanks for that! We all decided they [the
parents] have to know this. The whole thing was a bloody nightmare, erm, but we were all completely
happy in the decision that we had to tell this family this information because we would all want to
know it.
SiteB FM1
Two participants (clinical geneticists) had consulted the panel about two separate cases and were less than
satisfied with the outcomes because they were advised to report something that had only once been reported in
a paper as being linked with learning difficulties. The clinical team involved with one case recognised that the
panel had to maintain a degree of objectivity but felt that they ought to have considered both the indication for
testing (a slightly raised NT) as well as the social circumstances (which were difficult). In addition, the clinical team
did not feel that the panel had reached a decision quickly enough and that the length of time they had to wait
for a response was inappropriate.
There was some discussion among the health professionals about the extent to which the panel decision
should be seen as final and which expertise should be represented on the panel. It was felt that there
should be a broad range of experts, including cytogeneticists, midwives, genetic counsellors and lay
representatives. One of the health professionals suggested that the panel should also be tested against a
set of abnormal variants of known significance to be certain they were consistent. But, overall, there was
support for a panel to help clinical decision-making among the fetal medicine consultants as well as clinical
geneticists. One consultant in particular felt that the experience of the panel had been positive and that
the EACH panel was a success:
. . . my understanding is that, you know, erm, laboratories in consultation with their clinical geneticists
are pretty clear what would benefit from going to panel, erm, and the panel has been very successful.
SiteA, FM4
Reporting array results to parents
One cytogeneticist interviewed early in the study expressed concern about only informing parents of
abnormal results. They felt that normal results should also be reported in order to reassure parents.
Although it was originally decided that laboratories would not release formal reports of a normal CMA
result, this decision was changed early in the study because of increasing pressure from cytogeneticists.
Clinicians then had the option of reporting the normal result to parents. Reporting emerged as a common
theme among the parents who had not been informed and these parents felt that it was inappropriate
to have heard nothing at all following the test and would have liked to have received some official
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notification of the normal result. In some cases, this lack of notification left them uneasy about whether or
not the results were in fact normal. This concern about whether or not there was actually an anomaly
extended beyond the pregnancy and into the early stages of the child’s life. Some parents remained
anxious about the health of their child.
Reporting of an ‘abnormal’ result
Health professionals were concerned that parents would be surprised by an abnormal result. The parent
data confirmed that they often felt they had been ‘blindsided’ by an abnormal result because previous
tests had given false reassurance:
There’s the initial 2 or 3 days waiting for the three big ones and then there’s this 2-week period where
they test, and we didn’t about that part because nobody has any problems with that, and this was
when we were lured into a false sense of security ‘cos the woman who, from [tertiary unit], that
phoned said that when that result comes back [polymerase chain reaction] and those are all clear [it’s]
very, very rare, you know the rest is usually OK.
SiteC, WOM2
This couple received an abnormal array result just a few days after the QF-PCR but were grateful to have
been involved in the EACH study because it had given them additional information on which they could
base their decision on whether or not to continue the pregnancy.
More generally, when the CMA offered a definitive answer, the parents were pleased to have had the array
and felt that they gained a lot from the process. Two sets of parents interviewed had been given a result
with a known deletion/duplication, which had a direct impact on their decision to terminate the pregnancy.
They were able to gather detailed information on the conditions and became extremely knowledgeable
about the difficulties faced by affected children. The risks of disability were taken into account when
making these choices:
. . . sort of mental health problems, you know the job I do I work in mental health . . . the kind of
schizophrenia that I think apparently comes with [condition] is sort of quite treatment resistant . . .
they very often can’t sleep at night because they’ve got leg cramps and you know it’s a small medical
issue but in terms of quality of life it’s really important.
SiteC, WOM1
Health professional participants speculated about the factors that influenced parent decision-making and
these were generally consistent with the factors described by the parent participants. Although it was
generally acknowledged that decision-making was multifactorial, there were a number of important
common issues, such as the impact of an affected child on the family and particularly on the other children.
In the short term, this centred on the amount of parental time that would need to be dedicated to the
affected child, and, in the longer term, this centred on the perceived burden on other children of caring for
a disabled child:
. . . if they’ve got unaffected children, erm, then sometimes they think well will it be a burden on the
children that I’ve got, I won’t be able to look after the children and take them about and do things
that, because I’m going to be in and out of hospital with this child etc., etc.
SiteA, GC1
. . . and we decided not to continue with the pregnancy, erm, just the thought of the newborn having
heart surgery and then going on with what, I don’t know, erm, yeah, I didn’t feel . . . and obviously
already having one child you know, impacts greatly on them really as well so it’s never an easy
decision really.
SiteB, WOM1
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The type of disability was discussed by the parents and health professionals as being important. Developmental
delay was seen as a major factor in decision-making and more likely than physical disability to lead parents to
decide to terminate their pregnancy. As one fetal medicine consultant put it:
. . . parents are far more likely to choose to continue with the pregnancy or at least in my experience
they’re far more with a structural abnormality than a risk of developmental delay.
SiteB, FM2
One set of parents reflected the thoughts of many of the couples interviewed. They had made the decision
to continue with the pregnancy despite significant structural abnormalities. They stated:
For us it’s more if they’re mentally going to be OK we can cope, physically you just, you just adapt.
But I didn’t know how I’d cope with a mentally handicapped child . . . we’re not particularly bothered
about a physical disability but we were really, really worried about mental disability.
SiteB, WOM9
In addition to the quality of life for the child, additional influencing factors included the law, the number of
existing children, the family circumstances and religious beliefs. Clinicians alluded to the influence of social
pressure and how parents often asked what others in the same situation generally did. Perhaps unsurprisingly,
the influence of social pressure was not discussed by parents as directly having an impact on decision-making,
but was evident in their accounts. For example, one woman spoke of how one of her friends had stopped
speaking to her after she terminated her pregnancy. However, she was keen to stress that this friend, as well
as others who were quick to judge, did not have a disabled child. Some women experienced feelings of
selfishness or guilt for ending a pregnancy; however, for most parents, their motives had been the reverse:
I think you’d have to think very carefully whether that’s the life you’d want for yourself and whether
you can watch your child go through that knowing that you made that decision for them to do it,
because maybe you weren’t quite brave enough to make the other decision.
SiteC, WOM1
In addition, a woman who had decided to terminate stated:
I almost felt a bit selfish wanting to bring this little boy into the world just for us to have this baby in
our arms who was only ever going to have a total struggle for the rest of his life.
SiteA, WOM3
Knowledge of the condition gained through CMA armed the parents with relevant information on the
impact the condition would have on these influencing factors. They seemed to base their choices around
the risks of the worst possible scenario for the given condition. The data suggest that parent decision-
making was multifactorial and that the health professionals involved had a good understanding of the
issues that influence parents in their choices. The array was an important part of the decision-making
process for parents and enabled them to feel they were making more informed choices.
Theme 4: embedding chromosome microarray into standard clinical practice
The introduction of new technologies
The health professionals discussed the process of developing and introducing new technologies. Using
historical examples as a means of illustrating the benefits and potential pitfalls, they cautioned against
technology for technology’s sake. The commissioner group in particular were careful to place patients at
the centre of decisions regarding the implementation of new technologies. The inevitability of new
technologies was seen as something that clinicians would continually face. They discussed examples of
technology that were now fully embedded in clinical care but which took time to be widely embraced
(such as ultrasound). It was noted that although health professionals are not necessarily requesting new
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technologies, technologies are continually being developed and patients expect those technologies will
become available to them. The commissioner group accepted that clinicians wanted to be at the forefront
of technology and that this would ultimately enable them to deliver better care. However, they were keen
to ensure that the new technology could offer additional and useful information.
Is it gonna improve the care of the patient? ‘Cos at the end of the day, in theory that’s what we’re
trying to do, we’re trying to improve the care and the outcomes that patients get, not to kind of so
they can go and meet their mates down in London and brag about this lovely shiny machine that
they’ve tricked this gullible commissioner to pay them lots of money to do it, you know.
COMM6
The clinicians interviewed were very positive about the potential impact of CMA for parents, despite their
cautions about new technologies in general. Although the use of CMA was seen as ‘new’ in the context
of fetal diagnosis, arrays were established in paediatrics. Some of the clinicians had direct experience
with introducing CMA in the paediatric setting and, drawing from this experience, discussed some of the
perceived benefits. The availability of CMA in the paediatric setting was seen as a success in terms of the
diagnostic yield and the ability to give answers to parents:
Arrays have taken our detection rate, erm, of chromosomal abnormality from about 3% of the people
that we see, erm, of the kids that we see, erm, in that category of children with, with developmental
abnormalities, to 20% with 15% being clinically significant, so that’s a huge sea change in terms of
our diagnostic capability.
SiteA, CG4
One commissioner commented that it was important to understand the diagnostic yield of a test as this
demonstrated the direct impact. In relation to the paediatric population with unexplained developmental
delay, clinicians described CMA as a ‘game changer’, giving answers to families who, for years, had not
had a diagnosis. This had not only been a huge relief to families but had, in some cases, enabled them to
seek support by way of benefits or through the education system for their child.
Support for the use of chromosome microarray in fetal diagnosis
The majority of the health professional participants welcomed CMA and were very keen to see the success
of arrays in the paediatric setting repeated in the prenatal setting. They tended to equate the additional
information gleaned with offering better choices to parents. However, there was a sense among some that
the array would present counselling dilemmas that they felt ill-prepared for. Overall, there was a sense of
inevitability around the introduction of the test and it was felt that there would soon be demand from the
general public and consumer groups for the NHS to offer the test:
I’m probably more in favour of it rather than not, erm, because I think it is about, I think we’ve got to
be . . . well that’s why we do big studies to get, to get the information really so I’m very yeah, let’s
wait and see, but I think you know, because it’s being offered, sometimes in the private sector or in
America, one of things is that people go on the internet and they read and they will find out about it
and I think we’re gonna start, people are gonna start to ask about it, erm, and we’ve got to be able to
justify if, why we’re not offering it.
SiteA, FM3
At the heart of discussion around the support for CMA were the implications for the parents and the
necessity of ensuring that they were fully informed prior to testing:
I think there is a significant onus on those who are er helping couples make decisions about whether
or not they want to apply the technique to give them all of that information in the way that it’s
accessible, erm, but I think provided you do that, then it’s a very positive thing.
SiteA, CG4
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Interviewing the commissioners provided valuable insight into how commissioning works following the
changes to the commissioning process in April 2013. The quality of the research evidence available was
seen as central to ensuring that national recommendations were appropriate:
What we’d be looking for is a recognised, they’re either an RC, randomised control study or a
recognised trial that’s published. We’d look at the amount of research that’s being done and we’d
look at the quality ….. and we’d use our either our public health colleagues predominantly to help us
who are experts in evaluating research evidence to tell us whether they felt that actually there was
enough evidence in terms of the type of trial that was undertaken and whether the quality of the
research recommendations were such that they felt that we could use it for evidence and obviously if
NICE [National Institute for Health and Care Excellence] are also supporting, erm, then we would likely
support it.
COMM4
One national commissioner summarised her role:
The only thing is that different clinicians have different ideas, so my job is to get them to agree, so if
Joe Bloggs down the road says you know ‘We need to implement micro arrays’ but, erm, Mr Jones
down the other end says ‘oh no, no, we’re into new sequencing’, erm, and me in the middle will say
‘Well I want this testing done, I don’t mind what technology you use, however, you’ve got to be the
same price and the same outcome and that’s what you’ve got to tell me’.
COMM2
However, participants identified some problems in commissioning arrangements. One area of concern for
clinicians was the perceived lack of meaningful communication with the commissioning groups:
Well I think it’s much easier when, when a genetic service has a good relationship with its Commissioners,
erm, and that’s gonna be a fundamental stumbling block, erm, because our, my, and my Directorate
Manager relationship with the 13 CCGs [Clinical Commissioning Groups] within this region is very limited
at the moment because we don’t really know how to contact them.
SiteA, CG5
Some participants identified NHS England specialised services clinical reference groups (CRGs) as a vehicle
for introducing CMA into NHS practice. CRGs bring together clinicians, commissioners and public health
experts with the patients who use the relevant services; they are responsible for preparing national
specialised service-level strategy and developing specialised service contract products, such as specifications
and policies. One of the local commissioners stated that both the fetal medicine and medical genetics CRG
were supportive of CMA but another local commissioner expressed concern around the role of the CRG.
One local commissioner felt that recommendations were made that were unrealistic:
At a national level they don’t get involved in the funding elements of that so one criticism, I suppose,
that has been made by some area team commissioners about the national process is that well it’s all
very well and good for clinical reference groups to sit in a darkened room and write, gold plated
service specification that no one can deliver.
COMM4
Many of the commissioners related their roles back to patient care and delivery. For example, they
expressed concerns about equity of access to tests as well as the need for patient feedback regarding
aspects of care. One commissioner in particular explained their involvement with the Genetic Alliance and
how this had been pivotal to the development of a care pathway for a particular disorder:
. . . for example we did a conference on, er, we wanted to review the care pathways for Marfan’s
syndrome, erm, so we invited the specific Marfan’s Patient Association to come along to the whole
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meeting and participate. Present, erm, give us feedback and we’d go to report at the end which has
to be signed off. We tend to work very much with patients because they bring a different perspective.
COMM6
Cost and resource implications of funding chromosome microarray in fetal
diagnosis
In terms of the cost of CMA in comparison with conventional karyotyping, there was general agreement
that, over time, array CGH would become less expensive. It was acknowledged that the initial outlay
would be for equipment. However, as the test would be performed only in regional cytogenetic
laboratories that were already performing arrays in the paediatric setting, the equipment was already in
place so the additional cost would be negligible. Furthermore, it was pointed out by a cytogeneticist that:
. . . we as a, as a lab now are doing CGH follow-up on fetal loss so some of these EACH samples have
actually again have had the array carried out and you know we, we’re able to use that information to
you know to sort of say well OK we’ve done this analysis already, we don’t need to do it on this fetal
loss material so, I mean it’s actually saving you know.
SiteA, CG2
Health professional participants felt that the time taken to interpret an array was comparable to a
karyotype. Many pointed to how the array technology would become less expensive and offer a better
diagnostic yield whereas the cost of karyotyping would increase:
It’s not the actual cost of the machinery, etc., but if you look at how many karyotypes you do and
how many abnormal results you, because that’s what you’re looking for. I mean it sounds awful but
you’re not looking for normal you’re looking for an abnormal.
SiteA, GC1
Professional participants envisaged that CMA would replace karyotyping and this would reduce diagnostic
costs. Clinicians directly involved in patient care were mindful of cost issues, but the commissioners in particular
focused on the broader issue of negotiating cost priorities. Commissioner participants tended to focus on the
difficulties faced by key decision-makers in deciding where efficiencies could be made. Although it was agreed
that, in the context of CMA, cost savings would be made in the long term, the savings were seen as quite
difficult to actually quantify:
. . . it’s a difficult line to tread if you’re talking about terminating pregnancy and that’s you know, so
well if say 5% of cases would, erm, would discontinue, it’s a very difficult line to tread and say ‘Well
these are our, you know we won’t have the impact on the NHS for the next 5, 10, 15, however many
years’ so, it’s a tricky one.
COMM1
. . . in genetics it’s a diagnosis and a testing service that we provide. That’s all we provide in genetics.
It’s quite an expensive, erm, service, because some tests are very expensive . . . if you had the test
pre-conception and you make that decision whether you want to ‘cos, erm, then if you want to go
ahead and try for a child, and then you can’t quantify, it’s just not feasible.
COMM2
The professionals’ accounts of parents’ reproductive choices were framed with reference to ethical
questions and concerns regarding the possibility of eugenic effects. The idea of potentially eugenic effects
was an uncomfortable one for health professionals and commissioners. However, they felt that, even if
these were set to one side momentarily, from a purely economic perspective it was impossible to quantify
the benefit of arrays against the potential long-term cost of not having the test available. Given the various
care pathways involved and the different support services that may be involved throughout the entirety of
the child’s life, even a basic economic quantification of benefit was seen as problematic. Given the nature
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of antenatal screening and testing and the inevitability of further development of such technologies,
the professionals questioned the value of attempting to quantify economic benefit in simple terms.
Despite widespread support for the introduction of CMA in fetal diagnosis, commissioners used a more
corporate language of efficiencies and savings. They discussed how they look for evidence of savings in
terms of what it would replace, or what would no longer be paid for, because ‘. . . we don’t have any new
money. We have to move it around’ (COMM2). Issues of investment were an area of disparity between
the commissioners’ and clinicians’ views. The commissioners were clear that their role was to ensure that
patients received the best possible care in the here and now. When asked about CMA and the ongoing
information that arrays would provide to clinicians as more and more were performed, one
commissioner said:
Well is this not research? And we don’t pay for research. We pay for treatments. We’re paying for
diagnostics and treatments. That’s what we pay basically. To get people better, either improve their
outcomes or the quality of their life for a longer period.
COMM5
Commissioners seemed less inclined to equate long-term initiatives, such as long-term follow-up and
maintaining a central database of information about this, with these patient-focused objectives. In
contrast, a clinician explained how advances such as CMA were more of a quality improvement issue:
. . . this is actually a quality improvement, erm, development, so we’re actually inevitably wanting to
introduce better and better tests and this is just the next in a series of better tests.
SiteA, CG5
Overall, the discussions focused on balancing the needs of patients in the present with the requirement for
developing technologies to continually improve patient care and outcomes in the future. The negotiation
of cost priorities was not seen as straightforward, but it was largely understood (among the professional
participants) that, as time went on, CMA would become less expensive and less time-consuming and
would be a feasible replacement for karyotyping.
Considerations for national policy to roll out chromosome microarray in
prenatal diagnosis
Health professionals felt that rolling out CMA on a national basis into standard care pathways would be
feasible. There was some variability in the estimated time frames for roll out across the UK, which ranged
from 6 months to 10 years, with the average estimation being 2 years for parents undergoing invasive
testing for fetal anomaly to have access to CMA.
Professional participants felt that in the units already undertaking arrays, either prenatally or postnatally,
there would be a seamless shift from the research to standard care. In units not already performing CMA
the shift was seen as more of a challenge in terms of needing to draw on expertise from a range of clinical
specialties. There was some caution about the potential for a piecemeal approach to implementation and
it was felt that appropriate resources should be invested to ensure equity of access:
The problem is, is, how you fund that and how you make sure equity of access across all fetal medicine
centres and you know that’s a challenge for national commissioning really, erm, you know, erm, the
only way you can ensure equity of access, erm, is to ensure that it’s commissioned as a service for all
patients. Introducing arrays in major fetal medicine centres will be relatively straightforward, erm, it’s
likely to happen anyway to a greater or lesser extent, erm, so you will get therapeutic creep because it
will be fairly obvious that it’s a cost-effective intervention once EACH is published. How quickly you can
get that on to a national platform is gonna come down to specialist national commissioning.
SiteA, FM4
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The national commissioners were certainly keen to stress that they too needed to ensure equity of access.
One in particular felt that the best way to achieve this was to centralise services:
It should be available, it should be available geographically, I think rather than be everywhere and
some, I mean some people who might not have arrays don’t necessarily have the expertise to use
them or report on them so it would seem sensible to me that you know, you have a mechanism by
which you have some sort of centralisation.
COMM6
In addition to the key issue of equitable access to services, health professionals placed heavy emphasis on
the importance of education around arrays in relation to adequacy of services provided. A programme of
education was seen as essential to train health professionals who would encounter CMAs, in order for
them to be able to convey the information appropriately to parents:
I think they need to have a teaching process to teach us properly . . . it could spiral out of control so
there has to be, as well as money being thrown to it from a national perspective, there has to be
money thrown to on the education of health professionals, on the education of society per se.
SiteB, MW1
It was also emphasised that written information in different languages should be available for women to
take away and consider, and that if health professionals were unsure about CMA then they should know
whom the most appropriate person to speak to would be.
Overall, the feeling among the health professionals was that CMA was something that would be welcomed
by the majority of stakeholders. They were reassured that the test was being properly evaluated prior to
roll-out and felt that the issues they were currently facing (around uncertainty, education, information
giving and equity of access) were eminently surmountable. One clinician summarised:
We plot out across the next decade and I know that we will be able to refine the information that
comes out of the laboratory to different types of clinicians and those clinicians will get used to it and
they’ll work out how to integrate those into their workflows, erm, and in 10 years’ time everyone will
be comfortable and happy about this and they’ll look at this time and say ‘Blimey do you remember
when we started doing arrays?’ and they’ll rock quietly in their chairs on their verandas and they
won’t quite believe how difficult it was because now it’s easy peasy.
SiteA, CG5
The future of prenatal testing
Across the health professional group, there was discussion around what the future of prenatal testing
would hold. This discussion focused on NIPT and whole-genome sequencing.
Comparisons were made between CMA and NIPT methods. One fetal medicine consultant pointed to how
it is possible to ‘screen the whole human genome from free fetal DNA’ (SiteB, FM2). It was acknowledged
that NIPT would be more acceptable to parents, who would negotiate their choice around the potential for
more, and possibly uncertain, information and the risk of miscarriage following an invasive procedure.
The necessity for an invasive procedure was seen by health professional participants as the greatest risk to
the future of array technology:
I think the key difference is between an invasive and a non-invasive and I think the thing most
threatening to EACH is not people’s perception of the dilemmas it may put them in, I think it’s purely
if it’s an invasive test and I think the future will be much more to do with non-invasive testing.
SiteA, FM3
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In the medium term, professionals felt that NIPT would be used for routine aneuploidy screening, whereas
CMA would be utilised as the diagnostic test in fetuses with structural anomalies and increased NT
undergoing invasive testing. Parents would be balancing the risk of miscarriage following an invasive test
with the potential for a false-negative result from a non-invasive test. One fetal medicine consultant
explained:
. . . at the moment, non-invasive prenatal diagnosis is essentially focused on Trisomy 21 and specific
Mendelian genetic disorders. I don’t think it will make any difference to the group of patients that
we’re talking about in the medium term, so I think you know for the next 5 years patients who have a
major fetal abnormality detected on ultrasound you know are not going to opt for non-invasive
prenatal diagnosis because their risks of having an underlying chromosomal abnormality which are not
diagnosed by non-invasive are going to be so high.
SiteA, FM4 (participant’s emphasis)
Fetal medicine consultants and clinical geneticists recognised the additional information provided by
whole-genome or exome sequencing but highlighted that the techniques were extremely costly. As a
result, they felt that sequencing was unlikely to become widely available in clinical practice in the near
future. Health professionals also commented that there would be similar challenges to surmount around
the interpretation of results and counselling parents:
. . . but the growth area in the future is going to be non-invasive prenatal testing and CGH array, erm,
or, or whole-genome sequencing at some point in the future which almost certainly will become
available as it becomes cheaper and cheaper, erm, and then we might identify more and more of, of
the funny anomalies, erm, is that good or bad? I don’t know, you know do we really want to remove
every child with an abnormality off the face of the planet?
SiteB FM2
. . . what’s on the horizon, erm, is whole-genome analysis and in theory you could replace, erm,
chromosome testing and arrays completely with whole-genome analysis and that means you
sequencing the entire genome. You would reveal every tiny variant within that person so you can’t
really start using this until you understand what those variants mean. If you think array is generating
confusion at the moment then the whole-genome analysis in a fetus will generate even more, so I
don’t see that array will be the final resting place.
SiteA CG5
The Reliable Accurate Prenatal non-Invasive Diagnosis study
A secondary aim of the EACH study was to contribute maternal blood samples to the RAPID study to
evaluate NIPT for aneuploidy funded by NIHR Programme Grants for Applied Research (RP-PG-0707-10107).
The results of this programme of work will be reported separately but a brief report on cell-free DNA aspects
of the EACH study is provided in Appendix 5.
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Chapter 4 Discussion
The EACH study was designed to evaluate the clinical effectiveness and cost-effectiveness of prenatalCMA compared with karyotyping within the UK’s NHS. The study involved 8 of the 17 NHS regional
genetics laboratories (representing six of the nine NHS Genetics Services in England) as well as the Welsh
Genetics Service. All the participating laboratories had experience of running CMA on postnatal samples
and, therefore, prenatal samples were integrated into existing postnatal laboratory array workflows.
Through the NHS FASP all women in the UK are offered combined ultrasound and biochemical screening
for common aneuploidies at 11–14 weeks’ gestation and ultrasound screening for structural anomalies at
18–20 weeks of pregnancy.2 Women at a high risk of chromosomal anomalies are offered invasive testing
with karyotyping of chorionic villus or amniotic fluid samples in QF-PCR-negative cases.2 Invasive testing
and assessment of structural anomalies is undertaken by fetal medicine specialists working in large district
hospitals or regional specialised fetal medicine centres. Cases for the EACH study were recruited from
10 of the largest specialised centres in England and Wales as well as 10 smaller units, reflecting current UK
practice. The design of the EACH study was therefore predicated both by the existing national prenatal
screening/diagnosis programmes and pathways but also by the published prenatal CMA data20 that
confirmed that targeting fetuses with ultrasound anomalies would optimise the yield of clinically significant
cryptic chromosomal anomalies.
The study has shown that, within this UK context, prenatal CMA in fetuses with a structural anomaly and
a normal QF-PCR detects 3.5% more pathogenic CNVs than karyotyping. This rate is consistent with the
early meta-analysis of Hillman et al.,36 which informed the EACH study, and their subsequent BAC array
study conducted in Birmingham, which reported pathogenic CNVs in 4.4% of 243 fetuses referred with a
structural anomaly on ultrasound.56 It is also consistent with the large National Institute of Child Health and
Human Development (NICHD)-sponsored trial which performed oligonucleotide- or SNP-based arrays in
755 cases with an ultrasound anomaly; 21 (2.8%) were classified as having a pathogenic CNV.57 However,
this is lower than the most recent systematic review of 18 studies (3359 cases), published in 2014, which
reported a pooled prevalence of pathogenic CNVs in fetuses with one or more structural anomalies of
6.8% (95% CI 6.0% to 7.7%).58 This review was dominated by the experience from a single laboratory in
the USA which reported pathogenic CNVs in 159 out of 2184 (7.3%) fetuses with ultrasound anomalies.59
Of note, a recent study from Belgium, which utilised 60,000 or 105,000 oligonucleotide arrays in 383
cases with undefined ‘ultrasound abnormalities’, identified submicroscopic ‘causal’ CNVs in 2.6% of cases,
while CMA added valuable information over conventional karyotyping in another 3.9% of cases.60
Currently, the NHS FASP recommends the offer of invasive prenatal diagnosis when ultrasound screening
identifies a NT of ≥ 3.5 mm.4 The EACH study therefore sought to address the effectiveness of CMA in this
specific group. Although CMA detected 4.5% more CNVs than karyotyping in fetuses with an increased
NT, there was no difference in the rate of pathogenic variants. This finding was consistent when the NT
cut-off point was increased to 5 mm or 6 mm. However, the rate of pathogenic CNVs on CMA was higher
in fetuses with a NT of > 5 mm than in those with a NT of 3.5–5 mm. We are not aware of any other
studies that have looked at the effectiveness of CMA at different NT cut-off points, although De Wit et al.58
found no difference in the rates of pathogenic submicroscopic CNVs in fetuses with a NT of > 3.5 mm and
those with a cystic hygroma. Grande et al.61 have recently published a meta-analysis of 17 studies (1696 cases)
addressing the incremental yield of CMA over karyotyping in fetuses with an increased NT. When a NT
cut-off point was defined, most authors used 3.5 mm and included cystic hygroma, as in the current study.
Overall, 5% more pathogenic CNVs were detected by CMA. In the subgroup of fetuses with isolated
increased NT (1403 cases with no additional structural anomaly), the pathogenic CNV detection rate was
4% (95% CI 2.0% to 7.0%) higher with CMA. In the largest single study to date which reported CMA
results in 215 fetuses with a NT of 3.5–9.0 mm, CMA detected CNVs in 1.4% (95% CI 0.5% to 4.0%),
but all three cases were classified as VOUS.62 These findings are also consistent with the NICHD trial, which
included 187 cases with a NT of ≥ 3.5 mm or a cystic hygroma or a NF of > 6 mm; the rate of CNVs not
detected by karyotyping (3.8%) was no different to that in the control group (for which CMA was
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performed for advanced maternal age in the absence of any detected fetal anomaly).63 Taken together, the
results suggest that the added diagnostic yield of CMA over karyotyping is significantly lower in fetuses with
an isolated increased NT than in fetuses with a structural anomaly (with or without an increased NT).
The results of the EACH study add to the growing evidence of the improved diagnostic accuracy of CMA
compared with karyotyping for the detection of numerical and structural chromosomal imbalances in
prenatal diagnosis. In a recent systematic review, using the combined rate of pathogenic imbalances
detected by karyotyping and CMA as the reference standard, Saldarriaga et al.64 reported a higher
sensitivity (0.942) for CMA than for karyotyping (0.673) with the same specificity (0.999). Negative and
positive likelihood ratios were also improved (0.049 vs. 0.291 and 1340 vs. 860, respectively).
The two recent meta-analyses discussed above both showed statistically significant heterogeneity between
studies.56,61 This is likely to reflect the inclusion of smaller cohorts with an artificially high detection rate.56
It is noteworthy that the results from the EACH study agree more closely with more recent, much larger,
studies. However, differences in anomaly case selection, CNV calling strategy and array platform may also
have contributed to the lower rates of pathogenic CNVs, than in the published meta-analyses, found in the
current study.
The rate of pathogenic CNVs is known to be higher in fetuses with multiple sonographic anomalies. In De
Wits’ recent systematic review of studies in fetuses with structural anomalies and a normal karyotype,58
9.1% with multiple anomalies had a pathogenic CNV, compared with 5.6% of those with an isolated
anomaly. In the EACH study, 11.1% of fetuses with multiple anomalies had a pathogenic CNV on CMA
compared with 8.8% of those with one anomaly, although this difference was not statistically significant.
A similar pattern was found in the NICHD study, in which CNVs (both pathogenic and VOUS) undetected by
karyotype were more common in fetuses with multiple (n = 206) than isolated (n = 312) anomalies (13.6%
vs. 6.7%).63 We also confirmed the specific benefit of CMA in fetuses with a cardiac anomaly.63,65,66 Other
CMA studies have reported pathogenic CNVs in 2.0–6.6% of fetuses with a cardiac anomaly, normal
karyotype and negative or no FISH results for 22q11.2 deletion syndrome.65,66 Yan et al.66 found the rate of
pathogenic CNVs in this group was not affected by the presence of additional structural anomalies.
Considerable effort went into optimising the laboratory protocols before recruitment to the EACH study
commenced. A detailed technical evaluation was performed by scientists at two of the participating laboratories
(WRGL and NETRGL), aimed at developing an agreed technical workflow for performing CMA using minimal
quantities of amniotic fluid (2–4ml), chorionic villi (2–5mg) and cultured cells (< 150,000 cells). Guidance was
provided about optimal methods of DNA extraction (using the iGENatalTM kit) and DNA quantitation (using
Qubit® 2.0 Fluorometer and Quibit® dsDNA BR assay kit)48 to use with the agreed array design. As a result,
98.9% of arrays in the EACH study were performed on uncultured samples. This is a substantial improvement
on the NICHD study in which the CMA result was derived from cultured cells in 21.5% of cases.57 The array
design chosen was based on the ISCA Consortium’s consensus49 and consisted of an 8-plex of 60,000 60-mer
oligonucleotides with a backbone resolution of ≈75 kb but with considerably higher coverage over telomeric
and pericentromeric chromosomal regions, in known microdeletion/duplication syndromic regions and also
for a number of developmental and haploinsufficent genes. Thus, the array design was felt to be optimal to
detect known microdeletion and duplication syndrome regions as well as other chromosomal imbalances. The
laboratories obtained their arrays from a number of commercial vendors and, in most cases, used the analytical
software supplied with the arrays. With the described laboratory workflow, 3.3% of arrays failed (vs. 0.8%
of karyotypes). This is higher than in other recent studies56,57 and, in part, may reflect the introduction of
prenatal arrays in addition to karyotyping in busy NHS genetics laboratories but also may be due to the
relatively small amounts of amniotic fluid and chorionic villi made available for DNA extraction (e.g. ≈5ml of
amniotic fluid in EACH vs. 20 ml exclusively available for DNA extraction in the NICHD study57). In fact, the
preliminary work carried out by Callaway et al.48 was undertaken in anticipation of this problem and almost
certainly contributed to the relatively high success rate with less then optimal volumes of starting fetal material
for CMA.
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The interpretation of CMAs and the strategy for calling CNVs is challenging. The identification of novel
VOUS, and the perceived difficulties these cause for clinical management, is seen as the most significant
disadvantage of prenatal CMA. To facilitate accurate and timely interpretation of prenatal CMA, the
EACH study was designed so laboratories had ready access to parental DNA; blood samples were collected
at the time of prenatal diagnostic procedure from 100% of mothers and 78% of fathers. Thus, for most
identified CNVs, parental inheritance could be determined from a single parent versus parent array
targeted at the area of imbalance. When necessary, FISH-ready clones were made rapidly available by
WRGL. In-house interpretation of CNVs has been facilitated by the development and evolution of online
international databases with results from normal individuals (e.g. Database of Genomic Variation67) and
those with phenotypic anomalies (e.g. DECIPHER68). As laboratories have increased their experience of
prenatal CMA many have also developed databases cataloguing CNVs. Through continuous updating
of clinical CMA databases (e.g. ISCA Consortium database69), understanding of genotype/phenotype
correlations and the clinical significance of novel CNVs is expanding rapidly with an emphasis on
penetrance of key phenotypic traits associated with an increasing number of CNVs.70 To reflect current
laboratory practice, local laboratory scientists used their standard in-house interpretation protocols
including minimum size cut-off points for deletions and duplications. In this context, deletions as small as
5.5 kb and 11 kb were detected and included in the reported cases (see Tables 15 and 16). The exception
to this was the agreed list of low-penetrance CNVs excluded from reporting. Furthermore, to provide
additional support to local genetics services in making CNV calls and reporting decisions, an expert panel
made up of five consultant clinical cytogeneticists and five consultant clinical geneticists, was available to
offer advice when requested. This strategy was chosen to reflect how CMA may be introduced into the
NHS. It differs markedly from the NICHD trial, for which all CMA results were interpreted at a single centre
and all VOUS were referred to an independent advisory panel.
Variants for which the possible genotype and phenotypic effects were uncertain (VOUS) were not reported
in the EACH study. Overall, 38 (3.4%) cases were called as VOUS and the rate was similar in the two study
groups. In the majority of cases (58%), the decision was made in-house by the local cytogenetics/clinical
genetics team while, of the 32 cases referred to the EACH panel because of local uncertainty, half were
not reported (i.e. regarded as a VOUS). The VOUS rate in the EACH study is very similar to the rate reported
in the NICHD trial, in which 24 out of 755 (3.2%) arrays performed for an ultrasound anomaly were
interpreted as ‘potential for clinical significance’. 57 These VOUS rates are higher than both the rates
reported by Hillman et al.56 in their meta-analysis of studies for which the clinical indication for CMA was a
structural anomaly (2.1%, 95% CI 1.3% to 3.3%) and the rates reported in the Leuven study (1.6%) of
oligonucleotide arrays in fetuses with ultrasound anomalies.60 It is also higher than the rate reported from
the meta-analysis of increased NT studies (0.8%, 95% CI 0.4% to 1.3%).61 This is likely to reflect the
60,000 oligonucleotide array design used in the EACH study in comparison with several studies included in
both meta-analyses that used BAC arrays. VOUS rates are known to increase as the resolution of the array
increases. Hillman et al.71 compared CNV detection rate in 62 fetal samples using two array platforms (1 Mb
targeted BAC array and 60,000 oligonucleotide array). The 60,000 array detected 4.8% (95% CI 1.6% to
13.3%) more pathogenic CNVs but 8% (95% CI 1.3% to 14.8%) more VOUS.71 Using information on CMA
genome coverage (rather than a direct comparison in the same fetal samples), Shaffer et al.70 estimated that
use of a 55,000 array would reduce VOUS rates by 32% compared with a higher resolution 135,000 array
while still detecting all but one pathogenic variant (98%). Thus, we believe that the array design employed
in the EACH study represents a sensible compromise between pathogenic and VOUS detection rates. It is
expected that, as experience of prenatal CMA increases, the number of VOUS calls will reduce.61
The second part of the laboratory evaluation within the EACH study was to compare TATs. To reflect NHS
laboratory practice, we adopted the definition used for CPA (which is one of the services within the UK
Accreditation Service), that is, from the date of sample receipt to the date of the final report. Based on this
definition, result times for karyotyping were consistent with the UK average (12 days) and times for CMA
were consistent with previous research studies.72 CMA results took a median of 3 days longer than
karyotyping (15 days vs. 12 days), although there was a large variation between laboratories. When further
testing was required to interpret the array, median TATs were increased to 22–26 days, depending on the
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test; however, we acknowledge that this may not reflect TAT if CMA were to replace karyotyping. The
TAT, as defined for CPA, is also predicated on whether or not rapid aneuploidy detection by QF-PCR is
performed prior to setting up the array. We therefore also compared times from set-up to report; in this
analysis CMA was 5 days quicker than karyotyping with a median time of 6 days. There remained
substantial differences between laboratories (with median times ranging from 2 to 9 days) suggesting that,
with greater clinical experience, a median TAT of 7 days is achievable.
There was complete concordance between the detection rate of cytogenetically visible euchromatic
unbalanced chromosomal abnormalities and the results obtained by CMA. As expected, array CGH
failed to detect 15 visible cytogenetic abnormalities, the majority of which were apparently balanced
rearrangements and, therefore, no euchromatic gains or losses were observed on the matched array.73
The proportion of cases with an abnormal karyotype but normal CMA (1.3%) is comparable to the Hillman
et al.56 series from the UK (2%) and the NICHD study (0.9%).57 Balanced translocations and inversions
are reported in < 0.1% of prenatal diagnostic samples,74 suggesting that such changes are more common
in prenatal series selected for fetal anomaly. Although an inherited rearrangement with a normal CMA would
not explain ultrasound findings in the index pregnancy, the finding is of relevance to future reproductive
counselling. Counselling parents with a de novo apparently balanced rearrangement is more challenging,
especially when the indication for testing is an increased NT with no structural anomaly. In a large cytogenetic
series, in which amniocentesis was performed primarily for maternal age, the risk of a serious anomaly in
fetuses with an apparently balanced de novo rearrangement varied from 3.7% for Robertsonian translocations
to 9.4% for inversions.75 Although many such cases will have an imbalance detected on CMA, either at one or
more breakpoints or unrelated to the translocation/inversion,76 the residual risk in those with a normal CMA
is unclear.
Confined placental mosaicism, in which the karyotypes of the placental and fetal tissues are divergent, has
been extensively reported and reviewed.77 It occurs in up to 2% of chorionic villus samples (compared with
< 0.5% of amniotic fluid samples78). Overall, within the EACH cohort there were three cases with CPM
(UCH312964, Birm3011 and SGH 86084) that were recognised prenatally and not reported. There were
two further cases in which the CPM was only finally recognised postnatally. The first was a Xp22.31 steroid
sulfatase enzyme deletion (UCH1285528) and was reported prenatally. Follow-up studies after delivery
showed that the Xp22.31 deletion was confined to the placenta.79 The case prompted an observation by
Kooper and Faas80 that similar false positives could be avoided if the source villi were dissociated into two
separate cell suspensions of cytotrophoblast and mesenchymal cells using an adapted version of the protocol
of Mann et al.81 This allows testing of DNA from both fractions whenever mosaicism is suspected. The second
case (CAM62826) was reported prenatally to be a trisomy 7 mosaic on karyotyping and non-mosaic trisomy
7 using CMA. Postnatal karyotyping of peripheral blood found no evidence of trisomy 7, confirming CPM.
These two cases, both with a normal outcome, represent the only false positives within the EACH study
giving a frequency of 2 out of 1123 (0.18%). Aside from these CPM cases, there were three additional cases
in the EACH study in which an apparent anomaly was identified by CMA (SGH 85534, QCH130141 and
UCH1176628) but follow-up studies found to be cultural or technical artefacts. In addition, there was one
case with a benign heterochromatic variant, t(Y;15) (NCL12275). All four cases were reported as normal.
An increasing number of prenatal studies are using SNP-based arrays. Srebniak et al.82 summarised the
advantages of SNP-based arrays over non-SNP arrays in the prenatal setting. SNP arrays can detect triploidy
and MCC, although this is less important in the current UK context, where rapid aneuploidy detection
with QF-PCR is recommended. With male fetal samples interfering levels of MCC can be excluded when
the sex chromosome plots are normal, but this is not possible with a female fetus and MCC testing is
recommended to be confident that the results are reflective of the fetal DNA.83 However, depending on the
array and software design, small CNVs can be detected with varying levels of MCC.81 SNP arrays are also
reported to be able to detect levels of mosaicism as low as 5% depending on origin.82 However, recent
studies have confirmed that oligoCGH arrays can detect mosaicism at a level as low as 10%.84,85 Finally, in
contrast to oligoCGH arrays, SNP arrays also offer the advantage of detecting loss of heterozygosity; large
regions of homozygosity throughout the genome can suggest consanguinity while regions of homozygosity
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involving chromosomes 6, 7, 11, 14, 15 and 20 can suggest clinically relevant UPD.82 In one of the 15
abnormal karyotype/normal CMA cases, additional molecular studies demonstrated paternal UPD(14) of the
chromosome 14 homologues in association with mosaicism supernumerary heterochromatic marker
14 chromosome86 and represented the one case in the EACH study for which use of a SNP array would
have provided a more comprehensive diagnostic utility.87,88
The health economic analysis indicated that the mean cost per test was higher for CMA than for karyotyping
(£322 vs. £234–272), as was the total cost of the pathway, including laboratory follow-up tests and clinical
follow-up (£599 vs. £486). CMA detected more pathogenic CNVs than karyotyping in the structural anomaly
group than the NT group (0.035 vs. 0.010 more per pregnancy) and, hence, the incremental cost per
pathogenic CNV detected by CMA compared with karyotyping was lower in the structural anomaly group
(£3635 vs. £9439). Results were sensitive to the number of pathogenic CNV results found by CMA, the
number of abnormal karyotypes and the cost of CMA. If the NHS was willing to pay an extra £10,000 to
detect an extra pCNV, then CMA would be cost-effective on 87% of occasions. Few economic evaluations
of CMA are available for comparison. Hillman et al.89 evaluated the cost-effectiveness of CMA compared
with nine combinations of conventional techniques in the NHS using data from a cohort of women with a
structural anomaly. Testing strategies including CMA detected the most CNVs. Using a base-case unit cost
for a 1-Mb BAC array of £405, the authors calculated that, compared with QF-PCR followed by karyotype
[if the polymerase chain reaction (PCR) was negative] followed by FISH for 22q11.2 deletion syndrome
(if the karyotype was negative and the fetal anomaly was cardiac related), CMA cost an extra £24,600 for
every additional CNV. Compared with karyotyping alone, CMA cost an extra £33,300 per pathogenic CNV
detected, which fell to £9768 if the unit cost of CMA was £360. The authors concluded that CMA was not
cost-effective, although they acknowledged that it may become so in future if the costs of CMA fall; the
EACH results support this (in the EACH study, the unit cost of CMA was £322). Hillman et al.89 included both
pathogenic CNVs and VOUS in their definition of additional cases detected. When VOUS were treated as
false positives, CMA was dominated by all other strategies (i.e. it was more costly and less effective).
The authors noted that treating all VOUS or false positives would underestimate the specificity of CMA
because some VOUS would in time be determined to be pathogenic. Definitive judgements about the
cost-effectiveness of CMA are problematic because it is unclear what the NHS is willing to pay to detect an
additional CNV.
The qualitative substudy aimed to inform the development of any policy product from the main study by
providing an evaluation of the acceptability of CMA to major stakeholders. It brings together parents’
perspectives with those of health-care providers (i.e. cytogeneticists, clinical geneticists, genetic counsellors,
midwives, fetal medicine consultants and commissioners). No previous studies have evaluated CMA across
this range of experiences. Two prior studies have reported parents’ experience of prenatal CMA; Bernhardt
et al.90 conducted 23 telephone interviews with women in the USA who received positive array results.
Sixteen of the group had prenatal testing for maternal age or positive screening results. In the UK, Hillman
et al.91 conducted 25 interviews with women after receiving the results of CMA, most of which were
normal. In contrast, the women in our study were interviewed at least 3 months after the outcome of the
pregnancy, allowing participants to comment on their experience of decision-making after a longer period
of reflection. Participants were generally supportive of the process of prenatal diagnosis in general and the
use of CMA in particular. However, in each of the participant groups, actual and potential problems were
raised for discussion, which clustered around three key issues.
The first was around achieving integration of CMA into the existing care pathways. Accessing CMA
involves referral to a fetal medicine centre. Health professional participants were concerned that delays in
referral could reduce options for women in terms of termination of pregnancy for fetal anomaly at later
gestations. The time between identification of a problem and referral to a specialist centre is a time of
great stress for parents and a time when appropriate support is needed.92 Participants highlighted many
advantages of CMA already reported in the literature, particularly the availability of more detailed genetic
information.36 Furthermore, CMA was perceived to be a quicker test than karyotyping. Even when a novel
variant was identified, the reporting time was felt to be no slower than karyotyping. Moreover, several
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health professionals acknowledged that, as more information became available about CNVs, reporting time
for arrays was likely to reduce.25,93,94 The management of VOUS was seen by health professionals as the
main challenge associated with implementation of CMA, which is consistent with previous literature.95–97
Professionals were primarily concerned with ensuring that parents who take up the offer of an array are well
informed about the test, particularly the potential for a VOUS. Education programmes for health professionals
and appropriate literature for parents were recommended, reinforcing recommendations from other studies
of CMA in prenatal diagnosis.90,91 Commissioners provided a unique insight into the factors that influence
commissioning decisions around new technologies. Evidence of clinical utility, improved diagnostic yield and
the actual cost featured high on their list of priorities. However, they were also keen to ensure that there was
equity of access to care and patients appeared central to their commissioning decisions in line with current
policy.98 Finally, many participants highlighted the future impact of NIPT on care pathways, acknowledging
the increased risk of miscarriage associated with invasive prenatal diagnosis. Although NIPT was seen as an
appropriate part of the aneuploidy screening pathway,99 several professional participants commented that the
higher diagnostic yield of CMA in cases with an ultrasound anomaly meant that this technology was more
appropriate for informing pregnancy management decisions.
The second issue was around informed consent. Parent participants had variable understandings of the
EACH study. Consistent with prior research,100 some parents participated in the research for altruistic
reasons and there was some lack of recognition that the results could potentially have an impact on their
own pregnancy. Many parents recalled being told about a concurrent study on NIPT and, although some
parents’ accounts demonstrated understanding of CMA as a genetic test, they mistakenly thought it would
screen for all genetic abnormalities. These sorts of possible confusion related to CMA have been reported
previously90,99 and were raised as concerns by health professionals. Even with apparent understanding
at the time of consent, parents who opt for the test can still be surprised by an abnormal result and
disappointed when health professionals are unable to interpret the results.90 Similarly, parents interviewed
for the EACH study described feeling lured into a false sense of security by a normal karyotype result and,
hence, were shocked by the array result.89 This highlights the difficulties of offering a test that is additional
to standard care in a research study. Parents are unprepared for receiving such news92,101 and, when
parents have not fully understood the implications of their participation in research, this can be
more problematic.
Despite many parents not fully understanding the array test, and some experiencing shock after receiving
an abnormal array result, they tended to accept it on the basis that CMA offered additional information.
The potential for uncertain information was either not an immediate concern for parents in the EACH
study or was a risk they were prepared to take in seeking clarification/reassurance. Many described gaining
a better understanding of potential problems which directly informed their decisions about pregnancy,
which was experienced as empowering. The premise that ‘knowledge is power’ prevailed, which was
consistent with previous studies, even though this knowledge may, in the end, be seen as ‘toxic’.90,91 Our
findings suggest that informed consent for CMA is challenging because the information is just one facet of
a complex scenario, which itself is a time of emotional distress for parents. Distress can have an impact on
parents’ recollection of what was said to them92,101 and this effect seems likely in this study.
The management of uncertain prognosis underpins much of the literature on prenatal diagnosis and it
featured in discussions about test integration and informed consent. CMA does not necessarily offer
certainty in terms of diagnosis or prognosis, raising questions about how much uncertainty can be
tolerated given the potential decision to end a pregnancy. Professionals in particular were concerned about
these issues; adopting an inclusive, interprofessional team approach to shared clinical decision-making was
an important mechanism for managing this concern. This approach is associated with more collaborative
team behaviour,102 leading to improved continuity of care and patient satisfaction.103 Our study suggests
that clinicians, especially fetal medicine consultants, value this collaboration more when they are faced
with uncertainty. Collaborative working was important to them in ensuring that parents received the best
possible information. Other strategies for managing uncertainty were raised. A few health professionals
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who had faced dilemmas over VOUS saw the use of targeted arrays as a way to reconcile the ambivalence
around uncertain results while acknowledging that this strategy did not remove all reporting uncertainty.85
The majority of the health professionals were keen to see CMA develop in the longer term and to gain more
information to offer to parents. Developing collaborative databases of information and ensuring long-term
follow-up were seen as fundamental requirements. The EACH study included a review panel to assist in
decisions about reporting CNVs. Clinician experience of, and satisfaction with, the panel was variable and
there was some ambiguity about the role of the panel in relation to decision-making. Although, in principle,
the panel is an excellent resource for clinicians faced with uncertainty about the clinical significance of a CNV
and whether or not to report it, clear guidance on what role the panel has in the final decision needs to be
developed to increase the professional user experience.
Finally, linked to the issue of managing uncertain prognosis, both parents and health professionals
identified the importance of reporting of results. CMA results were reported only if it was felt that the
CNV had a high probability of a phenotypic effect. This left some women with a ‘normal’ result unsure;
they had understood that there would be longer-term results from the study, albeit that many seemed to
have misunderstood the intricacies of the test. However, women who received prenatal testing often
remained anxious about the health of their child104,105 and not reporting a result has the potential to add to
the concerns of an already worried parent.
The geneticisation of health and disease has been identified as both dominant and problematic in how the
social categories normal and abnormal are defined.106 Much of the literature on user experiences of CMA
stems from its use in those with an established personhood status, for example children with developmental
delay and/or congenital anomalies. In this context, the concept of informed consent is of critical importance
to the understandings of the ethical and social acceptability of genetic testing as a medical practice. The
issue of informed consent recurs in the literature on parent perspectives of prenatal diagnosis.88,91 The
dominant biomedical narratives for prenatal diagnosis utilise notions of control, choice and reassurance, but
these narratives have been criticised for being too simple.106 Factors such as strong social support and
religious beliefs have influence regardless of social context while class and ethnicity are affected by social
structures. The notion of choice in prenatal diagnosis has been problematised because, following the
diagnosis of a serious fetal anomaly, parents have a time-limited decision about whether to continue or end
the pregnancy. For some parents, this is problematic because it is conceptualised as an ‘involuntary choice’101
and, for others, the problem lies with the lack of true alternatives to termination. Decisions after prenatal
diagnosis of fetal anomaly are, therefore, dependent on social context as well as individual views.
Underpinning these debates is the idea that the social context in which western populations live make it
difficult to say ‘no’ to new developments38,101 because the goal of a ‘healthy baby’ is perceived to be a
self-evident good.107 As genetic technology has progressed, so the options for prenatal diagnosis have
multiplied. Therefore, CMA is best conceptualised as a recent innovation in this dynamic sphere of activity.
Many of the issues raised in the analysis of the EACH data are best understood as a part of a much bigger
social and medical phenomenon. However, their occurrence in this novel situation provides opportunities to
understand how those existing dilemmas have shaped the acceptability of the intervention in the study and
how that may, in turn, shape policy in the future.
The EACH study has a number of strengths. It was designed to detect a clinically important difference in
cryptic chromosomal imbalances in two distinct groups of fetuses with ultrasound anomalies after exclusion
of a common aneuploidy by QF-PCR. This large cohort of women was recruited from 20 fetal medicine
units with samples analysed in nine cytogenetic laboratories across England and Wales. Pilot work optimised
laboratory workflows and a single oligoCGH array design was chosen, based on ISCA consensus, which
optimised detection of clinically relevant imbalances while minimising VOUS rates. CNV calls and reporting
decisions were made by local genetic teams but advice was available from an expert panel for challenging
cases. The results are therefore likely to genuinely reflect the impact of replacing karyotyping with CMA in
clinical practice. The study also included an economic analysis which investigated the cost-effectiveness of
such a replacement strategy using main unit costs averaged from all nine participating laboratories. The
EACH study also included an embedded qualitative study to determine the factors that influence parents’
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and health professionals’ choice and decision-making about CMA in this context. Importantly, the sample
included professionals making commissioning decisions about prenatal testing.
The study also has a number of limitations. Prenatal arrays were undertaken in addition to karyotyping on
‘routine’ clinical samples in busy NHS laboratories. As a result, limited amounts of fetal material were
available for DNA extraction, which accounts for the relatively high CMA failure rate (3.4%) in the EACH
study. Furthermore, TATs were calculated using the CPA standard for NHS laboratories even though arrays
may not have been set up as soon as possible after sample receipt. Therefore, a more clinically meaningful
time was calculated from the time of array set-up to final report. Unlike many prenatal array studies, we
attempted to collect pregnancy outcome for all cases but this was not available in 32% of the cohort.
However, we were able to get delivery details and some paediatric information from > 95% of the cases
with an abnormal karyotype and/or CMA. Understandably, termination of pregnancy rates were very high
but surprisingly, given the indications for testing, many parents opted not to have post-mortem examination,
limiting the phenotypic information available for a significant number of infants. The main limitation of the
health economic analysis was that cost-effectiveness was measured in terms of the incremental cost per
pCNV detected. Although this is an appropriate measure for evaluating CMA, it means that it is difficult to
make a firm judgement about whether or not CMA is cost-effective because it is unclear how much money
the NHS is willing to pay to detect an additional pathogenic CNV. Further research to identify how much the
NHS is willing to pay to detect an additional pCNV would be beneficial. In addition, we considered only costs
during pregnancy, not following childbirth and, therefore, we did not capture all the potential costs and
benefits associated with detected additional pCNVs. Moreover, the study was designed so that participating
women underwent both karyotyping and CMA. This is an appropriate study design to investigate the
diagnostic accuracy of CMA, but it meant that when the results of CMA and karyotyping were discordant it
was difficult to attribute the subsequent laboratory follow-up tests and clinical follow-up to each option.
It is acknowledged that, although the sample size for the qualitative study was sufficiently diverse for the
purpose, few parents with a ‘normal karyotype and abnormal CMA’ were interviewed. The narratives of the
two couples that did fall into this category offered a unique insight into the benefits of CMA as the test
directly informed their decision to discontinue the pregnancy.
The EACH study began recruiting in May 2012. Since then there have been significant advances in prenatal
testing for chromosomal anomalies which will have an impact on future implementation of CMA as well
as future research. Numerous studies summarised in a recent meta-analysis,108 as well as the NHS RAPID
project,47 have demonstrated the effectiveness of cell-free DNA in maternal blood to screen for trisomies 21,
18 and 13 using either sequencing (massively parallel or chromosome specific) or SNP-based methodology.
As a result, in November 2016, the Department of Health announced the introduction of cell-free DNA as a
second stage non-invasive screen for these trisomies.109 Benachi et al.110 studied the potential impact of
cell-free DNA in 387 cases of structural anomaly (which included 193 cases with increased NT) and out of
the 290 cases with a normal cell-free DNA analysis, 23 (7.9%) had additional pathogenic karyotypes.
Unfortunately, CMA was not performed. The application of cell-free DNA is already being extended to sex
chromosome aneuploidies111 and common microdeletion syndromes.112 Introduction of cell-free DNA testing
is anticipated to dramatically reduce the number of women undergoing invasive testing for chromosomal
anomalies. In 2012, the first report of whole-genome sequencing of amniocytes from a fetus with multiple
anomalies was reported113 and, since then, further cases of prenatal exome sequencing have been reported,
including a series of 30 prenatal and neonatal samples from cases with structural anomalies from
Birmingham.114 Targeting exons has the advantage that only 1–2% of the genome is sequenced, but these
key protein-coding regions contain up to 85% of mutations known to cause genetic disorders. In 2013, the
Prenatal Assessment of Genome and Exomes (PAGE) project was funded with the aim of analysing 1000
exome sequences (with whole-genome sequencing in a smaller cohort) from a fetus undergoing invasive
testing because of a structural anomaly.114 Samples will be collected from fetal medicine centres throughout
the UK, building on the EACH collaboration, and PAGE will identify what additional information exome
sequencing provides over CMA. Further studies will be needed to determine whether or not sequencing
should replace CMA and, ultimately, if this technology can be applied to detect other chromosomal
imbalances in cell-free fetal DNA in maternal blood.115
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Conclusions
The EACH study was designed to provide guidance to health service providers on whether or not CMA
should replace karyotyping in the prenatal diagnosis of fetal anomalies. The laboratory evaluation,
conducted in nine cytogenetic laboratories across England and Wales, showed that, in the group of fetuses
with a structural anomaly, array CGH detected 3.5% more clinically significant CNVs than karyotyping.
Although CMA also detected more CNVs in fetuses with increased NT, the increase in pathogenic variants
did not achieve statistical significance. Laboratory TATs were slightly longer for CMA than for karyotyping
owing to the design of the study. However, analysis of actual set-up to reporting times indicated that, in
clinical practice, CMA results would be available on average within 7 days. Cost calculations indicated that,
per patient, CMA is on average £113 more costly than karyotyping. Whether or not CMA is cost-effective
depends on how much money the NHS would be willing to pay to detect an additional pathogenic CNV.
CMA is likely to be more cost-effective in cases with a structural anomaly than in those with increased NT.
The qualitative evaluation of attitudes to CMA suggest that parents find the technology acceptable,
despite the uncertainties it may introduce, and that, generally, it is acceptable to health professionals and
commissioners. However, it will be important to ensure health professionals are able to better inform
parents about CMA in order to enhance patient understanding of the implications of the test. The sharing
of information on detected variants and the associated phenotypes and outcomes is seen as important to
ensure consistent interpretation of CMA results.
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Chapter 5 Implications of research
Summary of implications for practice
1. The evidence from the EACH study suggests that CMA should replace karyotyping in care pathways
when the indication for fetal testing is one or more structural anomalies or an isolated NT of ≥ 3.5 mm
on ultrasound scan after a normal QF-PCR result. Replacement for both indications will ensure there is a
consistent prenatal (and postnatal) diagnostic technology.
2. In order to achieve a detection rate greater than when using karyotyping, the experience from the
EACH study suggests that a minimum array-CGH resolution of ≈400 kb throughout the genome
is optimal.
3. The findings of the EACH study suggest that any variant that can be linked to a potential phenotype of
the future child on the basis of the genes involved should be reported, regardless of the size of the
imbalance. This should include high-penetrance neurosusceptibility loci. Other (incidental) variants
should not be reported.
4. The evidence suggests that until more national (and international) information on prenatal variants has
been collected, specifically linking clinical phenotypic and molecular data, there may be benefit in a
national advisory group that can provide expert advice to local health-care professionals about variants
of possible pathogenic significance. Such a group could also identify incidental findings not to be
reported. The operating model of the EACH review panel could serve as a template for such a group.
5. To ensure that consistent, high-quality, information is provided to parents and to help support shared
decision-making, consideration should be given to producing a national information sheet and
consent form.
Since completion of the EACH study and taking account of the findings, the Joint Committee on Genomics in
Medicine published recommendations for the use of CMA in pregnancy in June 2015.116 The recommendations
were endorsed by The Royal College of Pathologists in collaboration with The British Society for Genetic
Medicine, The Royal College of Obstetricians and Gynaecologists and The British Maternal and Fetal Medicine
Society. The implications for practice from the EACH study are consistent with the recommendations produced
by the Joint Committee.
Implications for future research
The evidence supporting the introduction of CMA in the prenatal diagnosis of fetal anomalies is robust.
It is anticipated that NIPT for trisomies will be introduced into UK clinical practice very soon. Future research
should focus on the role of next-generation sequencing not only on fetal DNA acquired by invasive testing,
but also on cffDNA in maternal blood. A particular concern is the rate of false-positive results generated by
high-depth sequencing. In addition, following on from the EACH health economic study and relevant to
future decisions around new genetic technologies, further research is needed to decide how much money
the NHS is willing to pay to detect an additional pathogenic CNV. Finally, following on from the qualitative
substudy, and relevant to the introduction of next generation sequencing, further research is needed on
methods of enhancing patient understanding and supporting collaborative decision-making when a CNV
is detected.
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Appendix 1 The EACH study patient information
leaflet
New Methods of Detecting Fetal Chromosome Abnormalities  
EACH Study (Incorportating Rapid Study) 
 
Professor Stephen Robson, Professor of Fetal Medicine, Royal Victoria Infirmary, Newcastle 
Professor Lyn Chitty, Professor of Genetics and Fetal medicine, University College London, 
Institute of Child Health, London 
We are inviting many of the women who attend our Fetal Medicine Unit to take part in a 
research study. Before you decide whether or not to take part it is important for you to 
understand why the research is being done and what it will involve. Please take time to read 
the following information carefully and discuss it with others if you wish. One of our team will 
go through the information sheet with you and answer any questions you may have.  
What is the purpose of the study? 
The aim of this study is to evaluate new methods of fetal chromosome testing. Our genes are 
made up of building blocks called DNA which are located on structures called chromosomes. 
All our cells contain 46 chromosomes (23 inherited from each parent).  Our genes act as 
instructions for passing on inherited characteristics such as eye colour and height from parent 
to child. They also provide the instructions for the baby’s development. As a result, changes 
in baby’s genes can lead to problems in development.  
If a problem is found on a pregnancy scan, 1 in 4 of these babies will have a chromosomal 
abnormality.  In some cases the baby has part or all of a chromosome missing while in others 
there is part or a whole extra chromosome. Down’s syndrome is an example of a 
chromosome abnormality where the baby has a whole extra chromosome.  
In order to diagnose a chromosome abnormality it is necessary to examine a sample of the 
baby’s cells. These are obtained by amniocentesis or chorion villus sampling (CVS). In either 
case the sample of cells is initially examined for common major chromosome abnormalities 
(for example Down’s syndrome). The result of this initial (rapid) test is available within 72 
hours. In addition a more detailed test called karyotyping is performed.  This test is offered as  
part of your normal standard care, and examines all of the baby’s chromosomes.The result of 
this longer test is usually available within 14 days. However, if only a small part of a 
chromosome has been gained or lost, karyotyping cannot detect this. As these gains or 
losses can contain several important genes they can have a major effect on the baby’s 
development. In this study we are using a new method of examining the DNA in our 
chromosomes - array comparative genomic hybridisation (or array CGH for short). The array 
test has the potential to detect around 5 to 10% more significant gains or losses of genetic 
material which are too small to be detected by karyotyping. Some of these gains or losses 
reflect normal variation and have no implications for a baby’s development, but others have 
been found to be responsible for some physical and/or developmental problems in children. 
As some of these changes may be inherited from a parent we will ask to take a sample of 
your blood and, if possible, your partner’s blood so that, if we find a change in your baby’s 
DNA, we can check to see whether it has been inherited from a parent (and so is less likely to 
cause problems for the baby’s development). 
The aim of this study is to find out how much more information about the baby is provided 
when we use the array test, rather than the standard karyotyping test. The study will also 
determine how quickly array test results can be obtained and will help inform the NHS 
whether array CGH should replace karyotyping for the detection of fetal chromosome 
abnormalities.  
Another new method of detecting some fetal chromosomal abnormalities is to examine 
maternal blood. We now know that when you are pregnant the baby’s DNA can be found in 
your blood. Using new tests we are able to identify the baby’s sex, blood group and possibly 
some genetic and chromosomal abnormalities such as Down’s syndrome.  In order to get the 
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greatest benefit from the samples collected in this study we propose, in addition to the array 
CGH study, to use your blood sample for another research study called RAPID which may 
help develop these additional new tests which, ultimately, may allow the diagnosis of some 
genetic and chromosomal abnormalities without the need for amniocentesis or CVS.   
 
Why have I been chosen? 
We are inviting all women who have decided to have an amniocentesis or CVS after a 
problem in their baby was seen on scan to take part in the study. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be 
given this information sheet to keep and asked to sign a consent form. If you decide to take 
part you are free to withdraw at any time without giving a reason. If you do not feel able to 
take part it will not in any way affect the care you or your family receives. 
 
What will happen to me if I take part? 
If you agree to take part we will ask you to donate a blood sample.  Where possible we would 
also like to take a sample of blood from your partner. We will use the sample taken at your 
CVS or amniocentesis to perform the array test, but only if there is enough material left after 
performing the routine karyotyping test. We will not take any additional amniotic fluid or 
chorionic villi. 
 
If the initial test, which is available within 72 hours or the CVS or amniocentesis, shows a 
major chromosomal abnormality we will not perform the array CGH test. We would still use 
your blood sample to see if we could have detected the abnormality in the baby’s DNA in your 
blood as part of the RAPID study.  
 
We will also seek permission to ask your doctor, or check your hospital notes, to confirm the 
outcome of your pregnancy. With your agreement we may contact you when your baby is 
around 2 years old to arrange a follow-up to find out how he/she is developing. A small 
number of women will also be asked if they are prepared to participate in an in-depth 
interview with a researcher about their experience – more information will be provided to 
those women interested in taking part.   
 
Will my taking part in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all information will be handled in confidence. 
Any information you give us will only be used by the research team in the course of the 
research. Any samples and data stored will be stored securely.  
 
What are the possible benefits of taking part? 
The results of the routine karyotype test will be available to you. If this shows a major 
chromosomal abnormality not detected on the initial (rapid) test then the implications of the 
result and your pregnancy options will be discussed with you by a specialist doctor. If the 
karyotype test is normal and the array CGH test is normal we will not inform you of the array 
result.  
 
Very occasionally, despite a normal result on the initial (rapid) and karyotype tests, the array 
test will detect a loss or gain of genetic material from one of the baby’s chromosomes. In this 
case the laboratory will perform an array test on your blood and whenever possible the baby’s 
father’s blood. If the same finding is present in one of the parents (as is often the case) then 
we can assume that the loss or gain of genetic material in the baby has been inherited from 
the parent and is very unlikely to explain the scan findings. However, if the loss or gain of 
genetic material is not present in a parent and particularly if it involves a number of important 
genes, we will report this finding to your doctor as it may account for the scan problems and 
could have important implications for the baby’s development. In this case a specialist doctor 
will discuss with you what the array result might mean for your baby and your pregnancy 
options. However some of the genetic variations detected by the array test cannot be 
accurately interpreted at the current time. Therefore only changes which we can interpret 
clearly on the basis of the available medical literature will be reported. 
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We envisage that the results of the study will enable us to develop more effective prenatal 
tests for rare chromosomal conditions as well as Down’s syndrome.   
 
What are the possible disadvantages and risks of taking part? 
The only additional sample to be collected is a blood sample. This will be carried out by 
someone who is skilled in taking blood. Some people may experience bruising at the site 
which will resolve over a few days. If the karyotype or array CGH test suggests an 
abnormality, there may be some distress caused by the need to contact the baby’s father (if 
he was not present at the initial consultation).  
 
What will happen if I don’t want to continue in the study? 
You are free to withdraw at anytime. If you withdraw from the study we will not access any 
further samples and will destroy any of your samples that were collected for the study.  
 
What will happen to any samples I give? 
Any unused DNA extracted from the baby’s amniocentesis or CVS sample and your blood 
samples will be stored as part of a Research Tissue Bank. The samples will be coded and no 
personal data (name and address) will be stored with the sample. The DNA samples will only 
be used in research studies designed to develop these new methods of diagnosing 
chromosomal abnormalities.  
 
What will happen to the results of the research study? 
The results from our project will be published as research papers in medical journals. No data 
will be published that will allow individuals to be identified.  
 
Where can I get further information or discuss any problems? 
Please contact a member of the research team at Royal Victoria Infirmary on 0191 282 0362 
to discuss any questions or worries about the study. If the problems are not resolved or if you 
wish to speak to someone independent of the study please contact the Patient Advisory 
Liaison Services (PALS) if you have any concerns regarding the care you have received, or 
as an initial point of contact if you have a complaint. Please telephone 0800 320 202, you can 
also visit PALS by asking at any hospital reception. 
 
Who is organising and funding the research?  
This research is organised by the Fetal Medicine Unit Research Teams at Newcastle upon 
Tyne Hospitals NHS Trust and Great Ormond Street Hospital for Children NHS Trust funded 
by the National Institute for Health Research. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect your interests. This study has been reviewed and given 
favourable opinion by the Newcastle and North Tyneside 2 National Research Ethics 
Committee.  The RAPID Study has also been reviewed, and was given favourable opinion by 
the University College London Hospitals Research Ethics Committee.  
 
Thank you for taking the time to read this information leaflet. 
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Glossary 
 
Genes 
Genetics is the branch of science that deals with how you inherit your physical and 
behavioural characteristics. The genetic information that controls these characteristics, 
such as the colour of your hair and eyes, is located in genes which are found in 
chromosomes. Our genes are made up of building blocks called DNA. 
 
Chromosomes 
Each cell in the body contains 23 pairs of chromosomes. These carry the genes that you 
inherit from your parents. In this way you can inherit a health condition or disease, or a 
tendency to develop a particular condition. One in each pair is inherited from each 
parent, so with one exception, there are two copies of each gene in each cell. 
 
DNA 
Deoxyribonucleic acid (DNA) is the long molecule that stores genetic information. 
DNA is made of two strands coiled together, each one a mirror image of the other. 
Because of this, it can be divided easily when a cell divides and the genetic code is 
passed on exactly. However, sometimes part of the DNA can become altered and result 
in small changes that could be responsible for developmental anomalies. 
   
Amniocentesis 
Amniocentesis is a test carried out during pregnancy which involves using a fine needle 
to remove a small amount of the amniotic fluid around your unborn baby. Amniocentesis 
is used to detect chromosomal abnormalities such as Down’s syndrome as well as 
certain other genetic conditions. Amniocentesis is known as a diagnostic test because it 
gives you a diagnosis. For example it tells you that your baby does or does not have 
Down’s syndrome.  Amniocentesis is carried out after 15 weeks of pregnancy. One in 
every 100 women (1%) who have an amniocentesis will miscarry.1 
 
Chorion Villus Sampling 
Chorionic villus sampling (CVS) is a test carried out during pregnancy which involves 
using a fine needle to remove a small amount of the placenta (afterbirth). CVS is used to 
detect chromosomal abnormalities such as Down’s syndrome as well as certain other 
genetic conditions.  CVS is known as a diagnostic test because it gives you a diagnosis. 
For example it tells you that your baby does or does not have Down’s syndrome. CVS is 
usually carried out between the 11th and 14th week of your pregnancy. One or two in 
every 100 women (1-2%) who have a CVS will miscarry.1  
 
Karyotyping 
Karyotyping looks at the cells taken during amniocentesis or CVS under a powerful 
microscope. This allows the person who is carrying out the test to examine the 
chromosomes directly. By counting the chromosomes and by checking their shape, it 
may be possible to detect changes that could be responsible for genetic abnormalities. 
 
Array CGH 
Array CGH (comparative genomic hybridization) examines DNA from cells  taken during 
amniocentesis or CVS.  It is used to detect very small gains or losses of genetic material 
which are too small to be detected by karyotyping. These  gains or losses deletions or 
insertions can be responsible for genetic abnormalities leading to physical and/or 
developmental problems in children.. 
 
1 More information on amniocentesis and CVS can be found in a leaflet called 
‘Amniocentesis – information for parents’ or Chorionic villus sampling (CVS) – 
information for parents’. These are available here: 
http/fetalanomaly.screening.nhs.uk/publicationsand leaflets.  
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Appendix 2 The EACH study patient consent form
New Methods of Detecting Fetal Chromosome Abnormalities (EACH 
Study) 
Patient Consent Form 
Initials 
1. I confirm that I have read and understood the information sheet dated 16.12.2011  
(version 2) for the above study. I have had the opportunity to consider the 
information,  
ask questions and have had these answered satisfactorily.  
2. I understand that my participation is voluntary and that I am free to withdraw at  
any time, without giving any reason, without my legal rights being affected.  
3. I understand that relevant sections of my medical records and the data collected 
during  
my participation in the study may be looked at by responsible individuals from the  
Universities of Newcastle or from the Newcastle  
upon Tyne Hospitals NHS Foundation Trust, where it is relevant to my taking part in 
this  
research (for example, for the purposes of audit).  
4. I agree to take part in the above study and for any excess villi or amniotic fluid being 
used 
for array CGH analysis  
5. I agree to 25ml of my blood to be used as part of the RAPID study to develop new 
methods  
of detecting fetal chromosomal abnormalities. 
------------------------------------------------------- 
6. If I continue with the pregnancy, I agree to be being contacted after the birth to 
arrange  
for my baby’s development to be assessed.  
7. I agree to being contacted at a later date  to ask if I am prepared to participate in an 
in-depth interview with a researcher about my experience in the EACH study  
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_________________________________ __________  ______________________ 
Name of patient     Date  Signature 
 
_________________________________ __________ ______________________ 
Name of health professional   Date  Signature 
 
When completed, 1 copy for participant, 1 copy for researcher site file 
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Appendix 3 The EACH study health professional
interview topic guide
Before interview starts 
1. Interviewer outlines purpose of interview, and explain offer of copy of transcript 
and summary results 
2. Interviewer explains use of audio-recorder (to improve accuracy) 
3. Interviewer explains anonymisation process prior to analysis (removal of identifiers 
and use of pseudonyms); 
4. Interviewer to assure confidentiality +  reassurance that clinical staff involved in the 
research will only have access to sections of transcripts, rather than full transcripts.  
5. Check for further questions 
6. Go through consent form and sign. 
The semi-structured interview approach adopted in these interviews focuses on 
encouraging the participant to explain their experiences in ways that make the most 
sense from their perspective. Apart from the introduction and conclusion, the 
questions listed below act as an aide memoire, rather than a definitive list of 
questions-in-order.  
 
Introduction 
1 How long have you worked in your clinical specialty ? 
  
  How long in current post ? 
 What types of role does your current post involve ? 
 
2 How did your unit get involved with the main EACH study ? 
 How involved are you personally ?  
 How does it affect your work ? 
 Any comments on experiences of working with the requirements of 
clinical research ? 
  
 Evaluation of previous practice re: conventional testing methods 
3 Views about working in the area of fetal anomaly detection 
 
4 Ask participant to describe how the research pathway differs from previous 
clinical practice 
  
5 Any advantages of the previous methods ? 
  
6 Any disadvantages ? 
  
   Evaluation of new care pathways / methods (karyotyping / arrayCGH) 
7 From a clinical perspective, how useful is array CGH  
 In counselling parents 
 In clarifying diagnosis 
 In other ways ? 
  
8 Are there any difficulties you have experienced whilst implementing array 
CGH in the context of the EACH study ? 
 E.g. lack of knowledge (self and others in the NHS) 
 Problems related to the testing method? 
 Problems related to the EACH study in particular ? 
 Anything else ? 
  
9 Do you know much about the comparative costs between array CGH and 
conventional karyotyping? 
 Which would you expect it to be more costly ?  
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 E.g. (money, patient time, clinician time, lab time) etc.  
  
10 How do patients seem to react to the different methods when you are in 
clinic? 
 Have you formed any impression of what patients prefer ? 
 If so, why ? 
 If not why not ? 
  
11 What about your colleagues – do you think they have a preference ? 
 Which pathway is best to work with ?  
 Why ? 
  
  
 Rolling out fancy ideas  
12 In your experience, what support do new tests / practices need to become 
adopted by the clinical community ? 
 e.g. organisational level, clinical directorate, resources, allied health 
professional support, patient support etc.  
 what can stop good technological developments  from being adopted 
in practice? 
 
13 Testing out new findings in a research project is interesting, but we are also 
interested in how they might work on a larger scale.  
How would implementation of array CGH  fare outside of the research project 
? 
  
14 If array CGH is found to be significantly better than conventional karyotyping, 
would it be feasible to roll this out across the UK? 
 Advantages ? 
 any potential problems that you can foresee ? 
  
15 If the care pathways in this project became standard practice, how long do 
you think it would take for provision to be accessible in most parts of the UK 
? 
 
16 Are there any factors that might help make policy development in this area 
more effective? 
 
 
Concluding views 
17 I have reached the end of my questions. Is there anything that you would like 
to add / feel has not been covered that should have been included? 
 
18 How did you feel about being interviewed on this aspect of your work? 
  
 
Final tasks 
Check to see if there are any further questions 
Thank participant for giving up their time to take part 
Check re consent for interview to be analysed and used in the study 
Check re (1) copy of transcript and (2) summary of findings 
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
98
Appendix 4 The EACH study patient interview
topic guide
Before interview starts 
1. Interviewer outlines purpose of interview, and explain offer of copy of transcript 
and summary results.  
2. Extend special thanks for agreeing to take part, and reassure that they don’t have 
to answer all the questions 
3. Interviewer explains use of audio-recorder (to improve accuracy) 
4. Interviewer explains anonymisation process prior to analysis (removal of identifiers 
and use of pseudonyms); 
5. Interviewer to assure confidentiality +  reassurance that clinical staff involved in the 
research will only have access to sections of transcripts, rather than full transcripts.  
6. Check for further questions 
7. Go through consent form and sign. 
The semi-structured interview approach adopted in these interviews focuses on 
encouraging the participant to explain their experiences in ways that make the most 
sense from their perspective. Apart from the introduction and conclusion, the 
questions listed below act as an aide memoire, rather than a definitive list of 
questions-in-order.  
Introduction 
1 Can you tell me a little about yourself? 
  How old are you 
  What would you do on a normal day? 
 
2 How long has it been since (outcome of pregnancy) happened ? 
 Can you tell me about your experience of pregnancy  before this one 
 
  
Experiences re: having the antenatal tests 
3 How did the need for antenatal tests emerge? 
 Experiences of antenatal care, particularly screening interventions  
 Check for awareness of screening aspect to key interventions 
 Did anyone talk to you about ‘array CGH’ ? 
 
4 What actually happened when the tests were carried out? 
  
5 What were the tests for?  
 Did any one discuss this with you at the hospital? 
 Did you want to talk about it with anyone else (e.g. partner, friends, 
family) 
  
6 What did the test results tell you about your pregnancy? 
 How did you get the results of the test/s 
 How did you feel about the result 
 
  
 Experiences after the test period 
7 What happened after you had the results back? 
 Did you talk to anyone about it (who?) 
 (if appropriate) How did you decide what to do next ? 
  
8 Looking back on that period, how do you feel about the experience now? 
 What is the most important thing for you about that period in your life? 
 Were the array CGH tests important to you? (why/not) 
 Were the array CGH results important to you? (why/not) 
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9 How did this experience of health care compare with your other 
experiences? 
 Other experiences of pregnancy 
 Other experiences with doctors / hospitals / GP / etc. 
 Was there anything particularly good about your care 
 Was there anything that could have been done better / improved  
  
10 Did you get all the information you needed at the time, or have you had to 
look elsewhere to get more information (e.g. the internet) 
 What information was most helpful to you at the time 
 What information did you need afterwards / now 
  
11 If you had a friend going through the same experience, what advice would 
you give them about the array CGH test? 
  
  
    
Concluding views 
17 I have reached the end of my questions. Is there anything that you would like 
to add / feel has not been covered that should have been included? 
 
18 How did you feel about being interviewed on this aspect of your life? 
  
 
Final tasks 
Check to see if there are any further questions 
Thank participant for giving up their time to take part 
Check re consent for interview to be analysed and used in the study 
Check re (1) copy of transcript and (2) summary of findings 
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Appendix 5 Report on cell-free deoxyribonucleic
acid aspects of the EACH study
P rovided by Professor Lyn Chitty (Institute of Child Health, University College London, 2015,personal communication).
Background
The presence in maternal plasma of cell-free fetal DNA, which is pregnancy specific and represents the
whole of the fetal genome, offers enormous promise for the development of a range of prenatal
diagnostic tests. Fetal sex can be determined by analysis of cell-free DNA and several other tests are
available for definitive prenatal diagnosis of several monogenic disorders. However, it is the development
of NIPT for aneuploidy that stands to have the greatest impact on maternity care. The first proof of
principle studies using next-generation sequencing were published by academic units in 2008. Larger
demonstration projects, led by industry, reporting high sensitivities and specificities (98% and 99%,
respectively) for the detection of trisomy 21 in high-risk pregnancies were followed by the commercial
launch of NIPT in Asia and the USA in 2011, and in the UK in 2012. It is clear that women and health
professionals welcome NIPT but concerns have been raised that ease of access to NIPT may undermine
informed consent as there is a risk of this test being seen as routine. These concerns may be overcome by
careful pre- and post-test counselling, but this will require education of health professionals and adequate
provision of counselling. In the UK, the limitation of NIPT services to private sector provision (at a cost of
£400–900) is resulting in inequality of access with increasing demands from women for implementation in
public sector maternity care. However, this has significant implications for service provision. Should the test
be developed in NHS laboratories or be outsourced to the commercial sector? How should we manage the
1–6% of pregnancies where NIPT fails? The current cost of NIPT is likely to prohibit implementation in the
NHS as a replacement for traditional trisomy 21 screening: should we therefore offer it to high-risk women
as an intermediate test?
Development of non-invasive prenatal testing for aneuploidy
The funding provided by Efficacy and Mechanism Evaluation assisted the RAPID team with the evaluation of
NIPT for aneuploidy by providing consumables for the sequencing of cell-free DNA extracted from ≈1100
maternal blood samples, collected as part of the EACH study, and the development of the bioinformatics
algorithm used for the massively parallel sequencing of maternal plasma. This has allowed the RAPID team
to deliver an evaluation of NIPT for aneuploidy in the NHS through the NIHR Programme Grants for Applied
Research RAPID programme (RP-PG-0707-10107) using sequencing performed at the local regional genetics
laboratory at Great Ormond Street Hospital NHS Foundation Trust. The overall aim of this part of the RAPID
programme was to deliver a report on all aspects of NIPT implementation (laboratory evaluation, health
professional and patient education, and evaluation of the care pathway and a detailed health economic
analysis) to the National Screening Committee to inform the decisions on if, how and when to introduce
NIPT into the NHS maternity care pathway. The final report has been submitted to the national Screening
Committee for comment in May 2015. In November 2016, the Department of Health announced the
introduction of NIPT for new, non-invasive, prenatal Down, Edwards and Patau syndromes.109
DOI: 10.3310/eme04010 EFFICACY AND MECHANISM EVALUATION 2017 VOL. 4 NO. 1
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Robson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
101
Evaluation of non-invasive prenatal testing for the detection of
other chromosomal imbalances
Recently, the scope of NIPT has been increased to include selected subchromosomal abnormalities, but the
number of samples reported has been small, leading to considerable uncertainty in test sensitivity and
specificity. As part of the RAPID programme, a novel calling pipeline based on a segmentation algorithm
for the detection of fetal microdeletion and microduplication syndrome in maternal cell-free DNA has been
developed. The algorithm has been tested on 31 samples with known subchromosomal abnormalities and
many of those from whom these samples were taken were recruited as part of the EACH study.
With the same read depth used in our NIPT for aneuploidy pipeline, our algorithm detected 15 out of
18 samples with a CNV larger than 6 Mb (sensitivity 83%) and three out of three samples with maternally
derived abnormalities (sensitivity 100%). There were two false-positive calls in 534 samples with no
known subchromosomal abnormalities (specificity 99.6%). Using funding from the Great Ormond Street
Biomedical Research Centre, deeper sequencing has been performed. With the higher read depth, 26 out
of the 28 samples with fetal subchromosomal abnormalities were detected.
We concluded that test sensitivity is a function of the fetal fraction, read depth and the fetal CNV size.
Fetal fraction is a strong determinant of sensitivity and at least one of the two false negatives was due to
low fetal fraction. The lack of an independent method for determining fetal fraction, especially for female
fetuses, leads to uncertainty in the test sensitivity, which has implications for the future of this technique as
a clinical diagnostic test.
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Appendix 6 Summary of patient and public
involvement
Patients and public were involved throughout the EACH study, as follows.
1. Design: the application had a lay coapplicant (Jane Fisher, Antenatal Results and Choices, London, UK)
who helped design the study and contributed to the study application and each version of the protocol.
2. Methods: Jane Fisher, along with the two lay members of the Trial Steering Committee and two lay
members of the Reproductive Health Research Group (Newcastle University, Newcastle, UK) contributed
to the content of the patient information leaflet and the patient consent form. Jane Fisher also
contributed to the interview guide used in the qualitative substudy.
Report: Jane Fisher contributed to the content of final report and prepared the lay summary.
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